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Abstract 
Adenosine and adenosine derivatives are recognised as cardioprotective 
agents due to their ability to activate myocardial adenosine receptors.  
Antioxidants such as nitroxide radicals have also been demonstrated to provide 
cardioprotective effects by scavenging oxygen based damaging free radicals.  
In this thesis, three series of C2-linked adenosine 5-N-ethylcarboxamide 
derivatives bearing antioxidant nitroxide and phenolic moieties were designed 
and synthesised.  It was envisaged that linking of the antioxidant moiety to the 
adenosine skeleton would produce adenosine analogues that bind to and 
activate adenosine receptors and, in addition, scavenge harmful oxygen-
centered free radicals generated in the body.   
Evaluation of the prepared compounds as A2AAR agonists using the cAMP 
accumulation assay identified a number of potent and selective agonists.  Of the 
compounds examined, the adenosine 5–N-ethylcarboxamide compounds, 
possessing various nitroxides linked through para-(2-aminoethyl)aniline 
linkages (namely compounds designated as 162, 164, 166, 168 and 170 in this 
Thesis) displayed high selectivity, with more than 200-fold selectivity for the 
adenosine A2A receptors  over adenosine A1 receptors, whilst retaining 
reasonable selectivity over adenosine A3 receptors.   
Of the adenosine compounds examined, PROXYL nitroxide (166) and tetraethyl 
isoindoline nitroxide (170) possessing a para-(2-aminoethyl)aniline linked 
adenosine 5–N-ethylcarboxamide unit approached high selectivity for the A2A 
receptors over the other adenosine receptor subtypes.  Four of the 
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highly-selective adenosine compounds (162, 164, 166, and 170) were further 
investigated in the simulated ischaemia model using rat atrial cardiomyoblast 
cells.  All four of these compounds showed strong protective effects in this 
assay.  There were some additional cardioprotective effects observed at the 
highest agonist concentration in the presence of the antagonist. This result 
indicates that the antioxidant moiety may contribute to the compounds 
cardioprotective effects at high levels of agonist concentration.   
Ethynyl- and ethyl-linked structural classes of adenosine 5–N-ethylcarboxamide 
compounds were also synthesised bearing tetraalkylisoindoline nitroxides.  All 
compounds from these series are less-potent A2A agonists than the previously-
mentioned candidates.  However, the ethynyl linked tetramethylisoindoline (178) 
and tetraethylisoindoline nitroxide (182) bearing adenosine 5-N-
ethylcarboxamide and ethyl linked tetraethylisoindoline nitroxide bearing 
adenosine 5-N-ethylcarboxamide (184) have a higher selectivity for A2B 
receptors than other adenosine receptor subtypes.   
This project has resulted in the synthesis and characterization of twelve novel 
C2-substituted adenosine analogues with three different linker groups.  Most of 
the target compounds were tested for their binding ability to adenosine receptor 
subtypes, and some analogues were found to be potent and selective 
adenosine receptor subtype agonists.   
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1.1 Cardiovascular diseases 
Cardiovascular diseases are a leading public health concern throughout the 
world.  Globally, more than 17 million people die from cardiovascular diseases 
every year.1  Of these, 80% of deaths occur in low-income and middle-income 
people or developing countries.  Heart disease, a type of cardiovascular 
disease, is the most common cause of death in developed countries.1  
Cardiovascular disease is classified further as peripheral vascular diseases and 
cerebrovascular diseases, and includes coronary heart disease (CHD), 
rheumatic heart disease, stroke, chronic heart failure, heart attack (myocardial 
infarction), and diabetes.2   
 
The pathophysiology of cardiovascular diseases is very complex because of the 
involvement of several biological pathways, which all originate in the vascular 
endothelium.3  Interference in these pathways is considered to be the main 
factor in cardiovascular risk.  Activation of the vascular endothelium and 
oxidative stress play important roles in atherosclerosis4 and hypertension,5, 6 
which eventually result in the progression of cardiovascular damage.  High 
cholesterol levels,7 impaired glucose tolerance8 and inflammation also 
contribute to cardiovascular damage.   
 
During the past several decads, extensive research has focused on treating 
cardiovascular diseases from a different perspective such as the use of 
precautionary therapies and curative medications.  Several factors have been 
found to contribute to cardiovascular diseases.  These factors are classified into 
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two types: unavoidable and avoidable factors.  Unavoidable factors include age, 
sex, menopausal status and genetic composition.  Avoidable factors can include 
environmental pollution, diet, smoking, some diseases (e.g., diabetes, 
hypertension), lack of physical activity9 and ethanol consumption.10  
Cardiovascular diseases result from an inadequate blood supply to the brain, 
heart and peripheral vasculature.2  The term ischaemia describes the deficiency 
or shortage of blood supply (to hold back blood).11  These ischaemia-related 
heart diseases are the most common cause of death in the world,12 and 
research has focused on finding new ways to design and synthesise drugs that 
will achieve cardioprotection.   
1.1.1 Ischaemic heart diseases 
Coronary artery disease (CAD) is also called ischaemic heart disease.12  
According to the World Health Organization, in 2008 ischaemic heart disease 
accounted for 7.25 million deaths worldwide and, by 2015, 25% of the global 
adult population will be affected by the major risk of hypertension.13  Ischaemic 
heart disease involves a narrowing of the coronary arteries, the vessels that 
supply blood to the mayocardium, mainly because of deposition of plaque in the 
arterial walls, a process called atherosclerosis.14  Plaques are composed of 
cholesterol-rich fatty deposits, collagen, other proteins, and excess smooth 
muscle cells.14  Thickening and narrowing of the arterial walls, as well as 
impeding the flow of blood and starving the heart of oxygen, are the symptoms 
of this disease (also called “ischaemia”).15  This disease can cause a muscle 
cramp-like chest pain called angina pectoris.16   
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Ischaemia occurs where there is an interruption or occlusion of the blood supply 
to an organ or tissues, which deprives the cells of oxygen and nutrients, and the 
ability to generate energy, a condition called hypoxia.11  This hypoxia can 
initiate a series of chemical events that result in cell dysfunction, cellular chaos, 
interstitial oedema, and necrosis, and eventually lead to anaerobic cell death.11  
Hypoxia can affect various parts of the body, resulting in cardiac ischaemia, 
brain ischaemia,17 cutaneous ischaemia, and ischaemia of the bowel and 
limb.11  Hypoxia can cause serious disorders by damaging metabolically active 
tissues and eventually various organs linked by the circulatory system.11  A 
deficiency of oxygen supply (hypoxia) increases the intercellular concentration 
of lactic acid through a process called acidosis, which alters normal enzyme 
kinetics within cells.11   
 
Ischaemia often occurs during surgical procedures, especially vascular 
procedures and transplantations.18  Abnormalities can be detected in the 
electrocardiogram (ECG), which may show the first indications of ischaemic 
heart disease.18  These abnormalities may occur even with an absence of 
symptoms of angina or myocardial infarction and may indicate the possible 
presence of ischaemic heart disease.18  In hypoxic muscle cells, glucose 
consumption can increase by 12-fold.15  The depletion of cellular energy stores, 
particularly of adenosine 5-triphosphate (ATP) is considered to reflect the 
failure of cellular homoeostasis and is diagnosed by the loss of the ion gradient 
across the cell membrane.15   
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Hypoxia develops within 10 seconds of the coronary blockage.11  Different 
tissues can remain hypoxic for different periods.  Skeletal muscles can recover 
after some period of ischaemia; however, irreversible neuronal injury typically 
occurs within minutes.19  Cardiac cells can survive for about 20 minutes under 
ischaemic conditions and, if blood flow is restored within this time, the normal 
aerobic mechanism resumes.15 In aerobic condition, the toxic metabolites are 
removed from the site of the ischaemic event.  However, this restoration of the 
blood supply may also lead to further local tissue injury.11  Ischaemia and 
reperfusion injuries are the root causes of the pathophysiology of cerebral 
ischaemia, stroke, myocardial infarction and some of the problems with organ 
transplantation.20   
1.1.2 Reperfusion injury 
Reperfusion is the restoration of blood supply to ischaemic tissues, which 
facilitates the removal of toxic metabolites from these tissues.11  These toxic 
metabolites flow into and throughout the systemic circulation and can lead to 
serious injury including ischaemic tissue injury, called ischaemia–reperfusion 
injury.11  This restoration of blood initiates a series of events that can lead to 
further tissue injury.21  Once the blood supply is restored, a cascade of 
biochemical and molecular changes occur that lead to free radical-mediated 
damage.21  Oxygen-centred free radicals, including superoxide radicals, are 
mainly involved in ischaemia–reperfusion injury.21  These free radicals are 
produced intracellularly within the mitochondria in the post-ischaemic 
endothelium and may be responsible for major changes in the endothelium.15  
Superoxide radicals may be responsible for the production of highly reactive 
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and damaging hydroxyl radicals.22  Superoxide radical production is controlled 
naturally by the endogenous enzyme superoxide dismutase in normal and non-
stressed physiological conditions.23-26  This natural defence mechanism is 
overwhelmed in ischaemia and reperfusion conditions, and the hydroxyl radicals 
produced can cause damage to a variety of biological components including 
amino acids, proteins, enzymes and nucleic acids.22, 27-30   
1.1.3 Free radicals 
Free radicals are ions, atoms or molecules with one or more unpaired electrons 
in their outer shell.  Radicals are formed by homolytic bond cleavage.   Free 
radicals can react readily with other radicals to form stable species and can be 
oxidised to cations or reduced to anions.  In 1900, the first organic free radical 
triphenylmethyl radical (Figure 1.1) was identified by Moses Gomberg.31   
 
Figure 1.1: Chemical structure of a triphenylmethyl radical. 
Free radicals are generated in biological systems by a wide variety of processes 
such as ionising radiation, inflammation or exposure to toxic xenobiotics, and as 
metabolites of membrane lipid transformation.32  These radical species also can 
be generated by external sources including cigarette smoke33 and other forms 
of pollution, by exposure to radiation and by exposure to chemical processes 
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such as those involving photosensitized decomposition and the decomposition 
of non-endogeneous diacetyl peroxide, peresters and azo compounds.34  
However, not all radicals are highly reactive or damaging.  Free radicals can 
also play an important role as mediators of cell signalling processes that 
regulate vascular function.35, 36   
1.1.4 Oxidative stress 
Oxidation and reduction reactions represent the basis for several biochemical 
mechanisms that generate metabolic changes in biological systems.37  
Oxidative stress is defined as the imbalance between the increased production 
of reactive oxygen species (ROS) and reactive nitrogen species (RNS) and the 
lowered activity of radical-scavenging mechanisms in biological systems.38  
Oxidative stress is involved in the various mechanisms of injury in many types 
of disease processes.  The free radical species ROS and RNS are produced in 
low amount in all layers of the vascular membrane, such as the endothelium 
and smooth muscle and in several metabolic processes via the actions of 
various enzymes.39 These enzymes include nicotinamide adenine dinucleotide 
phosphate (NADPH) oxidase, xanthine oxidase, nitric oxide (NO) synthases, 
myeloperoxidase (MPO) and some mitochondrial enzymes.40   
 
The involvement of ROS and RNS is widely recognised as being important in 
several aspects of pathophysiological processes.39, 41  ROS are known to play 
an important role in oxidative stress. Increased oxidative stress can cause 
damage to cellular structures.  The overproduction of radical species (the active 
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form of oxygen or nitrogen) can damage biological molecules including proteins, 
amino acids, nucleic acids and DNA molecules by various mechanisms.42 
The toxic effects of oxygen were investigated in several animal species.  In 
1954, Gerschman et. al. reported that the observed oxygen toxicity could be 
attributed to the partially reduced form of oxygen.43  These ROS and RNS 
encompass hydrogen peroxide (H2O2), superoxide anion radicals (O2
–), 
hydroxyl radicals (OH), nitric oxide (NO), and peroxynitrite (ONOO–) radicals.44, 
45  An excess of the active forms of these radicals (R) or other ROS, leads to 
the oxidation of other cellular components and forms the peroxyl radical 
(HOO), which can initiate the chain oxidation reaction.  This radical chain 
process leads to more damage and generates oxidative stress conditions.   
 
ROS are responsible for the increased oxidative stress and decreased lifespan 
in various living species.46  The free radical theory of ageing states that the 
organism’s age depends on the accumulation of damage over time, attributed to 
oxidative stress induced by ROS.47  This theory is supported by the imbalance 
between the ROS produced by mitochondria, and the activity of internal radical-
scavenging defence mechanisms.48   
 
Physical exercise, can also increase oxidative stress.  Intense physical activity 
increases mitochondrial activity in skeletal muscles and the subsequent 
production and leakage of ROS from mitochondria.49  Ischaemia–reperfusion 
injury and activation of neutrophils, may occur during intense physical exercise, 
and also further increase in the production of ROS.50  Cigarette smoke can also 
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increase oxidative stress because it contains a large number of free radicals 
that can cause endothelial cell dysfunction and mitochondrial damage.33, 51  
 
In living organisms, free radicals may cause more damage to the immature 
brain than the adult's brain because of underdeveloped free radical-scavenging 
mechanisms and the presence of a higher concentration of iron that can 
promote radical formation.17  As a result, free radical damage in infants can 
cause neurological complications such as birth asphyxia, perinatal brain injury 
and ischaemic injury etc.17  However, antioxidant analogues are recognised to 
provide protective effects for this type of free radical damage.   
1.2 Antioxidants 
Antioxidants are compounds that prevent or defend against the cellular damage 
caused by free radicals via inhibition of oxidation of atoms or molecules.32  
Oxidation is a chemical reaction in which loss of a hydrogen atom or an electron 
or addition of oxygen to a molecule.52  Oxidation can generate free radicals, 
which then initiate a chain radical reaction that can damage the cellular 
components of biological systems.53  Antioxidants terminate this chain reaction 
by scavenging the free radical intermediates and preventing further oxidation of 
other species.53  The antioxidant activity of species such as thiols, ascorbic acid 
and polyphenols is due to their ability to act as reducing agents (i.e. they 
undergo oxidation themselves).53  The antioxidant mechanism of 
cardioprotection typically involves either the generation of lynchpin radicals in 
ischaemia–reperfusion injury or the direct scavenging of the superoxide anion.54  
Clinical studies have shown that anti-inflammatory agents act as antioxidants 
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significantly reduce the levels of C-reactive protein (CRP) and membrane attack 
complex (MAC) protein in infarcted tissues.54  These CRP and MAC protein 
levels increase during inflammatory and cardiovascular conditions.55   
 
In biological systems, the potential damaging effects of free radicals are 
regulated through intracellular body fluids by the actions of several enzymes 
including superoxide dismutase (SOD), glutathione peroxidase (GSH-Px), and 
glutathione-S-transferase.56  The family of glutathione-S-transferase enzymes 
catalyses the transformation of thiols, glutathione and some reactive 
electrophiles to thioethers called S-conjugates.56  These reactive intermediates 
are formed by several mechanisms including NADPH-dependent enzymatic 
dethiolation and thiol exchange or radical-mediated processes.56   
 
Non-enzymatic defence mechanisms act by preventing the excessive 
production of free radicals.  The body employs several means to prevent the 
overproduction of free radicals.  The first method is metal chelation, which 
involves binding metal ions, particularly iron and copper ions, at the site of 
initiation of the chain reaction.  This method is a potent technique for preventing 
the radical production and it is used as a major strategy for preventing lipid 
peroxidation and DNA fragmentation.57  Metal binding to the proteins transferrin, 
ceruloplasmin and metallothionein is broadly effective to counteract radical 
generation.  A second process involves the modification of the target site to 
make it resistant to the metal ion-dependent oxidation.53  This process can 
protect cells from radiation-derived oxidation; for example, to protect melanin 
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from ultraviolet radiation and carotenoid from electronically excited species such 
as singlet oxygen.37   
 
A third biological process that prevents the overproduction of free radicals is the 
introduction of non-enzymatic antioxidants to protect the tissues.  The main 
issue is that once the radical species are formed, they initiate a radical chain 
reaction and produce more radical compounds.  This radical generation can be 
prevented by the production of the non-radical and unreactive end products. 
This process of deactivation of the radical chain reaction by inserting 
antioxidants or other radical species prevents further damage.   
 
Another strategy is to move radical species away from potential target species 
to avoid cellular damage.  High-efficiency breakup mechanisms are used in 
cellular systems, where only a few antioxidant molecules are required to 
deactivate thousands of potential target molecules.  Such chain-breaking 
mechanisms often involve polyphenolic antioxidants including -tocopherol, 
which reduces peroxyl radicals and is itself converted to the tocopheroxyl 
radical.  This radical is then scavenged by external dietary antioxidants 
including ascorbate vitamin C (2) and thiols.58  Several other naturally occurring 
dietary antioxidants include retinol vitamin A (8), kaempferol (4) and quercetin 
(5) (Figure 1.2).   
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Figure 1.2 Dietary and synthetic antioxidants. 
A number of techniques can be used to measure the antioxidant activity of 
phenolic compounds.  All antioxidant compounds exhibit a moderate 
electroactivity. The following electron transfer (ET) based assay evaluates the 
capacity of an antioxidant to reduce an oxidant that usually changes colour 
when reduced59.  The ET based radical scavenging assay encompasses one of 
the most popular antioxidant assays that contains 2,2-diphenyl-1-picrylhydrazyl 
(DPPH) radical 9 as well known radical scavenger (Scheme 1.1).  The ET 
technique is also a  powerful tool to measure the antioxidant activity of 
hydroxycinnamic acid derivatives.60 
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Scheme 1.1: DPPH radical scavenging assay principle. 
Several synthetic compounds have also been reported as radical scavengers 
that have different mechanisms of action.  After the discovery of superoxide 
dismutase (SOD) activity in 1969, there has been a significant development in 
the understanding of radical chemistry61 and, since 1988, in the arginine-
dependant synthesis of NO radicals.62  It has also been demonstrated that 
nitroxides are very efficient radical scavengers that exhibit antioxidant actions.63  
For example, several synthetic compounds reported as radical scavengers 
including AAD-2004 (6)64, Neu-2000 (3)65 and NXY-059 (7)66, 67 (Figure 1.2) 
exhibit anti-inflammatory and antioxidant properties by spin trapping in cortical 
neuron culture.   
1.2.1 Nitroxide radicals 
Nitroxides (also known as aminoxyls or nitroxyls) are synthetically stable free 
radicals.  In 1965, Griffith and McConnell demonstrated that nitroxides are free 
radical species with paramagnetic properties.68  Nitroxides exhibit paramagnetic 
behaviour because of an unpaired electron.  The general molecular formula is 
R2NO (Figure 1.3).    
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Figure 1.3: General chemical structure of a nitroxide. 
The majority of stable nitroxides are secondary amine N-oxide radical species 
with quaternary α–carbon atoms.  The stability of a nitroxide radical depends on 
several factors.  The delocalization of an unpaired electron (resonance) over the 
N–O bond and hetero atoms provides remarkable kinetic and thermodynamic 
stability to the nitroxide moiety (Scheme 1.2).  Therefore, it shows resistance to 
dimerization.69 
 
Scheme 1.2: Resonance stabilisation of a nitroxide radical. 
The groups attached to the radical centre can also strongly influence the 
stability of the nitroxide radical.  Nitroxides become more stable with bulky 
groups around the nitroxyl moiety.  This steric effect resists the bimolecular 
combination reaction that occurs between a nitroxide and a more reactive 
radical.  
The stability of nitroxides is also maintained by their resistance towards the 
formation of stable adducts with other oxygen centred radical species.  Although 
nitroxides can undergo reaction with a variety of reactive oxygen species, this is 
not through direct interaction with the oxygen centred radicals.  Dimerization 
does not occur due to the loss in delocalisation stabilisation of two nitroxide 
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species.  The dimerization of two nitroxide molecules is also energetically 
unfavourable (2 x ~130 kJ/mol) because of the weak nature of the resultant N–
O–O–N bond (~140 kJ/mol) that would form.70, 71  This nature maintains the 
stability of nitroxides and is also useful for protecting the nitroxide radical from 
dimerization.72, 73   
 
The stability of nitroxides is dependent on the unpaired electron remaining 
delocalised over the two hetero atoms.  The nitroxide stability is, therefore, 
dependent on the absence of degradation pathways, which mainly arise through 
the substituents present on the carbon α to the nitroxide moiety.74  The 
delocalisation of unpaired electron spin density in the aromatic ring of tert-butyl 
phenyl nitroxide increases the thermodynamic stability of the nitroxide system.  
However, the reactive carbon centred radical thereby formed promotes the 
bimolecular degradation of the nitroxide moiety to give the corresponding amine 
and nitrone species74 (Scheme 1.3).   
 
Scheme 1.3: Bimolecular degradation of a phenyl substituted nitroxide. 
The degradation pathways that affect the stability of nitroxides arise mainly due 
to the presence of methyl (CH3-), methylene (RCH2-) and methine (R2CH-) 
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hydrogen atoms adjacent to the nitroxide moiety.  Nitroxides possessing β–
hydrogen atoms become unstable because of facile disproportion to give the 
hydroxylamine and nitrone (Scheme 1.4).74   
 
Scheme 1.4: β–Hydrogen induced disproportion of a β–H substituted nitroxides. 
Non-cyclic bis(tert-alkyl) nitroxides such as di-tert-butylnitroxide (DTBN), as well 
as cyclic nitroxides, are stable species also known as aminoxyls and nitroxyls.  
These stable radicals possess methyl groups (that have no β–Hydrogen) on the 
carbons α to the nitroxide.75  Methyl groups impact stability to the nitroxide 
radical by limiting access to reactive species and avoiding radical dimerization.   
There are several common types of cyclic nitroxide radicals that have been 
exploited in research studies including, 1,1,3,3-tetramethylisoindoline-2-oxyl 
(TMIO); 2,2,5,5-tetramethylpyrrolidine-1-oxyl (PROXYL) and 2,2,6,6-
tetramethylpiperidine-1-oxyl (TEMPO) nitroxides (Figure 1.4).   
 
 
Figure 1.4: Structures of stable nitroxide radicals.
72, 73  
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Nitroxides have been reported as effective ROS scavengers with some 
advantages over other reactive radical trapping agents.  Specifically, the 
isoindoline-based aminoxyls, namely 1,1,3,3-tetramethylisoindoline-2-oxyl 
(TMIO)76 (22) and its analogues, are known to have several advantages77 
compared to other nitroxides including the PROXYL (25) and TEMPO (24) 
containing species.  The fused aromatic ring of the isoindoline skeleton provides 
resistance to ring-opening reactions over the decomposition pathways of other 
aminoxyls and demonstrates excellent electron paramagnetic resonance (EPR) 
properties with narrower line-widths.  In addition, these nitroxides demonstrated 
excellent thermal and chemical stability in several chemical reactions.  
Substitution on the aromatic ring of the isoindoline allows the creation of more 
complex structures suitable for several applications with little impact on the 
stability and reactivity of nitroxide radical species.78, 79  These modifications of 
isoindoline nitroxide can be beneficial in increasing the water solubility of 
nitroxides, and this has been used to expand the potential scope of the 
application of nitroxides in various therapeutic contexts.80  Isoindoline nitroxides 
are implicated in radical trapping and as potent antioxidants in biological 
systems.81, 82 
 
As nitroxides are more stable than other reactive radical species, their use has 
been exploited in various applications.  Nitroxides demonstrate their effect 
through electron transfer mechanisms, including redox metabolism via one or 
two electron-reduction reactions involving either an interconvertible 
hydroxylamine, an oxoammonium cation or a radical ion.  These three-stage 
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oxidative electron-transfer processes also explain the ROS-metabolizing action 
of nitroxides (Scheme 1.5).81, 83 
 
Biological studies have found that some nitroxides can accumulate in cells at 
high concentration with lifetimes of over 100 minutes.84  This property of 
nitroxides has been exploited in EPR imaging and biomarkers.75  These findings 
have initiated further research into nitroxides and their applications in the 
therapeutic field.85   
 
Scheme 1.5: Redox reactions of a nitroxide.
81, 83
 
1.2.2 Applications of nitroxides: 
  Radical trapping and spin labelling: 1.2.2.1
The biological activity of nitroxides was first investigated in 1964 by Emmerson 
and Howard-Flanders.86  Further studies on nitroxides described the protective 
antitumor activity of nitroxides,87 and also their roles as powerful bioregulatory 
molecules in the nervous system, immune system and cardiovascular system.88  
Nitroxides are kinetically stable systems compared with other radical species, 
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and their intracellular lifespan has been found to be long enough to be detected 
by electron paramagnetic resonance (EPR) spectroscopy.  Therefore, these 
stable nitroxide radicals have been used in several animal models of disease 
and also in human diseases to try to find ways to avoid the production of ROS, 
which can generate oxidative stress.   
 
The nitroxide TEMPOL (4-hydroxy-2, 2, 6, 6-tetramethylpiperidine-N-oxyl) 28 
(Figure 1.5) is the most widely studied nitroxide, and it has been shown to be 
permeable through cell membranes and to reduce the formation of toxic 
hydroxyl radicals.89  
 
Figure 1.5: The chemical structure of nitroxide, TEMPOL.  
In 1990, Schnackenberg, Welch, and Wilcox90 reported that the intravenous 
administration of TEMPOL decreased blood pressure and lipid peroxidation in a 
hypertensive rat model.  TEMPOL also reduced glutathione levels in human 
blood cells,91 and was found to protect cells and tissues from the damaging 
effects of ROS.  In vivo, nitroxides rapidly undergo reduction to the 
corresponding hydroxylamine, which demonstrates their involvement in redox 
biochemistry.92   
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 Nitroxide antioxidants 1.2.2.2
Nitroxides act as antioxidants against free radical-induced oxidative damage in 
biological systems and provide chemo-protection and radioprotection.93  
Extensive research has focused on the action of nitroxides as antioxidants in 
several biological systems ranging from isolated molecules to membranes, cells 
to organs and in whole animals.94, 95  These nitroxides can operate at different 
levels in the cell, for example, preventing radical formation, intercepting formed 
radicals, repairing oxidative damage, and increasing the elimination of damaged 
molecules as well as promoting the death of cells with excessively damaged 
DNA96.  Antioxidant mechanisms are studied in cells using isolated 
biomolecules created by microsomal preparation methods.97  Cell protection is 
observed by preserving the colony-formation ability of the cells and by avoiding 
DNA degradation.  The mechanism proposed to explain this protection is that 
nitroxides oxidise reduced metals and limit the production of H2O2 and, 
consequently, the production of ROS.   
 
Nitroxide radicals react with free radicals and intercept them before they can 
damage lipids, proteins and DNA molecules.  These radicals also act as 
cytotoxic mediators in the immune system and as neurotransmitters in the 
central nervous system.98  Nitroxide analogues and their derivatives have been 
investigated as potential protective agents in rat models of myocardial 
ischaemia–reperfusion injury.99   Experiments have confirmed that, under the 
ischaemic condition, nitroxides are completely reduced in the heart, and this is 
decreased by ~33% in non-ischaemic conditions.100   
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Several stable nitroxides have been reported to exhibit intracellular radical-
scavenging actions with recycling capacities.101, 102  These nitroxides were 
developed and tested for their free radical-scavenging and antioxidant 
abilities.63, 75, 76  TEMPO and its analogues have been shown to protect against 
cerebral and cardiovascular ischaemia103 and reperfusion injury89 by decreasing 
the infract size.  This discovery of the actions of nitroxide radicals has led to an 
interest in the role of dietary antioxidants and evidence suggesting that 
antioxidants may protect against many neurological and cardiovascular 
diseases.104-107  Several hindered phenolic and polyphenolic compounds also 
exhibit antioxidant and anticancer activity.108-111   
1.2.3 Phenolic antioxidants  
Phenolic compounds also exhibit antioxidant properties similar to those of 
nitroxides.  In particular, hindered phenolic compounds have been reported to 
demonstrate excellent antioxidant activity and are known as “natural” 
antioxidants.  These sterically hindered phenolic compounds have improved 
reactivity towards small free radicals and are more biologically stable than non-
hindered phenolic species when oxidised.  Phenolic antioxidants including 
butylated hydroxytoluene (BHT) generate stable free radicals by donating a 
hydrogen atom to diffuse the more reactive radical species.  This phenoxy 
radical is more stable, but it can still react with other radicals or can be 
polymerised, although these reactions are slower than those that are initiated by 
more reactive species.   
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Substituents on the ring play an important role in determining the antioxidant 
activity of phenolic antioxidants.  Electron-donating substituents on the phenyl 
ring increase the radical-scavenging potency of phenolic compounds by 
weakening the phenolic O–H bond.112  Substitutions at the ortho position 
determine the stability of the phenoxy radical.  A bulkier substituent produces a 
more hindered phenoxy radical, which helps increase the radical-scavenging 
activity.  Substitution at the para position avoids the dimerization of the phenolic 
radical compounds.   
 
A variety of compounds incorporating the phenolic structures have been 
reported.  Some if these phenolic compounds have been claimed to be 
responsible for the trapping and stabilising of reactive free radicals, including 
single oxygen, hydroxyl, superoxide and peroxyl radicals and also lipid soluble 
radicals.  These properties of phenolic compounds (some examples of which 
are shown in Figure 1.6) provide desirable effects in various biological 
functions. 
 
In particular, the hindered phenolic species have been reported to reduce low-
density lipoprotein (LDL) oxidation and morbidity in the lipoprotein and have 
reactivity towards radicals.112  Many novel phenolic antioxidant compounds 
capable of oxidative modification of LDL have been reported.  LDL oxidation 
has been found to be a major contributor to atherosclerosis, and logically its 
inhibition by antioxidants should be beneficial in preventing and treating 
atherosclerosis. The well-known phenolic compound -tocopherol (vitamin E) 
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exhibits antioxidant activity by trapping and stabilising reactive free radicals and 
efficiently inhibiting lipid peroxidation.113   
 
The antioxidant capacity of a compound is measured by its reactivity towards 
the reactive radical species.  Likewise vitamin E (29), Galvinoxyl (34) is also a 
free radical inhibitor that is often used to investigate the antioxidant activity.  
The rates of reaction of other phenolic compounds have been compared with 
that of Galvinoxyl.  BO-653 (31) and vitamin E (29) were found to have similar 
reactivity, which is higher than that of another commonly used hindered 
phenolic compound Probucol (32)114(Figure 1.6).   
 
Figure 1.6: Phenolic and radical antioxidants. 
The hydroxycinnamic acids (HCA) are also a class of phenolic antioxidants, 
which are highly abundant in food and may account for one-third of the phenolic 
compounds in our diet. Hydroxycinnamic acid compounds are of increasing 
interest in health research because they are recognised as potent 
antioxidants.115, 116  These compounds have been reported as radical chain 
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breaking antioxidants that achieve this action through radical scavenging 
activity. This activity has been attributed to hydrogen or electron-donating 
capacity and their ability to delocalise or stabilise the resulting radical within the 
structure.  The additional unsaturation incorporated in hindered 
hydroxycinnamic acid compounds gives extra stabilisation to the phenoxy 
radical species accordingly increasing their antioxidant activity.  These active 
phenolic compounds are employed in various biological applications.117, 118   
 
HCA derivatives display their effects on cell membrane stabilisation through 
their anti-hypoxic, hepatoprotective and anti-inflammatory mode of action.  It 
has been reported that there is a direct relationship between the antioxidant 
activity and the membrane stabilisation activity of these compounds.  HCA 
derivatives (p-caumaric (35), ferulic (36), and caffeic (37) acids) also 
demonstrate high antibacterial, antifungal activity and also antiviral activity119.  
Some of the alkyl and cycloalkylamino derivatives of cinnamic acids also exhibit 
hypolipidemic and antiatherosclerotic effects120 (Figure 1.7).  Several adenosine 
combining hindered phenolic antioxidant species are found to be biologically 
active and useful in various therapeutic applications.121  
 
Figure 1.7: Examples of derivatives of hydroxycinnamic acids.   
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1.3 Adenosine 
Antioxidants are not only radical scavenging and H-transfer molecules, but they 
can also generate an effect through switching on endogenous cellular 
antioxidant mechanisms.  Many clinical and experimental studies have 
confirmed that stimulation of the adenosine receptor activates the antioxidant 
mechanism of enzymes.122, 123  By stimulating neutrophils, adenosine inhibits 
the superoxide anion generation.  This adenosine-induced inhibition acts via 
activation of cell surface receptors without cellular uptake of adenosine.124  
Neuronal cells are highly sensitive to free radical induced oxidative stress.  
Adenosine is used as a neuro-protective agent in the condition of free radical-
induced ischaemia-reperfusion injury and ischaemic stroke.125   
1.3.1 Structural features of adenosine 
Adenosine (39) is a naturally occurring nucleoside, formed during physiological 
processes by degradation of the adenosine triphosphate (ATP) nucleoside (a 
cell energy source).  Its structure is composed of an adenine-based purine 
nucleoside attached to a ribose sugar at the N9-position.  The ribose sugar ring 
is numbered independently in the chemical structure (Figure 1.8).  Adenosine 
derivatives are usually synthesised by modification at the exocyclic amine (N6), 
the heteroaromatic ring carbon (C2) or the exocyclic (C5) ribose ring methylene 
group.  Adenosine is the only endogenous agonist for adenosine receptors and 
regulates a number of physiological processes through the activation of 
adenosine receptors.   
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Figure 1.8: Chemical structure of adenosine (39)  
1.3.2 Adenosine receptors 
A receptor is a protein macromolecular complex often found on the surfaces of 
the cell membrane that receives or transmits chemical signals through the cell 
wall.  The chemical signals are generated through the binding of a particular 
agent to these receptors which is extremely structurally selective.  A ligand 
binds to the receptor through various interactions including covalent, ionic, 
dipole–dipole, and ion–dipole, hydrogen bonding and the charge-transfer 
complex.  The binding of a ligand generates a chemical signal, which is further 
converted to a specific cellular and/or tissue response.  Several ‘drug-receptor 
interaction theories’ have been proposed to explain how a drug can generate or 
stimulate a specific biological response.126   
 
Several types of receptors are involved in various physiological processes.  One 
of these types of receptors is called a purinergic receptor.  They are involved in 
signalling actions mediated by purine nucleosides or nucleotides.  The term 
purinergic receptor is used to describe classes of plasma membrane receptors 
that are also called purinoceptors.  Purinergic receptors are involved in a 
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number of cellular functions including the migration of neuronal stem cells, 
proliferation, vascular action, apoptosis and cytokine secretion.127, 128  The 
purinergic receptors are categorised into three types: P1 (adenosine) receptors, 
P2Y (all nucleotides) and P2X (ATP), where P1 and P2Y are G-protein-coupled 
receptors (GPCR) and P2X are ligand-gated ion channels.129   
 
GPCRs are receptors with a peptide sequence that pass through the cell 
membrane seven times, and therefore, are known as seven-transmembrane 
domain receptors or 7TM receptors.  GPCRs are the most heavily targeted 
receptors in the pharmaceutical industry, because of their significant role in 
many diseases.  Resulting in 40% of modern drugs being based on targeting 
these receptors.130  GPCRs interact with different types of proteins and 
participate in several important biological functions.  They interact with hetero-
trimeric G-proteins (Figure 1.9) and with the accessory proteins called GPCR-
interacting proteins (GIP).131   
 
The GPCR couples with the membrane-associated heterotrimeric G-protein 
made up of G, G and G subunits.132  These subunits are in complex form 
when in the resting state.  The G subunit is the flexible signalling subunit.  In 
the inactive complex form, the G subunit binds to guanosine diphosphate 
(GDP).  After the activation of this receptors, a nucleotide-exchange reaction 
occurs on the G subunit and the GDP is replaced by guanosine triphosphate 
(GTP).133    
28 
 
These G-proteins exist in three different families of proteins including Gi, Gs and 
Gq, which express selectivity for particular receptors. Gs and Gi proteins 
stimulate and inhibit the adenylate cyclase enzyme, and Gq protein interacts 
with the enzyme phospholipase-C respectively.134  The G subunits of these G-
proteins differ in structure (Figure 1.9).   
 
 
Figure 1.9: Three-dimensional crystal structure of the G-protein coupled receptor (GPCR) embedded in the 
cell membrane attached to heterotrimeric G protein.
135 
Adenosine receptors are the P1-type G-protein coupled receptor, which are 
activated by the adenosine nucleotide released in cells.  The adenosine 
nucleotide is found in living cells and is involved in several metabolic functions 
through both intracellular and extracellular mechanisms.  In cells, adenosine 
participates in all metabolic processes, and its concentration is modified by 
pathophysiological conditions (i.e. during disease or disorder).136, 137    
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Adenosine is produced intracellularly by two metabolic pathways, which both 
involve the hydrolysis of AMP to adenosine by 5-nucleotidase followed by the 
catabolism of S-adenosylhomocysteine137 (Figure 1.10).  The adenosine 
concentration increases within the cell membrane during pathophysiological 
conditions and is released from the cell.  The released adenosine can then bind 
to adenosine receptors and acts as a local metabolic regulator or, what has 
been described as a “retaliatory metabolite”.138  Adenosine is also involved in 
the regulation of several types of cells including endothelial cells, smooth 
muscle cells and macrophages.139   
 
 
 
Figure 1.10: Intracellular adenosine synthesis.
140
 
Several studies have demonstrated the strong effect of adenosine purine 
nucleoside on the regulation of various physiological and biochemical 
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functions.141  The local tissue concentration of adenosine increases when 
exposed to oxidative stress.  This ischaemic event protects the heart from the 
further ischaemic injury, which has focused attention on understanding the 
protective effects of adenosine.142-144  Adenosine exerts its effect through 
several receptors called adenosine receptors.  Adenosine receptors are 
classified into four different receptor subtypes, namely A1, A2A, A2B, and A3 
subtypes20 (Figure 1.11).  These receptor subtypes are identified according to 
their pharmacological properties and cloning studies.  These adenosine 
receptor subtypes are members of the GPCR family, which are classified 
according to the receptor coupling to adenylate cyclase through Gi (A1, A3) and 
Gs (A2A, A2B) protein.  The receptor subtypes are involved in the inhibition (A1, 
A3) and stimulation (A2A, A2B) of adenylate cyclase activity and subsequent 
cyclic adenosine monophosphate (cAMP) production.145, 146   
 
Figure 1.11: Adenosine receptor activation.
147
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Adenosine receptors were first investigated as potential drug targets in 1981.148, 
149  Adenosine A1 receptor (A1AR) agonists are involved in cardiac arrhythmias 
and neuropathic pain.  Adenosine A2A receptor (A2AAR) agonists are useful for 
myocardial perfusion imaging and as anti-inflammatory agents.  Adenosine A2B 
receptor (A2BAR) agonists are used in the treatment of cardiac ischaemia.  The 
Adenosine A3 receptor (A3AR) subtype is involved in inflammation, cancer and 
cardioprotection.  These cardioprotective effects are generated through binding 
interactions of the four extracellular adenosine receptor subtypes.  The 
protective effect of adenosine in reperfusion injury has also been reported.150  A 
study of acute myocardial infarction showed that administration of adenosine 
reduced the infarct size.151, 152  In particular, adenosine plays a role in ischaemic 
preconditioning to protect the heart from ischaemia153 and also protects against 
acute myocardial infarction.   
 Adenosine A1 receptors (A1AR) 1.3.2.1
The A1 receptor is the first subtype of the G-protein coupled receptors that was 
discovered.  It is involved in a wide range of biological functions through 
different signalling pathways, which are based on the coupling of the A1AR to 
the different G-proteins.154, 155  In this mechanism, the A1AR agonist binds to the 
Gi1/2/3 and G0 proteins and inhibits the enzyme adenylate cyclase by decreasing 
the concentration of the secondary messenger cAMP.156, 157  The binding of the 
A1AR activates K
+ ion channels and inhibits Ca2+ ion channels that activate the 
enzyme phospholipase C158-160 throughout the body.   
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The A1AR are distributed widely throughout the body and mediate different 
biological functions.  This receptor is present in the brain, spinal cord, heart, 
liver, testis and white adipose tissues in higher concentrations.161  The A1AR is 
found in lower concentrations in the lungs, kidney and small intestine162, 163 and 
is present in the smooth muscles throughout the vascular system.164   
 
Activation of the A1AR is involved in several myocardial pathological conditions 
including ischaemia, reperfusion injury in arrhythmogenesis, coronary and 
ventricular dysfunction, and chronic heart failure.165-168  In the heart, stimulation 
by the A1AR acts as a myocardial depressant by decreasing the conduction of 
electrical impulses and suppressing the pacemaker cell function, resulting in a 
decrease of the heart rate.  A1AR have also been detected in several types of 
cancer, with suspicion that they may be involved in the stimulation of 
chemotaxis of tumour cells.169   
 Adenosine A2A receptors (A2AAR) 1.3.2.2
The adenosine A2AR was first suggested in 1979 by Calker et al. 
170 and in 
1980 by Londos and co-workers.157  A2AR are classified further according to 
their ligand binding affinity as A2AAR (high affinity for adenosine 0.1-1.0 µM) and 
A2BAR (low affinity for adenosine ≥ 10 µM) by Bruns
171 on the basis of initial 
work by Daly and co-workers.172  It is a type of GPCR, whose activity is 
mediated by G-proteins and stimulates adenylate cyclase and the synthesis of 
cAMP.    
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A2AAR are present throughout the body and are found in low abundance in the 
heart, lungs, blood vessels, and other areas of the brain.160.  These receptors 
are highly expressed in blood platelets, leukocytes, thymus, spleen and 
olfactory bulb.  These receptors have been involved in several 
pathophysiological conditions.  Current research has focused on developing 
new A2AAR agonists in order to determine the structure of the A2AAR receptor.  
This development has been achieved by cloning the A2AAR from several 
species including rat,173 human brain,174 mouse175 and guinea pig brain.176  The 
A2AAR agonists have also been found to increase blood flow during a cardiac 
nuclear stress test.177 
 
The A2AAR agonists play a key role in several diseases including 
inflammation,178 ischaemia-reperfusion injury179 and cancer180 and have 
cardioprotective effects.141  The A2AAR provides cardioprotection via 
vasodilatation by increasing myocardial blood flow, and by supporting the 
synthesis of new blood vessels as well as protecting tissues from collateral 
inflammatory tissue damage.181  The A2AAR is beneficial in controlling 
inflammatory leukocytes by reducing oxidative metabolites such as superoxide 
and H2O2 in activated neutrophils.
124, 182, 183   
 
The activation of A2AAR may contribute in the pathophysiology of glaucoma due 
to the increase in ocular perfusion pressure.184  Current evidence suggests that 
the increased internal ocular pressure (IOP) leads to blindness via induction of 
ischaemia and lowering IOP via blood reperfusion to cause ischemia-
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reperfusion injury and retinal inflammation.185  Intravenous infusion of 
adenosine in healthy volunteers led to the reduction of IOP and increasing 
blood flow to the optic nerves.  Experimental evidence has also shown that 
application of adenosine and selective A2AAR agonists induced dilation of retinal 
blood vessels via activation of A2AAR.
186  Therefore, A2AAR agonists might be 
an ideal agent in the treatment of glaucoma. 
 
In addition, activation of the A2AAR on cells of the immune system plays a role 
in controlling the activity of inflammatory cells including neutrophils, 
macrophages and T lymphocytes.  Therefore, A2AAR agonists may be 
applicable as endogenous regulators of inflammation and cardioprotection.187, 
188  However, A2AAR also negatively regulates over-reactive immune cells.  The 
A2AAR influence the activity of the indirect pathway of the basic ganglia in the 
brain.  In the brain, the A2AAR mediate the release of glutamate and dopamine, 
making them a potential therapeutic target for neurological diseases.   
 Adenosine A2B receptors (A2BAR) 1.3.2.3
The A2BAR are low-affinity GPCRs that are involved in the activation of 
adenylate cyclase.160  These receptors are small in number, and a high 
concentration of adenosine is needed to generate a response.  The adenosine 
A2BAR has been implicated in the proliferation and differentiation of mast cell-
mediated angiogenesis.189-191  Additionally, adenosine stimulates the production 
of interleukin 4 (IL-4) and IL-13 in mast cells via A2BAR activation.
192   
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A2BAR have been suggested to be present in a relatively high density in, the 
gastrointestinal tract, caecum, large intestine and urinary bladder. They are 
thought to be present at a lower concentration in the lung, blood vessels, eye 
and mast cells.193  Adipose tissue and the adrenal gland, brain, kidney, liver, 
ovary and pituitary gland are thought to have a very low concentration of the 
A2BAR.
160   
A2BAR are involved in several pathophysiological conditions including coronary 
artery disorders,194 atherosclerosis,195 pulmonary hypertension associated with 
lung disease,196 liver ischaemia–reperfusion injury,197 colitis198 and type II 
diabetes.193   
 Adenosine A3 receptors (A3AR) 1.3.2.4
A3AR are GPCRs that bind specifically to Gi/ Gq proteins and are involved in 
many pathophysiological functions.  Activation of the A3AR inhibits adenylate 
cyclase activity, which decreases the cAMP level and stimulates phospholipase 
C and D, resulting in the elevation of intracellular inositol 1,4,5-triphosphate and 
Ca2+ levels.199  The A3AR is involved in neutrophil degranulation in neutrophil-
induced tissue injury and the regulation of other immune cells of the innate and 
adaptive immune systems.  The A3AR also participates in intracellular signalling 
and stimulates mitogen-activated protein kinases including extracellular signal-
regulated kinase1/2 and p38 by upstream activation of protein PI3K.200   
 
A3AR are distributed widely in the body.  The A3AR can be detected using radio-
ligand binding and functional assays in organs from various species.  The 
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highest levels of these receptors are present in the testis, liver and brain. They 
are present at low levels in the central nervous system, placenta, heart, bladder, 
uterus, spleen, and eye of sheep, rats and humans.201-203  Some of the 
functional A3AR are detected on the cell surface.
204  Expression of the A3AR 
can be detected at the mRNA level in both rodent and human organs.  The 
A3AR is overexpressed in cancer and inflammatory cells, rheumatoid arthritis, 
psoriasis and Crohn's disease and exhibits low expression in normal cells.205-207  
Adenosine expresses itself in all the receptor-binding and biological functions 
via agonist and antagonist mechanisms.   
1.3.3 The concept of agonism and antagonism  
Endogeneous natural ligands, including hormones and neurotransmitters bind 
to their receptors, which induces a further biological response.  The ligand of a 
adenosine receptors induces a conformational change in the receptor (a 
transmembrane protein) which initiates the intracellular response.  The agonism 
and antagonism concept explains the different types of binding of a drug 
molecule to its receptor.   
 
Adenosine receptor selective ligands are synthesised by first studying their 
binding interaction with GPCRs and are usually categorised as (partial) 
agonists, neutral antagonists, (partial) inverse agonists, and positive and 
negative allosteric modulators.    
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Over the past two decades, it has become clear that the available GPCR 
ligands preferentially stimulate one signal-transduction pathway over another 
signalling pathway.  This phenomenon is referred to as functional selectivity or 
biased signalling.208-210  Biased signalling implies that an agonist for one 
pathway may act as an antagonist or inverse agonist for another signal-
transduction cascade.  Exploiting the functional selectivity of compounds is an 
important research field that will help develop drugs with fewer side 
effects.209,211  Selective activation of the beneficial signalling pathways without 
simultaneous activation of side effect-inducing pathways can be used to 
improve the therapeutic window of a drug.   
 
An agonist is a compound that binds to a receptor, reorients receptor and 
protein conformation, and causes similar biological actions as the endogenous 
species (such as hormones and neurotransmitters) which triggers the natural 
response.  An antagonist is a chemical or biological entity that inhibits the 
effects of a natural agonist ligands (hormone, neurotransmitter) and is also 
called a blocker of the receptor binding site or competitive inhibitors.   
 Adenosine agonists 1.3.3.1
An agonist can cause complete or partial effects when it binds to its receptor 
under different physiological conditions.  Agonists can be exogenous ligands 
(such as drugs) or endogenous ligands for the receptor.  Agonists are 
categorised according to the binding ability of the ligand as full agonists, partial 
agonists and inverse agonists (Figure 1.12).  Full agonists activate all sites of 
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adenosine receptors, and side effects are associated with receptor activation.  
Partial agonists bind to their receptor and show a partial response, and that can 
provide the solution to avoiding side effects by activating only the specific site of 
the receptor.212  The inverse agonists show a negative intrinsic effect or partially 
or fully block the receptor, resulting in low or no biological response and are 
also called antagonists. 
 
Figure 1.12: Mode of action of a agonists.
213
 
 Adenosine antagonists 1.3.3.2
Antagonists that bind at the same site as the natural ligands are called 
competitive antagonists, and agents that bind to mixed-receptor sites are known 
as nonselective or non-competitive antagonists (Figure 1.13).  Caffeine, 
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theophylline and other methylxanthines are non-selective antagonists for 
adenosine receptors.  Several antagonists are used in therapeutic 
applications.214  It has been proposed recently that antagonists of distinct 
adenosine receptor subtypes may be beneficial in the treatment of asthma215, 216 
or certain neurological diseases, such as Parkinson’s disease.217   
 
Figure 1.13: Mode of action of a competitive and noncompetitive antagonists.
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Adenosine mediates various physiological and pathophysiological functions via 
agonist and antagonist mechanisms.  All four adenosine receptors can be 
influenced differently via these mechanisms.  Structural modifications to the 
parent adenosine molecule can significantly change activity towards these 
receptors, which are essential in maintaining various pathophysiological 
conditions.  Specifically, cardiovascular diseases are a major health concern in 
40 
 
the world and therefore research has been focused towards the adenosine A2 
receptor subtypes, which are believed to be mainly involved in the 
pathophysiology of cardiovascular diseases. 
 
1.3.4 Active adenosine A2AR agonists and antagonists in clinical trials 
 Adenosine A2AAR agonists  1.3.4.1
In the past two decades, a number of biologically important agonists and 
antagonists that that can selectively exhibit A2AAR affinity, have been 
synthesised.  The study of these compounds has progressed further with the 
discovery of the importance of the A2AAR agonist–ligand interactions.  The C5- 
modification of adenosine produces the potent and nonselective adenosine 
receptor agonist 5-N-ethylcarboxamide (NECA) (Figure 1.14).   
 
Figure 1.14: Adenosine A2AAR agonists. 
Substitution at the C2-position of adenosine has been determined to be 
essential for the A2AAR activity and selectivity.  Most of the A2AAR agonists are 
synthesised by C2-modification of NECA (40). In this regard, the C2-modified 
ammonium salt of 4-[2-[(6-amino-9-b-D-ribofuranosyl-9H-purin-2-yl) thio] ethyl] 
benzenesulfonic acid (PSB 0777, 41) is a potent full A2AAR agonist that has 
41 
 
been reported to stimulate acetylcholine-induced contractions in rat intestine 
segments.218  This compound is expected to be potentially useful for the 
treatment of inflammatory bowel disease (Figure 1.14). 
 
C2-modified alkynyl linked adenosine compounds are also known to possess 
A2AAR agonist activity and selectivity.  In this regard, Apadenoson (48) is a 
highly selective A2AAR agonist’s which has potential utility as a pharmacological 
stress agent in myocardial perfusion imaging (MPI).219  The selective A2AAR 
agonist YT 146 (46) acts as a vasodilator that also inhibits the synthesis of 
inflammatory mediators to reduce ischemia/reperfusion injury.220  Furthermore, 
this alkynyl analogue HENECA (YT146, 46), is being studied for 
cardioprotective effects.221   
 
A synthetic analogue A2AAR-selective agonist UK-432097 (42) was designed for 
the treatment of chronic obstructive pulmonary disease, but it failed phase II 
clinical trials and still being used as an internal probe to examine the active site 
structure. The protein-binding capacity of C2-terminal amino acid conjugates, 
the A2AAR agonist CGS 21680
222 has been studied and it has shown 140 times 
greater selectivity for A2AAR compared with the A1AR and it has effects on 
neuronal transmission.223-225   
 
The highly selective A2AAR agonists Apadenoson (48) (Stedivaze
TM) and 
Binodenoson (CorVueTM) are in phase III trials for myocardial perfusion 
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imaging.226  Regadenoson (Lexican, 43) is used as a coronary vasodilator and 
Sonedenoson is being evaluated as a new therapy for wound healing and 
human diabetic foot ulcers.227  ATL313 (47), a A2AAR selective agonist 
profoundly protect the mouse liver from reperfusion injury (Figure 1.15).   
 
 
Figure 1.15: Pharmacologically active A2AAR agonists. 
 Adenosine A2AAR antagonists  1.3.4.2
A2AAR antagonists also play important roles in elucidating structure activity 
relationships (SARs) and are synthesised primarily by modification of the 
xanthine ring with caffeine and theophylline (from tea) as well-known examples.  
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The xanthine synthetic analogue DMPX (49)228 and the caffeine analogue (E)-8-
(3-chlorostyryl)caffine (CSC)229 were reported to be selective antagonists of the 
A2AAR.  In addition, the A2AAR antagonist Istradefylline (KW 6002, 51) has been 
used in the treatment of Parkinson’s disease to reduce the movement disorder 
(dyskinesia) caused by conventional anti-Parkinson’s drug therapy (Figure 
1.16).230, 231   
 
Further insights into the allowable structural diversity of receptor antagonists for 
these receptor subtypes were discovered through the X-Ray crystal analysis of 
a non-xanthine-based analogue ZM 241385 (51) bound to the A2AAR.  This 
compound has a 90-fold selectivity for the A2AAR over the A2BAR.
232  
Preladenant (SCH420814, 52) and several other similar analogues were 
developed with longer hydrophobic chains at the C2-position. These 
compounds were found to be highly potent and selective adenosine A2AAR 
antagonists and were intended for use in the treatment of Parkinson’s 
disease233 (Figure 1.16).   
 
Figure 1.16: Pharmacologically active A2AAR antagonists. 
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The hypotensive and bradycardic activity of adenosine was first investigated in 
1929 by Drury and Sezent Gyorgyi.234  Adenosine is currently used in the 
treatment of several cardiovascular diseases under the brand name Adenocard 
and Adenoscan.  The recent determination of the crystal structure of some 
adenosine receptors confirms that the 7TM topology is common between 
various families of GPCR receptors.  Adenosine receptor agonists have more 
beneficial effects than do antagonists, and the crystal structure provides 
information about the binding interaction of agonists to the protein receptors, as 
shown in Figure 1.17.   
 
 
Figure 1.17: Comparison of receptor-ligand interaction binding for the A2AR with the agonists adenosine 
(39) and NECA (62) along with antagonists ZM 241385 (51).
235
 Structure of human A2AR in cartoon 
representation are bound to the ligands (a) ZM 241385; (b) NECA; and (c) adenosine; (d,e) polar and non-
polar interactions involved in agonist binding to human A2AR are shown for NECA and adenosine. Figure b 
and c the hydrogen bond interactions (H3 and H7) activates the A2A receptor. However, these bonding is 
abscent in antagonists Figure a. Figure d and e van der waals interactions with amino acid residues. 
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There is a great deal of interest in studying GPCR–drug interactions, particularly 
those concerning the A2AARs.  A2AAR agonists that act in the periphery to cause 
vasodilation and to decrease blood pressure, can also induce cardiovascular 
side effects such as hypotension.188  These effects can trigger a baroreflex 
(body’s homeostatic mechanism to maintain blood pressure) in the heart, 
leading to increases in heart rate and cardiac output, and therefore the demand 
for oxygen.  These conditions would be seriously detrimental under prolonged 
ischaemic conditions and would work against any cardioprotective effects of 
A2AAR activation in cardiomyocytes.  However, it has been demonstrated that 
adenosine itself has cardioprotective effects during myocardial ischemia236 and 
reperfusion,237 and is expected that an A2AAR subtype-specific agent would 
cause fewer side effects.   
 Adenosine A2BAR agonists  1.3.4.3
Several ligands for the A2BAR have been identified in recent years
193, 238 and 
have been studied as pharmacological targets and to evaluate their therapeutic 
potential.  However, the important advances in identifying A2BAR agonists 
through improved in vitro pharmacological profiling have been recently 
published.239  Previous SAR studies of NECA and adenosine derivatives have 
indicated that N6 is a useful position for A2B receptor binding-site recognition.  
Some examples of N6-substituted adenosine derivatives endowed with 
satisfactory levels of A2BAR potency have been reported.  In particular, the 
introduction of (substituted) phenyl rings at the N6-position of adenosine led to 
the A2BAR selective compounds.
238   
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Based on some patent claims, a series of substituted 2-amino-4-phenyl-6-
phenylsulfanylpyridine-3,5-dicarbonitriles were synthesised as agonists for 
adenosine receptors.240  A series of five 2-amino-6-(1H-imidazol-2-
ylmethylsulfanyl)-4-(substituted) phenyl pyridine-3,5-dicarbonitrile derivatives 
has been also reported to display high-potency agonistic activity for the A2BAR 
over the A3AR subtype.
241  The A2BAR agonist 2-phenylaminoadenosine 
(CV1808, 53) has been shown to be effective as a coronary vasodilator and as 
an antihypertensive and antipsychotic agent.242, 243  The potent and highly 
selective non-adenosine compound A2BAR agonist 2-((6-amino-3,5-dicyano-4-
(4-(cyclopropylmethoxy)phenyl)-2-pyridinyl)thio)-acetamide (BAY60-6583, 54) 
has been shown to have similar potency to NECA 244, 245 (Figure 1.18).   
 
Figure 1.18: Adenosine A2BAR agonists 
 Adenosine A2BAR antagonists  1.3.4.4
Several A2BAR antagonists with high affinity and good selectivity have been 
identified among structures based upon a xanthine core suitably substituted at 
the 1-, 3- and 8- positions.246  Kim et al.247 reported that a substituted 
phenylcarbamoyl-methoxy-phenyl chain at the 8 position of a series of 1,3-
dipropylxanthines could specifically direct the antagonist activity to the A2BAR.   
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C8-modifications of adenosine analogues without a ribose ring are found to give 
the selective A2BAR antagonists that are also involved in cardiac actions.  In this 
regard, 3-ethyl-3,9-dihydro-1-propyl-8-[1-[[3-(trifluoromethyl)phenyl]methyl]-1H-
pyrazol-4-yl]-1H-purine-2,6-dione (GS6201, 55) attenuates an inflammatory 
response during acute myocardial infarction in mice and reduces caspase-1 
activity in the heart.195  The highly potent human A2BAR inverse antagonist N-(4-
acetylphenyl)-2-[4-(2,3,6,7-tetrahydro-2,6-dioxo-1,3-dipropyl-1H-purin-8-
yl)phenoxy]acetamide (MRS 1706, 56) with extended chain was reported to be 
a selective A2BAR antagonist with Ki value of 1.93 nM. (Figure 1.19).   
 
 
Figure 1.19: Adenosine A2BAR antagonists 
Despite the number of selective A2AAR agonists and antagonists that have been 
reported, only a few adenosine derivatives have succeeded in clinical trials for 
cardiovascular diseases.  This failure is due to widespread signalling effects of 
adenosine and unwanted side effects.  It was believed that dual acting 
adenosine molecule would be beneficial to overcome these complications.   
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1.4 Dual action adenosine agonists-Rationale for the research 
The focus of current research is shifting towards the development of lead 
compounds that can act on more than one target.  This modern approach to 
drug design combines two or more active parts of different molecules within one 
molecule to generate a multitargeted drug.   
The novel dual acting antioxidant 5-(3-methyl-pyrazole-5-ol-1-yl)-1,1,3,3-
tetramethylisoindoline-2-yloxyl (57) with an isoindoline nitroxide within the 
Edaravone structure is act as a potential active drug for cardiovascular101 and 
cerebrovascular ischemia in the brain-protection.248  The dual acting compound 
UA-8 ( 13-(3-propylureido)tridec-8-enoic acid, 58) provides the cardioprotective 
effect against the ischaemia-reperfusion injury249 (Figure 1.20). 
 
Figure 1.20: Dual action compounds in Ischaemia 
The majority of research on multi-targeted adenosine ligands has been carried 
out by Ken Jacobson and co-workers.  In 1985, Jacobson et. al. first published 
their investigation into adenosine “binary conjugates” molecules. These 
compounds are coupled to organic molecules such as peptides and amines and 
act as ligands at adenosine receptors (Figure 1.21).  This work initiated 
research that resulted in the coupling of both adenosine agonists and 
antagonists to biotin (a compound that forms a complex with glycoprotein 
avidin), substance P-receptor binding entities as well as lipids.  At the time, 
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some of the work was patented and many additional publications detailed the 
synthesis of bifunctional adenosine analogues.250   
 
Figure 1.21: Bifunctional adenosine receptor-binding analogues and binary conjugates. 
The broader interest in the field of binary conjugates of adenosine A1AR and 
A3AR agonists commenced with a publication in 2000, 
251 and a continuance of 
the original patent was granted in 2003.252  Further work in the field of 
bifunctional adenosine drugs rose again in 2003 when Liang and Jacobson filed 
a patent for the use of adenosine receptor agonists and antagonists together as 
a novel approach for treating ischaemic injury to the heart.252  In the patent, the 
activity of the binary conjugate MRS1528 (62) was explained, i.e. it acts as an 
agonist for the A3AR and as an antagonist at the A2AAR.   
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In 1986, Burns et al characterised the A2 adenosine receptors and termed them 
A2AR.  During the 1989s, Hutchison and co-workers found that C2-substituted 
adenosine compounds were selective A2AR agonist ligands and possessed 
hypotensive activity.253  In 1992, Cristalli and colleagues published further 
research that demonstrated that C2-substituted alkynyl linked with 5-
ethylcarboxamide adenosine compounds increased A2AAR selectivity.
254  In 
1997 255 and 2001,183 Martin and Sullivan et al further developed C2-substituted 
adenosine compounds by preparing compounds containing a 2-cyclohexyl 
linked with hydrazine chain (63) and an alkynyl chain (64).  These compounds 
enhanced A2AAR selectivity and were effective in coronary vasodilation and 
inhibiting human neutrophil oxidation.  Pfizer patented several C2-, N6- and C5- 
modified adenosine compounds (65 and 66) as anti-inflammatory agents with 
inhibition of neutrophil function at a concentration of < 40 nM 256 (Figure 1.22).   
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Figure 1.22: Pharmacologically active A2AAR and A3AR selective analogues. 
Interest in A2AAR has been rekindled by a finding that suggests both agonisms 
of this receptor and its inhibition by antagonists may have therapeutic 
applications.  In 2001, Ohta and Sitkovsky reported that A2AARs are 
imperatively involved in the limitation and termination of the prolonged 
inflammation.257   
 
In 2007, Gregg and co-workers published new research on dual acting A1AR 
agonists that contained antioxidant species and had the potential to produce 
cardioprotective effects.258  Furthermore, in 2009 and 2012, Foitzik and Hausler 
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reported the cardioprotective effects of A2AAR selective adenosine 
compounds259 attached by an aminoethylaniline linker possessing antioxidant 
functionality, which were shown to reduce ROS activity.  The C2- and C5- 
modified adenosine compounds VCP874 (69) and VCP728 (70) attached by an 
aminoethylaniline linker were shown to have an excellent A2AAR potency and 
selectivity.  They demonstrated good EC50 values of 45 nM and 6.6 nM, 
respectively121 (Figure 1.23).   
 
Figure 1.23: Pharmacologically dual-action antioxidant coupled A2AAR and A3AR-selective analogues. 
Adenosine compounds that act via A2AAR on leucocytes significantly inhibit the 
inflammatory process.  Adenosine compounds with the para-(2-
aminoethyl)aniline linker at the C2-position are known to have A2AAR selectivity.  
Attachment of the antioxidant structure by a flexible linker is predicted to 
contribute to the A2AAR pharmacophore, improving A2AAR selectivity and thus 
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localising antioxidant function to the desired site of action.  Once positioned, this 
can move in the vicinity of its intended site of action, scavenging cytotoxic ROS 
before they can cause further injury (the antioxidant species will be active from 
the moment of administration and the ROS scavenging properties are therefore 
not strictly limited to A2AAR orthosteric site, but apply more generally) (Figure 
1.24).   
 
The value of this approach has been given support by binding studies 
undertaken using molecular modelling that have analysed the crystal structure 
of bifunctional compound 70.  Here the attached antioxidant moiety would 
extend beyond the orthosteric binding site of the adenosine derivative.  The 2.7 
Ǻ-resolution crystal structure of the human A2AAR agonist in complex with a 
selective A2AAR agonist UK-432097 has shed light on the ligand-induced GPCR 
binding and activation260 (Figure 1.24).121   
A  B  
Figure 1.24: Adenosine receptor crystal structure in complex with A)UK-432, 097 (42), B) compound 
VCP728 (70).   
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Currently, there is a need for potent A2AAR agonists with combined antioxidant 
species to test this theory.  In addition, cardiovascular and other inflammatory 
diseases have complex pathogenesis, and currently available adenosine and 
antioxidant compounds are still not able to do enough on their own, treating only 
a limited number of these complications.  Treatment involving adenosine 
analogues have selectivity problems and hence forming unwanted side effects 
and low efficacy.  Antioxidant therapy is more effective in a combination of other 
related treatments.   
 
These days, it is common practice to administer a cocktail of drugs with 
complementary effects to patients.  However, this combined drug therapy 
introduces complications associated with pharmacokinetics, distribution, toxicity, 
and patient's compliance and elevate the risk of side effects.  To circumvent 
some of these issues, the focus of current research is shifting towards the 
generation of multi-targeted lead compounds.  This new generation of designed 
drug compounds combines two or more active parts in a single molecule that 
each initiates independent but complementary action when administered.  A 
single administration of multi-targeted compounds can have benefit in the 
predictability of their pharmacokinetics (PK) and pharmacodynamics (PD) 
properties and also in improved patient compliance.  It is anticipated that, this 
bifunctional approach could have beneficial effects from the combined entities 
which would not only be additive but synergistic in nature, resulting in increased 
efficacy.    
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It has been demonstrated that both the stimulation of adenosine receptors and 
presence of antioxidants such as nitroxide radicals have independently shown 
beneficial effects in reducing the duration of ischemia.  These effects also limit 
ischemia-reperfusion injury in models of acute myocardial infraction.  It was 
proposed that compounds that possess both adenosine-receptor binding and 
antioxidant capabilities would demonstrate potent cardioprotective actions and 
be more effective than the two independent moieties. 
The goal of this project therefore was to explore multi-targeted compounds that 
can act as selective A2AAR agonists.  These compounds (some initial target 
structures are shown in Figure 1.25 and 1.26) would also possess a moiety that 
is able to react with ROS (and other free radical species).  Thus, these 
compounds could potentially act as effective preventive treatments for 
inflammatory diseases and also provide cardiovascular protection. 
 
Figure 1.25: Antioxidant coupled p-aminoethylaniline linked adenosine target compounds (Series 1).  
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Figure 1.26: Antioxidant coupled with ethynyl (Series 2) and ethyl (Series 3) linked adenosine target 
compounds. 
The aim of this project therefore is to synthesise a range of bifunctional 
compounds which would ideally provoke cardioprotective responses when 
administered to people experiencing ischaemia, and at the same time limit 
reactive radical-based reperfusion injury.   
 
  
57 
 
 
 
 
 
 
 
 
 Results and Discussion Part A: Adenosine 2
analogues with para-aminoethylaniline linker 
possessing antioxidant moieties 
 
 
 
 
 
 
 
 
  
58 
 
2.1 Preliminary Considerations 
There have been many efforts to attempt to elucidate the various SARs for the 
adenosine receptor subtypes.  These efforts are continuing, and the 
understanding of key structural features has improved, which is essential to 
enhance subtype affinity and selectivity.256  Most of the current adenosine 
receptor ligands are based on the structure of endogenous adenosine, and 
therefore tend to be polar in nature.261  The nitrogen atoms at position 3 and 7 
on the adenosine structure are particularly essential for high affinity for the 
adenosine receptors (Figure 2.1).256, 262   
 
The ribose moiety attached to the N9-position of the adenosine molecule is the 
β-D-ribofuranose stereoisomer.  The experimental evidence clearly indicates 
that the ribose group binds to the receptor pocket via its hydroxyl groups and, 
therefore, is essential for binding affinity and adenosine receptor activation.263  
Further evidence shows that the adenosine molecule is arranged in an anti-
conformation within the receptor binding pocket, and thus the essential 
pharmacophore must possess this particular ribose stereoisomer.264  This 
ribose stereoisomer with at least one free 2- or 3-hydroxyl group is necessary 
for the agonist activity at adenosine receptors.   
 
Although all available ribose hydroxyl groups are hydrogen-bonded to the 
receptor pocket, modifications at the C5- and even C3-position are known to 
be tolerated.256  Even the furanose oxygen can be replaced by a carbon with 
retention of activity.261  In addition, C2-256 and N6-positions on the purine ring 
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are most tolerant towards modifications with other groups.  Indeed, structural 
modification at C2 and N6 is thought to be responsible for the increased 
receptor subtype selectivity and affinity.265  Most of the C6-modifications on the 
purine ring undertaken to date lead to more potent and selective A1AR agonists.  
However, co-substitution at the C2- and N6-positions does not necessarily lead 
to additional affinity for the A2AAR over the A1AR.
265, 266   
 
The C6–amino proton appears to be necessary for high receptor affinity.263  
This property may indicate either some unfavourable steric interaction for 
N,N-disubstituted adenosine analogues or a hydrogen bond forming the role of 
the C6-amino proton with the N6 binding domain of the orthosteric binding site.  
However, certain bulky N6-substituents are known to be A2AAR tolerated such 
as the hydrophobic 6-diphenylethylamino group.  Almost all other N6 
modifications considered favour A1AR affinity.  Non-bulky modification at the 
endogenous C6–amino223, 262, 267-269 group is also known to be tolerated by 
A2AAR.
270  Consequently, the additions of non-bulky side chains at the 
C6-amino group were employed for all of the synthetic targets used in this 
project.  
 
The 5-modification most essential for an increase in agonist receptor affinity 
such as the N-ethylcarboxamide moiety (5-NECA).  The NECA itself is a 
prototypic A2A adenosine receptor agonist.
223, 266, 268, 271  This modification is 
also known to improve pharmacokinetic stability to adenosine derivatives 
because of the lack of interaction with adenosine deaminase.270  An ethyl amide 
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at the C5- position is better tolerated by the A2AAR, however, larger alkyl 
groups bound to the amide decrease the receptor affinity.  These characteristics 
suggest either a critical role for the amide proton in forming a hydrogen bond 
with the C5- binding domain of the orthosteric site or a severe steric limitation 
encountered within the C5-binding domain.270  Therefore, the 5-NECA moiety 
was selected as the only modification at the ribose 5-position.121  The critical 
points of chemical reactivity for the adenosine derivatives are labelled in Figure 
2.1.   
 
Figure 2.1: Adenosine A2AAR selective compound CGS21680 (74). 
Compounds possessing C2-substituted groups are typically selective for the 
A2AAR, and exhibit high affinity and specificity for the A2AAR.  Much attention 
has focused on the development of aryl-alkyl amino substituents with the aim of 
increasing the potency and selectivity of A2AAR agonists
272 (in fact, these are 
reported mainly as having decreased A1AR affinity and activity).
223  The C2- 
binding domain of the orthosteric site, therefore, sits at least largely (if not 
totally) distal to the N6 and purine riboside binding domains, and has a critical 
polar interaction adjacent to C2.266  It is otherwise hydrophobic in nature, 
preferring aromatic rings attached via two methylene groups to the polar C2-
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linking atom (Figure 2.1).  The size of the hydrophobic C2-domain appears to 
be better suited to an attached aromatic ring because the affinity of the 
saturated cyclohexyl-bearing compound is significantly less than that of C2-
arylalkyl amino compounds.265   
 
It is proposed that a linker involving a ‘bulky’ substituent linked with a two 
carbon chain at the C2-position of adenosine could endow the generated 
analogue with some subtype selectivity at adenosine receptors.  C2- 
substituents are well tolerated, and a range of different substituents display 
variations in subtype selectivity.  In particular, A2AAR selectivity appears to be 
maximised by an electronegative bonding atom,261-263, 265, 267, 270, 272 a two or 
three-atom spacer and a bulky, nonpolar group such as a cyclohexyl or phenyl 
ring,259, 263 which can be itself further substituted.   
 
It has been further proposed that the introduction of radical species attached to 
the bulky linker substitution at C2-position of adenosine may improve the 
receptor subtype selectivity and also be able to scavenge free radicals present 
at the site.  To test this theory, it was speculated that the antioxidant moieties 
be tethered to the receptor binding adenosine using a ‘linker side chain’ that 
would extend outside the binding pocket of the receptor.  In such compounds, 
the antioxidant functionality would still be joined to the receptor binding entity, 
but, the ability of such dual action compounds to interact with the receptor 
would not be compromised.   
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Another advantage of the ‘linker’ approach with an aniline-based unit such as 
the aryl alkylamino chain linker would be that the antioxidant portion of the 
molecule would be located outside the hydrophobic part of receptor pocket.  
The antioxidant fuctionality would consequently interact more easily with 
reactive free radical species.121   
 
In the literature of adenosine analogues, a number of different linker groups 
have been used.  This linker groups were used to bridge from the receptor-
binding adenosine functionality to another moiety, including a fluorescent group, 
a radiolabelled group, or another receptor binding entity.  The compound 
CGS21680 (46) has been shown to possess high affinity and specificity at the 
A2AAR.  By incorporating the commercially available para-(2-aminoethyl)aniline 
(124), which has an aniline ring attached through an ethylamino group at the 
C2-position in the target compounds.  This type of compound preserves the 6-
carbon distance between two amino groups and also maintains high A2AAR 
selectivity (Figure 2.1 and 2.2).   
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Figure 2.2: Candidate moieties  and their actions in the initial structural class of target adenosine 
analogues. 
In this study, all three series of compounds were synthesised with C2- 
substitution on the adenosine NECA molecule.  Further design and different 
extensions to this structural C2-modification on adenosine was achieved with 
appropriate linker groups and the desired antioxidant function.  This approach 
confers a bifunctional mode of action upon the target molecules without 
compromising binding efficiency.   
 
Nucleophilic C2-substitutions on adenosine can be accessed via an SNAr 
(nucleophilic aromatic substitution) process.  The literature provides an example 
of the most nucleophilic atoms (i.e. S265, 273, 274, O261, 266 and N,121, 223, 259, 274), 
which are primary choices of nucleophilic atoms that can be used to attack at 
the C2-position of adenosine.  This position is activated for SNAr by the 
installation of a lower (highly electronegative) halogen atom (F, Cl, I).  These 
synthetic variables are discussed below in further detail.   
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2.2 Synthesis of C2-substituted TMIO adenosine analogues 
possessing substituents attached by the 
‘aminoethylaniline linker’ moiety 
The initial adenosine-based synthetic targets of this work can be synthesised 
using two different approaches.  In the first approach, the appropriate carboxy 
nitroxide bearing an amine functionalised linker is generated and then coupled 
to the adenosine intermediate 146 (Approach 1)(Scheme 2.1).   
 
Scheme 2.1: Overview of first approach retro-synthesis of 161. Reagents and conditions:  EtOH, DIPEA 
75-80 °C; 
In the second approach, the amine functionalised linker is first attached to the 
adenosine intermediate to give compound 159 which is then coupled with the 
appropriate carboxy nitroxide (Approach 2) )(Scheme 2.2).   
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Scheme 2.2: Overview of second approach retro-synthesis of 161. Reagents and conditions: EDCI/HOBt, 
DMF, DIPEA 25 °C. 
The published methodology using approach 1 for achieving these targets first 
involves the synthesise of an appropriately functionalized carboxy nitroxide and 
its subsequent reaction with the 4-(aminoethyl)aniline linker chain (127).  The 
resulting compound can then coupled with C2- and C5- modified adenosine 
intermediates (146).  To generate the desired target 127, the first step was to 
synthesise the appropriate carboxy isoindoline nitroxide 106. 
2.2.1 Synthesis of antioxidant carboxy nitroxide intermediates 
possessing substituent attached to ‘aminoethylaniline linker’ 
moiety (127).  
 Synthesis of antioxidant carboxy TMIO intermediate (106) 2.2.1.1
The stable nitroxide 5–carboxy-1,1,3,3-tetramethylisoindoline-2-yloxyl (CTMIO) 
(106) is typically synthesised from commercially available phthalic anhydride 
(98) using the five-step procedure published first by Bottle et al.275  However, a 
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useful intermediate, brominated isoindoline precursor 5-bromo-isoindoline 
(102), is synthesised according to the method developed by Micallef et al. in 
1999276 from an adaptation of published methods (Scheme 2.3).   
 
 
Scheme 2.3: Synthesis of 5-carboxy-1,1,3,3-tetramethylisoindoline-2-yloxyl (C-TMIO) (106).Reagents and 
conditions:(i) Glacial CH3COOH, reflux 75 min., 83%; (ii) Mg, CH3I, toluene, reflux 3.0 h; 31% (iii) Br2, 
DCM, AlCl3, 0
o
C 1.0 h, 65% (iv) dry CO2, THF, n-BuLi, 30 min, 83% (v) Na2WO4.2H2O, H2O2, NaHCO3, 
Stir 72 h. 77%. 
Commercially available phthalic anhydride (98) and benzylamine (99) were 
reacted in a nucleophilic acyl substitution reaction to generate N-benzyl 
phthalimide (100) in an 83% yield.  Compound 100 was then tetramethylated in 
a Grignard reaction using methylmagnesium iodide to form 2-benzyl-1,1,3,3-
tetramethylisoindoline (101) in 31% yield.  Compound 101 was then brominated 
and subsequently debenzylated in a single-step procedure to obtain 5-bromo-
1,1,3,3-tetramethylisoindoline (102) in a 65% yield.  Compound 102 was 
lithiated and quenched with carbon dioxide to give intermediate compound 5-
carboxy-1,1,3,3-tetramethylisoindoline.  In situ sodium tungstate and hydrogen 
peroxide oxidation of the crude intermediate compound afforded the desired 
67 
 
nitroxide 5-carboxy-1,1,3,3-tetramethylisoindoline-2-yloxyl (106) in a yield of 
77% over two steps.(Scheme 2.3).   
The antioxidant carboxy TMIO 106 was then in hand to react with linker 4-(2-
aminoethyl)aniline moiety (124) to generate the appropriate antioxidant bearing 
side chain to synthesise the C2-modified adenosine target compound (161).   
 Synthesis of antioxidant carboxy TMIO coupled with para-2.2.1.2
(aminoethyl)aniline chain linker (127). 
The antioxidant-bearing side chain 127 was initially synthesised separately in a 
three-step reaction sequence involving coupling of the core compound 124 with 
the antioxidant carboxy isoindoline nitroxide 106 to form a stable amide (125).  
In the first-step, the more reactive primary aliphatic amine of the commercially 
available compound 124 was protected with di-tert-butyl dicarbonate to give the 
mono-Boc-protected compound N–tert-butoxycarbonyl-2-(4-aminophenyl) 
ethylamine (125) (Scheme 2.4).   
 
Scheme 2.4: Overview of N-Boc protection of linker amine. Reagents and conditions: (i) (Boc)2O, DCM, 
100 min., 89%. 
This was accomplished using a standard amine N-boc-protection method using 
di-tert-butyl dicarbonate.277, 278  Dichloromethane (DCM) was substituted for 
chloroform as the solvent for convenience, and the reaction was maintained at 0 
°C to minimise undesirable reactivity at the 4–aminophenyl group.  After 100 
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min, the starting material was consumed and < 5% of the undesired di-boc-
protected species was recovered.  The reaction was conducted on a 1–2 g 
scale.   
 
The primary aliphatic amine is a stronger nucleophile than the aniline and 
attacks the anhydride carbonyl to form the sp3 hybridised intermediate.  
Reformation of the carbonyl eliminates a tert-butyloxycarboxylate anion, which 
quickly releases CO2 and the tert-butoxide anion.  This anion abstracts the extra 
proton from the Boc-protected amine to form the product 125 and tert-butyl 
alcohol (Scheme 2.5).  The addition of the boc group to the primary amine 
lowers the overall polarity of the compound, giving an Rf value of 0.67 in (9:1) 
DCM/MeOH.   
 
 
Scheme 2.5: Mechanism of N-boc protection of linker amine 
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The structure of 125 was supported by 1H NMR and 13C NMR spectroscopy and 
mass spectrometry (MS) with the obtained spectra in agreement with the 
published values.  The Boc-protected amine was characterised using electron 
ionisation MS (EIMS), which showed the expected molecular ion of M+Na at 
259.1433 m/z (EI+ (HRMS) showed a deviation of 0.0011 from a calc. mass of 
C13H20NaN2O2) and by a melting point of 56–58°C which supported the 
successful synthesis of 125.121  In the 1H NMR spectrum, a new peak appeared 
as a singlet at 1.45 ppm for the nine protons of the tert-butyl group.  In the 13C 
NMR spectrum, three additional peaks appeared.  A strong peak corresponding 
to the equivalent Boc carbons appeared at 28.4 ppm, the quaternary Boc 
carbon appeared at 79.1 ppm, and the new Boc-amide carbonyl appeared at 
155.9 ppm.   
 
The Boc-protected amine linker (125) was coupled with the carboxylic acid 
functionality of isoindoline nitroxide antioxidant 106 to form an amide. The 
standard peptide coupling agent EDCI and reaction conditions were employed 
in the formation of the amide.   
 
The novel compound N-tert-butoxycarbonyl-2(4-N-(5-carboxy-1,1,3,3-
tetramethylisoindoline)aminophenyl)ethylamine (126) was synthesized from 
compound 125 following the published procedure for amide coupling by 
employing the carboxy isoindoline nitroxide compound 106 and EDCI in the 
presence of HOBt to give N-tert-butoxycarbonyl-2(4-N-(5-carboxy-1,1,3,3-
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tetramethylisoindoline)aminophenyl)ethylamine (126) in 77% yield (Scheme 
2.6).   
 
Scheme 2.6: Overview of EDCI amide coupling of CTMIO nitroxide with para-aminoethylaniline linker 
moiety (127), Reagents and conditions: (i) EDCI/HOBt, DMF, DIPEA 25 °C, 77%; (ii) 4 M HCl solution, 1,4-
dioxane:water(1:1), 55–60 °C, 5 h.,89%.  
1-Ethyl-3-(3-dimethylaminopropyl)carbodiimide hydrochloride (EDCI) acts as an 
acid activating agent, forming O-acylisourea a reactive ester intermediate in situ 
with the carboxylic acid of the antioxidant moiety.  This O-acylisourea formed 
has an activated leaving group and is attacked by the 1-Hydroxybenzotriazole 
hydrate (HOBt) to form HOBt ester.  A thermodynamically stable urea by-
product is released.  The nucleophilic aniline is reacted with HOBt ester to give 
the novel amide target (Scheme 2.7).   
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Scheme 2.7: Mechanism of EDC promoted amide formation. 
Compound 126 appeared on a TLC plate as a single spot, at a Rf value of 0.64 
in ethyl acetate/pet ether (8:2).  Compound 126 contained a free radical species 
and was difficult to characterise by 1H NMR and 13C NMR spectroscopy as 
paramagnetic broadening was observed, however signals of the aniline linker 
moiety could be detected.  The melting point of product 126 was 158–160 °C.  
The structure of 126 was supported by HRMS, which showed the expected 
molecular ion of M+Na at 475.2450 m/z (EI+ (HRMS) showed a deviation of 
0.0010 from a calc. mass of C26H34NaN3O4).   
 
The acid-labile Boc-protecting groups of the amide linkers were then removed 
using 4 M HCl to provide the novel primary amine 2-(4-N-(5-carboxy-1,1,3,3-
tetramethylisoindoline)4-aminophenyl)ethylamine (127) (Scheme 2.6).  The 
nitroxide containing linker compound 126 was stirred at 55–60 °C for 2–3 h in a 
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mixture of 1,4-dioxane and water with a dropwise addition of 4 M HCl over 10 
minute.  Analysis by TLC indicated a loss of starting material, and ninhydrin 
staining highlighted the generation of a product expected to be the reformed 
primary amine 127 on the TLC plate with an intense purple colour with an Rf of 
0.46 in chloroform/methanol (9:1).  The compound was purified by column 
chromatography to give an 89% yield of the deprotected primary amine product 
127 with the sharp melting point of 176–178 °C.  
 
The structure of 127 was supported HRMS, which showed the expected 
molecular ion of M+H at 353 m/z (EI+ (HRMS) showed a deviation of 0.0011 
ppm from a calc. mass of C21H27N3O2).  In the 
1H NMR spectrum, paramagnetic 
broadening was observed due to the nitroxide radical that resulted in some 
signals not being detected or giving poor integration.  However, signals 
corresponding to the aniline and the ethylene linker moiety could be detected, 
the aromatic signals at 7.21 and 7.61ppm.   
2.2.2 Synthesis of C2-substituted adenosine intermediates (146) 
Adenosine receptors were first investigated as a potential drug target in 1981148, 
149 and the compound NECA was quickly identified as the prototypic A2 
adenosine receptor agonist.279  Adenosine analogues with amide functionality at 
the C5-position have been the focus of research since that time.  Further 
investigation of the A2A adenosine receptor in 1990
280 and the discovery that the 
C5 amide adenosine analogues are active at this receptor has subsequently 
prompted more work in this area.   
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 Convergent approach to synthesis of adenosine intermediate  2.2.2.1
A general synthesis of C2-modified N-alkyl-5-N-carboxamide was published by 
Jacobson and Kim et al. in 1994 and has been subsequently adopted as the 
standard procedure for generating such analogues.  The synthetic route most 
commonly reported in the literature 223, 259, 263, 272, 274, 281-283 has several 
drawbacks for the targets of this research project.  Convergent synthesis has 
been performed on numerous occasions with varying degrees of success, and 
this approach was initially explained here.  Such synthetic methods involve 
separate modification of the appropriate –D-ribose sugar, followed by a 
Vorbrüggen coupling of the anomeric N9 of the purine ring compound. This 
compound has been modified at C6 and which can then be substituted at C2 as 
required259, 262, 270, 272, 274, 281, 282 (Scheme 2.8).   
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Scheme 2.8: Convergent approach to adenosine A2AAR agonists: Reagents and conditions: (i) Candida 
rugosa lipase, 1,4-dioxane, 0.1 M sodium phosphate buffer (pH = 7); (ii) TEMPO/BAIB, MeCN/H2O (1:1); 
(iii) EDCI, DMAP, MeOH; (iv) R-NH2, t-BuOH, 80 °C; (v) HMDS, MeCN, (NH4)2SO4, TMSOTf; (vi) EtNH2, 
THF; (vii) R-NH2, EtOH, 120 °C. 
The literature shows that the convergent approach gives poorer yields than a 
linear approach.  Modification of the ribose ring has proved challenging, time-
consuming, and only produced moderate yields.  The Vorbrüggen reaction was 
difficult to scale up, and substitution at the 2-chloro requires sufficiently harsh 
conditions, which threaten the stability of the ribose and antioxidant moieties. 
Instead, a linear approach proved more reliable than the convergent method 
and afforded acceptable yields.259   
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A linear synthetic approach to this class of compounds tends to have many 
steps and, therefore, provides reduced overall yields.  The literature proves that 
the potential starting materials, including inosine284, 285 and xanthosine286, 287 
derivatives, are often difficult to work with.  This difficulty is because of their 
poor solubility, which requires the use of harsh reaction conditions including the 
use of DMSO, DMF, and strongly acidic media.  In addition, the similarity in the 
reactive groups, which make the regioselectivity modification difficult.  This 
linear synthetic approach towards C2-substituted adenosine compounds was 
based on the work of Hutchison and was improved upon here by modifying the 
methods of Foitzik121, 259 and Scammells.121  This work began from guanosine 
as the starting material and progressed to selective N6-, C2- and C5-modified 
adenosine derivatives.  The single change of 5-ethylcarboxylate was 
introduced instead of 5-methylcarboxylate in this scheme because of 
convenience and because it produced a better yield and improved the quality of 
the product synthesised.  The synthetic methodology was published121, 259 and 
is presented here in detail as it pertains to this project.   
 Adenosine intermediate for C2-functionalization with a linear 2.2.2.2
approach121 
The planned series of adenosine target compounds was obtained successfully 
via the 2-fluoro-2,3-O-isopropylideneadenosine-5-N-ethylcarboxamide (146) 
intermediate, which was synthesised from guanosine in seven steps of efficient 
synthesis (Scheme 2.9).   
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Scheme 2.9: Overview of synthesis of the key adenosine intermediate (146). 
Because all of the target compounds bear the 5–NECA modification (Figure 
1.15 and 2.1), this was installed first.  Then C6-modifications were achieved 
with regioselective substitution by the installation of an active, leaving group at 
the C6-position (144). The nucleophilic aromatic substitution (SNAr)-reactive 
fluorine was achieved at C2 (145).  The C6-leaving group was quickly replaced 
by the amino group (146).  The detailed reaction steps are discussed below.   
 
The secondary 2,3-alcoholic groups of guanosine (138) are more nucleophilic 
than the primary 5-alcoholic group, which is the required target for our initial 
part of the synthesis.  To avoid any side reactions from these secondary 
alcoholic groups throughout the process, they were protected by forming a 
cyclic acetal with an isopropylidene-protecting group, according to the 
procedure originally outlined by Hampton288 (Scheme 2.10).   
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Scheme 2.10: Overview of 2, 3-alcohol protection (139)
288
 Reagents and conditions: (i) Acetone; 2, 2-
dimethoxypropane, 19 h. 75%. 
Another benefit of the formation of protected guanosine is the increasing 
solubility of the substrate in a variety of solvents other than DMSO.  Solubility of 
guanosine is one of the obstacles in the development of the efficient synthesis, 
and guanosine is a highly polar species and is less soluble in solvents other 
than DMSO.   
 
The reaction was carried out using the acid catalyst para-toluene sulfonic acid 
under anhydrous conditions with acetone as the solvent, however, acetal 
formation was hindered by the presence of water with 2, 2-dimethoxypropane.  
The workup involved using water and sodium bicarbonate to neutralise the 
acidic environment and to precipitate the desired product 2,3-O-
isopropylideneguanosine (139) in a yield of 75%.  Complete drying of product 
139 was very difficult because of the aqueous work-up, so a quick methanol 
wash was introduced after filtration of the product from the aqueous medium.  
The use of para-toluenesulfonic (tosic) acid in 10-fold excess as the acid 
catalyst aided the solubility of the substrate in this reaction because it formed 
acetone-soluble salts with the purine nucleoside.288  The isopropylidene 
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protecting group is very labile under acidic conditions, and all further reactions 
were carried out using neutral or basic conditions.   
 
Because of the overall length of the synthetic sequence, the first reaction was 
undertaken on a scale of 10 g of starting material. Yields were typically 
excellent (75-90%).  It remains a highly effective reaction in terms of its ease 
and general applicability to protect nucleoside 2,3–hydroxyl groups, and it 
continues to feature prominently in the recent literature.289,290,291,271, 292,293   
 
The reaction gives the single reaction product (as identified on TLC) with a Rf of 
the product of 0.72 in EtOAc/MeOH (7:3).  In the 1H NMR (d6-DMSO) spectrum 
of compound 139, two singlets appeared at 1.5 ppm and 1.3 ppm with an 
integral corresponding to three protons each.  In the 13C NMR spectrum, two 
additional signals corresponding to the two methyl groups of the acetal moiety 
appeared at 25.6 ppm and 27.5 ppm.  The melting point of product 139 is 260–
262 °C and is consistant with literature value.  The HRMS of the isolated 
compound supported the synthesis of 139, which showed the expected 
molecular ion of M+H at 324.1286, (EI+ HRMS showed a deviation of 0.0014 
ppm from the calc. mass of C13H18N5O5).   
  
The next step in the synthesis of 146 was the oxidation of the 5-hydroxy group 
of 139.  The traditional oxidising agents used to oxidise primary alcohols involve 
harsh conditions and toxic reagents (e.g., Cr(VI) oxides; periodate/ruthenium;294 
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KMnO4; Pd/O2).
295  The standard methods of oxidation of the 5-hydroxy group 
gave poor yields and were carried out in strong acidic or alkaline conditions, 
which resulted in degradation of the substrate.223  These methods can also 
create a problem with regioselectivity for compounds with more than one 
oxidisable group.  The 5-hydroxy group of compound 139 was then oxidised to 
the corresponding 2,3-O-isopropylideneguanosine-5-carboxylic acid (140).  
The Epp and Widlanski296 oxidation implemented using the mild oxidising agent 
system including, the free radical species TEMPO and a stoichiometric amount 
of the organic oxidant bis(acetoxy)iodobenzene (BAIB) (Scheme 2.11).295   
 
Scheme 2.11: Overview of the 5-hydroxyl oxidation (140). Reagents and conditions: (i) [Bis (acetoxy) 
iodo] benzene (BAIB), TEMPO, MeCN, H2O, 18 h,79%. 
This oxidation progressed under aqueous conditions (1:1 solution of 
acetonitrile/water) with the two-step mechanism that led to the formation of the 
aldehyde which was oxidised further to give the 5-carboxylic acid (Scheme 
2.11).  The aqueous conditions were used to allow the reaction to stir overnight 
(Epp & Widlanski296 (3 h) and Middleton292 (4 h).  In this process, the 
hydroxylamine formed was reoxidised to TEMPO in the presence of BAIB, 
which contains hypervalent (+3) iodine 279.  The nitroxide radical is very stable 
because of the absence of -protons on the ring, which can cause 
disproportionate reactions and form a cyclic hydroxylamine and nitrone.297 
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Although it is not completely proven, the following mechanism was proposed by 
de Mico (Scheme 2.12).293   
 
 
Scheme 2.12: Mechanism of the primary hydroxyl oxidation. 
The reaction has several additional benefits including the use of relatively non-
toxic reagents that can be used safely in the presence of a wide range of 
functional groups and protecting groups such as acetal and ethers296 and 
secondary alcohols.279  These reagents are highly selective for the oxidation of 
primary alcohols.279  The by-products of oxidation were iodobenzene and acetic 
acid, which could be easily removed via precipitation of the product from 
acetone and diethyl ether.298,289  Often, in oxidation reactions, the solution is 
homogeneous and opaque; however; in these reaction conditions, the solution 
was heterogeneous and biphasic before the workup.    
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The workup, which involved adding some acetone and then adding the solution 
to a large volume of Et2O, produced a precipitate. This precipitate was filtered 
and gave reliable crude yields in the range of 70–80%.  The Rf of compound 
140 in 4:1 EtOAc/MeOH returned to 0 (as identified on TLC) because of the 
increase in polarity around the 5-carbon from the introduction of the 
electronegative oxygen to form the carbonyl group.  The purification of the acid 
was not successful using recrystallisation and column chromatography.   
 
There are two main characteristics of the 1H NMR (d6-DMSO) spectrum of 
crude compound 140.  The signal at 3.54 ppm for the 5-methylene protons was 
absent because of their removal by the successful oxidation of the 5-carbon. 
Conversion to the carboxylic acid also removed the signal observed at 5.06 
ppm for the remaining hydroxyl proton.  In the 13C NMR spectrum, the signal for 
the oxidised 5-carbon moved 112 ppm downfield from the corresponding signal 
for 139 because of the powerful deshielding effect of the electron-withdrawing 
carboxyl group and reappeared at 171.37 ppm.  The melting point of the desired 
acid 140 was 210–212 °C259 and is consistent with literature value.  The 
synthesis of compound 140 supported by HRMS, which showed the expected 
molecular ion of M+H at 338.1134 m/z, (EI+ HRMS showed a deviation of 
0.0033 ppm from the calc. mass of C13H16N5O6).   
 
Despite evidence that the compound produced was desired target 140, purity of 
the carboxylic acid was not satisfactory.  Forming a novel intermediate ethyl 
ester 142 at the 5–carboxyl group was a more reliable and higher-yielding route 
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to the desired 2,3-O-isopropylideneguanosine-5-N-ethylcarboxamide (143).299  
Novel 5-ethylester 142 was synthesised under standard esterification 
conditions (Scheme 2.13).   
 
Scheme 2.13: Overview of 5–ethyl ester formation (142). Reagents and conditions: (iii) SOCl2, ethanol, 15 
h, 64%. 
Compound 140 was reacted at 0 °C in absolute ethanol with a fourfold excess 
of thionyl chloride to give the reactive acid chloride in situ.  The mixture was 
stirred at room temperature overnight, which allowed the ethyl ester to form 
through nucleophilic acyl substitution.300  The alcohol was used in large excess 
(as solvent) optimising the yield of 2,3-isopropylideneguanosine-5-
ethylcarboxylate (142) (Scheme 2.13).  The reaction solution was then basified 
with an excess saturated NaHCO3 solution to quench any remaining thionyl 
chloride and HCl.  The acidity of the conditions did not appear to affect the 
purine riboside linkage adversely.   
 
The workup involved removal of ethanol by distillation after basification, and the 
residue was stirred with the water to remove excess NaHCO3.  The desired 
product 142 was obtained in 65% yield.  The Rf of the product on TLC in 7:3 
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EtOAc/MeOH increased to 0.71 because of the decrease in polarity around the 
5-carbon from the introduction of the ethyl group to form the ester group.   
 
In the 1H NMR (d6-DMSO) spectrum of 142, a multiplet appeared at 3.7–3.9 
ppm with an integral corresponding to two protons and a triplet appeared at 0.9 
ppm for three protons of the ethyl group of the new ester substituent.  An extra 
two peaks corresponding to the carbon of the ethyl group also appeared in the 
13C NMR spectrum at 61.1 ppm and 13.8 ppm, respectively.  The melting point 
(272–274 °C) of the isolated compound 142 was consistant and sharp. The 
high-resolution mass spectrum of the isolated compound supported the 
synthesis of 142, which showed the expected molecular ion of M+H at 366.1449 
m/z, (EI+ HRMS showed a deviation of 0.0035 ppm from the calc. mass of 
C15H20N5O6).   
 
Compound 142 was converted to the desired 2,3-O-isopropylideneguanosine-
5-N-ethylcarboxamide (NECA) (143) by using liquid ethylamine (Scheme 2.14).   
 
Scheme 2.14: Overview of 5-amide formation (143). Reagents and conditions: (iv) Ethylamine, EtOH, -
20°C, 3 h. 88%.  
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Formation of the NECA 143 was achieved following a novel procedure by 
combining the 5-ethyl ester 142 directly in an excess of dry ethylamine that was 
used both as a reagent and as a solvent at a temperature of –20 °C for 3.0 h. 
The reaction mixture was allowed to room temperature and stirred overnight at 
room temperature. This overnight stirring was used for to react the unreacted 
starting material and to remove the excess of ethylamine. The reaction mixture 
was then diluted with absolute ethanol.  The product mixture was then adsorbed 
on silica and separated by column chromatography to obtain pure compound 
143 in an 82 % yield.   
 
The conditions were sufficient to enable nucleophilic acyl substitution of the 
ethoxy group by the nucleophilic amine to form the amide in excellent yield.  
The reaction was conducted no more than a 3 g scale.  Formation of the amide 
bond increased the polarity of the molecule, and the Rf value of compound 143 
declined to 0.43 (9:1 DCM/MeOH).   
 
The successful reaction to produce 143 was analysed by the 1H NMR (d6-
DMSO) spectroscopy.  A multiplet appeared at 2.7–2.9 ppm with an integral 
corresponding to the two protons and a triplet appeared at 0.6 ppm for three 
protons of the ethyl group of the new amide substituent.  An extra two peaks 
corresponding to the carbons of the ethyl group also appeared in the 13C NMR 
spectrum at 61.1 ppm and 13.8 ppm, respectively.  The results of analysis using 
HRMS and the melting point (278–280 °C) of the isolated compound were 
consistent with the expected results for desired compound 143, which showed 
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the expected molecular ion of M+H at 365.1574 m/z, (EI+ HRMS showed a 
deviation of 0.0001 ppm from the calc. mass of C15H21N6O5).   
 
Installation of a stable and effective leaving group was achieved by the 
(bezotriazole-1-yloxy)tris(dimethylamino)phosphoniumhexafluorophosphate 
(BOP)/ 1,8-diazabicycloundec-7-ene (DBU) method (Scheme 2.15) of Bae and 
Lakshman’s group.301  As the substrate was only sparingly soluble, the addition 
of DBU assisted the dissolution of the substrate, and stirring was continued 
overnight.   
 
Scheme 2.15: Overview of leaving group formation (144). Reagents and conditions: (v) MeCN, BOP, DBU, 
16 h, 25°C 98%. 
The role of the base is critical because it abstracts the N1-proton from the 
purine ring, which forms a tautomer with the nucleophilic C6-oxo anion.  The 
attack of the BOP reagent at the electrophilic phosphonium, forming an O6-
phosphonium intermediate and the nucleophilic OBt anion.  The OBt anion then 
attacks the now activated (partially positively charged) C6 in a SNAr addition–
substitution reaction, forming a Meisenheimer intermediate.299  Rearomatisation 
expels the phosphonium substituent to give the desired product and produces a 
highly thermodynamically stable phosphine oxide in the process (Scheme 2.16).  
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Scheme 2.16: Mechanism of leaving group formation. 
Different initiating bases have been explored in the literature302 and because 
DBU is widely considered the superior reagent, it was used here. Initial studies 
used BOP in its normal capacity as a coupling reagent to create a reactive in 
situ intermediate that would then undergo further immediate nucleophilic 
aromatic substitution.302,277  However, the intermediate itself, containing the O6-
benzotriazol-1-yl (6–OBt) moiety, is very stable and can be easily isolated in 
high yield and purity.301,289  This useful intermediate can be activated for 
nucleophilic aromatic substitution at the C6-position of the purine ring to then be 
one relatively straightforward diazotisation step away from the 2-halo series. 
The halogenated compounds provide starting material from which further 
substitutions at the critical C2-position of the purine ring in the A2AAR can be 
made.   
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The introduction of the benzotriazole group decreased the polarity around the 
C6-position of guanosine molecule to form the better leaving group. The Rf 
value of the product O6-(benzotriazol-1-yl)-2,3-O-isopropylideneadenosine-5-
N-ethylcarboxamide (144) decreased to 0.38 in 8:2 DCM/MeOH.  In the 1H 
NMR spectrum (d6-DMSO) of 144, four additional peaks from the phenyl 
protons of the heteroaromatic OBt substituent were located between 7.5 ppm 
and 8.3 ppm, with a multiplet at 7.55 ppm with an integral corresponding to one 
proton, a multiplet at 7.66 ppm with an integral corresponding to two protons, 
and a doublet at 8.19 ppm with an integral corresponding to one proton.  The 
multiplet at 7.66 ppm corresponds to the two aromatic protons furthest from the 
triazole heterocyclic and the doublet to the aromatic proton most proximal to the 
nitrogen–oxygen bond.  Six new peaks corresponding to the two quaternary and 
four proton-bearing OBt phenyl carbons appeared in the 13C NMR spectrum 
between 110 ppm and 130 ppm.  The melting point of the isolated compound 
144 was 140–142 °C.  The HRMS supported the synthesis of 144, which 
showed the expected molecular ion of M+H at 482.1898 m/z, (EI+ HRMS 
showed a deviation of 0.0002 ppm from the calc. mass of C21H24N9O5).   
 
Functional group interconversion of the C2-amine of compound 144 to the 
nucleophilic aromatic substitution-promoting fluorine was accomplished using 
the method of Kim et al.273 (Scheme 2.17). This method proceeded smoothly 
with good yields (60–75%) of 2-fluoro-O6-(benzotriazol-1-yl)-2,3-O-
isopropylideneadenosine-5-N-ethylcarboxamide (145) obtained on scales 
ranging from 50 mg to 2.0 g.    
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Scheme 2.17: Overview of fluoro substitution at the C2-position (145). Reagents and conditions: (vi) t-
BuONO, 70% HF in pyridine, 68%. 
The reaction conditions employed were reasonably harsh with HF (70% in 
pyridine) used as the fluorinating agent and pyridine as the solvent. This 
reaction required the temperature to be kept between –50 °C and –30 °C.  
Although distinguishable by TLC, the Rf value for the product 145 was 0.45 in 
1:4 P.S./EtOAc (Rf of 0.37 for the C2-amino compound 144).This change in Rf 
value indicates that the polarity of the molecule was decreased only slightly by 
the introduction of the highly electronegative fluorine atom.   
 
In the 1H NMR spectrum (d6-DMSO), the broad singlet at 6.68 ppm 
corresponding to the heteroaromatic aniline at the C2-position in 144 was not 
present in the product 145.  In the 13C NMR spectrum of the product 145, the 
peak for the C2-carbon of the purine ring was split by coupling with the fluorine 
to produce a doublet at 157.1 ppm with a coupling constant of 221.8 Hz.  
Further, less pronounced splitting occurred at C4 and C6 (J = 16.4 Hz).  No 
splitting was observed at sites more remote from C2.  The melting point of the 
isolated compound 145 was 145–147 °C.  The synthesis of isolated compound 
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145 was also supported using HRMS, which showed the expected molecular 
ion of M+H at 485.1699 m/z, (EI+ HRMS showed a deviation of 0.0007 ppm 
from the calc. mass of C21H22FN8O5).   
 
The labile benzotriazolyl leaving group present in compound 145 is readily 
displaced by nucleophilic amines.299, 302  Ammonia solution was used to form a 
6-amino product 2-fluoro-2,3-O-isopropylideneadenosine-5-N-
ethylcarboxamide (146) (Scheme 2.18).  This SNAr reaction occurred smoothly 
overnight in acetonitrile at room temperature.   
 
Scheme 2.18: Overview of N
6
-amino substitution (146) Reagents and conditions: (vii) 28% ammonia sol, 
MeCN, 2 h, 85%. 
The Rf of the product 146 decreased as the benzotriazolyl group was lost, and 
the polarity increased slightly.  The Rf  of compound 146 was determined to be 
0.62 in ethyl acetate/MeOH (7:3).  Purification via column chromatography gave 
good yields of a white solid for 250 mg to 1 g scale reactions.  A second 
component was separated during the column chromatography was identified as 
a small amount of amino-substituted product at the C2-position.  The diamino 
substitution was observed to be present in < 5% most typically when longer 
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reaction times led to some of the fluorine group being replaced by the amino 
group.   
 
In d6-DMSO, the major features of the 
1H NMR spectrum of the fluoro 
adenosine intermediate 146 are the absence of the signals from the 
benzotriazole aromatic protons, and the appearance at 7.85 ppm of a broad 
singlet with an integral corresponding to the two N6 protons.  The signals from 
the 2’- and 3’-protons completely coalesce from two resolved doublets in the 
starting material to a singlet peak at 5.35 ppm with an integral corresponding to 
two protons in the product.  Likewise, in the 13C NMR spectrum, six peaks for 
the benzotriazolyl aromatic carbons are no longer present.  Two identifiable 
signals, separated by 0.03 ppm were observed for the 2’- and 3’-carbons.  The 
melting point of the product 146 was 194–196 °C.  The synthesis of compound 
146 was supported by HRMS spectrum of 146, which showed the expected 
molecular ion of M+ at 366.1451 m/z, (EI+ HRMS showed a deviation of 0.0049 
ppm from the calc. mass of C15H19FN6O4).   
2.2.3 Synthesis of TMIO adenosine analogues with aminoethylaniline 
linker (161)(Approach 1) 
Coupling of the antioxidant linker with functionalised adenosine was the next 
step in the process towards target 161.  In this work, the novel C2-substituted 
target compound 2-(2-(4-N-(5-carboxy-1,1,3,3-tetramethylisoindoline-1-yloxyl) 
aminophenyl)) ethylamino-2,3,-O-isopropylideneadenosine-5-N-
ethylcarboxamide (161) was synthesised through the reaction of the 2-fluoro 
adenosine analogue (146) with an appropriate antioxidant-bearing 
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aminoethylaniline linker moiety 127 (Scheme 2.19) by following the 
Hutchison’s223 synthetic procedure. 
 
Scheme 2.19: Overview of coupling of nitroxide with aminoethylaniline linker to adenosine intermediate 
(approach 1) (161) Reagents and conditions: (i) DIPEA, Ethanol, 75–80 °C, 7 days, 58%. 
The reaction proceeded via a nucleophilic aromatic substitution (SNAr) reaction 
according to Hutchison’s method, and the reaction mechanism is explained in 
Scheme 2.20.  
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Scheme 2.20: SNAr mechanism for the synthesis of C2-substituted target compounds. 
Trivedi265, Caddell272 and Kim274 documented that nucleophilic substitution at a 
C2-bromo and chloro moiety, however, these substitutions was considered 
insufficiently reactive and time inefficient and were therefore not attempted.  
Instead, efforts were directed towards the more reactive C2-fluoro species.  
However, Takvorian has reported reaction temperatures well above the 
200°C,303 which are perhaps unnecessarily.  The rate-limiting step in the 
reaction is the initial nucleophilic attack on C2-carbon and the formation of a 
Meisenheimer intermediate, and this explains why the 2-fluoro compound is 
more reactive with respect to SNAr substitutions.  In this regard, the substituent 
with the highest electronegativity produces a more partial positive charge at the 
C2-position of adenosine and, therefore, electronic conditions are more prone to 
nucleophilic attack. 
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The synthesis of product 161 was achieved in ethanol using Hunig’s base (N, 
N-diisopropylethylamine)(DIPEA) by stirring at 75–80 °C for 7 days.  The Rf 
value of the product on TLC in EtOAc/MeOH (9:1) was 0.51 and the compound 
was purified by column chromatography using this solvent mixture to generate 
product 161 in 58% yield.   
  
The structure of the nitroxide-coupled adenosine product 161 was supported by 
the HRMS, which showed the expected molecular ion of M+H at 699.3506 m/z, 
(EI+ HRMS showed a deviation of 0.0017 ppm from the calc. mass of 
C36H45N9O6).  In the 
1H NMR spectrum, paramagnetic broadening was 
observed as expected due to the nitroxide radical that resulted in some peaks 
not being detected and giving poor integration.  However, the signal of the 
ethylene group from aniline linker could be detected at 2.91 and 2.98 ppm and 
the adenosine ribose ethylamide proton signals could be detected at 0.71 ppm 
and acetal two methyl protons appeared at 1.24 and 1.42 ppm.  The melting 
point of the isolated compound 161 was 66–68°C.  
 
In this approach, the reaction conditions used were very harsh, and the product 
was only generated in low yields.  This low yield was attributed to 
decomposition of the starting reactants or product formed.  In addition, this 
approach required extended reaction times (7 days).  Accordingly, an 
alternative approach was explored.  This approach first involved the attachment 
of the aminoethylaniline linker to the adenosine intermediate, followed by 
subsequent coupling with the carboxy nitroxide.  As the amine linkers could be 
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sourced in large scale, greater efficiency for the synthesis was thought to be 
possible through coupling the adenosine intermediate 146 with excess amine 
124 and then coupling this system to the nitroxide.   
2.2.4 Synthesis of TMIO adenosine analogues with aminoethylaniline 
linker (161) (Approach 2) 
As outlined in previous section, the reaction of 2-fluoro adenosine precursor 146 
with an excess of amine 124 was undertaken in order to give the maximum 
possible levels of the preliminary target 2-(2-(4-aminophenyl)) ethylamino-2,3-
O-isopropylideneadenosine-5-N-ethylcarboxamide (159).  
 
In this approach, the para-(aminophenyl)ethylamine-linked adenosine 
intermediate 159 was synthesised first and then the appropriate carboxy-
nitroxide was coupled directly to the adenosine intermediate 159.  The 
advantage of this approach is that various carboxy-nitroxides such as 5-
carboxy-1,1,3,3-tetramethylisoindoline-2-yloxyl (CTMIO, 106), 4-carboxy-
2,2,6,6-tetramethylpieridine-1-yloxyl (CTEMPO, 116), 3-carboxy- 2,2,5,5-
tetramethylpyrrolidine-1-yloxyl (CPROXYL, 117), 5-methylcarboxy-1,1,3,3-
tetramethylisoindoline-2-yloxyl (MCTMIO, 115) and 5-carboxy-1,1,3,3-
tetraethylisoindoline-2-yloxyl (CTEIO, 114) could also be coupled to the para-
aminoethylaniline linked adenosine intermediate 159 using very mild amide 
coupling conditions (Scheme 2.21).   
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Scheme 2.21: Overview of coupling of carboxy nitroxides with aminoethylaniline linked adenosine 
intermediate (Approach 2) 
Firstly, the adenosine intermediate 159 was synthesised from the reaction of 
compound 146 with amine 124 by using Hunig’s base DIPEA in 97% yields 
(Scheme 2.22).  The reaction was proceeded by an SNAr reaction mechanism, 
which is explained in Scheme 2.20.   
 
Scheme 2.22: Overview of coupling of aminoethylaniline linker to adenosine intermediate (159), Reagents 
and conditions: (i) DIPEA, MeCN, MW 180 °C;7 h.   
96 
 
The adenosine intermediate 159 was synthesised by using the conventional 
method of heating in oil bath.  This synthetic method takes 7 days to complete 
the reaction and only gives moderate yields (50%).  This methodology is time-
consuming and failed to achieve desired yield of product 159.  This low yield 
(50%) was attributed to the longer heating time which may decompose the 
starting reagents, or the product formed.  Accordingly, an alternative approach 
was implemented which successfully prepared the desired C2- 
aminoethylaniline adenosine analogue 159 through a substitution reaction using 
microwave assisted conditions in the reduced time span of 7 h with an excellent 
yield of 97%.  This approach provided a convenient synthetic route to the 
synthesis of the desired adenosine analogues. 
 
The reaction was carried out successfully either in ethanol or acetonitrile with oil 
bath heating (at 75–80 °C).  For complete conversion of the starting material, 
the reaction still took 7 days to complete.  This longer reaction time, is avoided 
by undertaken using microwave irradiation in which compound 146, compound 
124 and DIPEA were combined in acetonitrile, sealed in a microwave tube and 
heated at 180 °C.  Multiple experiments at various reaction times were 
conducted under microwave conditions and after 7 h, the complete conversion 
of the starting material was observed.  After which time, the reaction mixture 
was purified using column chromatography.   
 
The structure of 159 was supported by 1H NMR and 13C NMR spectroscopy and 
MS spectrometry.  In the 1H NMR spectrum, a new peak corresponding to the 
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ethylene protons of the linker appeared in the aliphatic region as two multiplets 
at 2.82 and 2.86 ppm integrated for four protons.  Two additional doublets 
corresponding to the aromatic ring of the linker appeared at 6.67 and 7.06 ppm 
which integrated for four protons.  In the 13C NMR spectrum, three additional 
signals appeared as strong peaks corresponding to the two methyl carbons at 
33.7 and 34.3 ppm.  The additional aromatic ring signals appeared at 79.1 ppm.  
The C2-substituted linked adenosine compound 159 was supported by HRMS, 
which showed the expected molecular ion of M+H at 483.2482 m/z, (EI+ HRMS 
showed a deviation of 0.022 ppm from the calc. mass of C23H31N8O4).  The 
melting point of 150-152 °C of isolated product 159 is consistent.  The obtained 
data were in agreement with the published values.121   
 
Compound 159 was then coupled with nitroxide compound (CTMIO) 106 using 
EDCI/HOBt coupling reagent and Hunig’s base in dry DMF to give 2-(2-(4-N-(5-
carboxy-1,1,3,3-tetramethylisoindoline-2-yloxyl)aminophenyl))ethylamino-2,3-
O-isopropylideneadenosine-5-N-ethylcarboxamide (161) (Scheme 2.23).  HOBt 
helps in the formation of active esters in the reaction mixture by reacting with 
the carboxylic acid at ambient temperatures.   
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Scheme 2.23: Synthesis of TMIO-substituted adenosine analogue possessing a substituted aniline linker 
moiety (161) (approach 2). Reagents and conditions: (i) EDCI/HOBt, DMF, DIPEA 25 °C; (ii) 1 M HCl 
solution, MeCN, 55–60 °C, 5 h. 
The reaction of 159 with 106 gave two reaction products (as identified by TLC), 
which were isolated using medium-pressure liquid chromatography (MPLC).  
The main product isolated was attributed to the expected adduct 161 in 81% 
yield.  In the 1H and 13C NMR spectra of the reaction product 161, paramagnetic 
broadening by the nitroxide radical results in some peaks not being detected or 
giving poor integration.  However, the signal of the ethylene group from aniline 
linker could be detected at 2.91 and 2.98 ppm and the adenosine ribose 
ethylamide proton signals could be detected at 0.71 ppm and acetal two methyl 
protons appeared at 1.24 and 1.42 ppm.  The melting point of the isolated 
product 159 was 66–68 °C.  The synthesis of desired amide 161 was supported 
by HRMS, which showed the expected molecular ion of M+H at 699.3506 m/z, 
(EI+ HRMS showed a deviation of 0.0013 ppm from the calc. mass of 
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C36H45N9O6).  The purity was found to be 97.6% by analytical HPLC in 80% 
methanol/20% water system.   
 
Deprotection of the isopropylidene group from compound 161 was achieved 
using 1 M HCl at at 55–60 °C in 4.0 h to give 2-(2-(4-N-(5-carboxy-1,1,3,3-
tetramethylisoindoline-2-yloxyl) aminophenyl)) ethylaminoadenosine-5-N-
ethylcarboxamide (162) (Scheme 2.23).   
 
The deprotection reaction gave a single reaction product 162 (as identified on 
TLC), which was isolated using MPLC and partial crystallisation in a mixture of 
methanol/ water solvent system with a yield of 70%.  The structure of 
deprotected product 162 was supported by HRMS, which showed the expected 
molecular ion of M+H at 659.3197 m/z, (EI+ HRMS showed a deviation of 
0.0010 ppm from the calc. mass of C33H41N9O6).  A melting point of 241–243 °C 
(decomp) was obtained for the product 162.  The purity was found to be 99.9% 
using analytical HPLC in an 80% methanol/20% water system.  In the proton 
NMR spectrum, paramagnetic broadening was observed which resulted in 
some peaks not being detected and giving poor integration of compound 162. 
However, signals of the aniline linker and adenosine moieties could be 
detected.   
 
The coupling reaction also gave a small amount of unknown impurity at the 
nonpolar region (as identified on TLC) in each reaction.  To confirm the 
structure of the by-product, which was suspected to be the dimer, several 
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experiments were undertaken.  Firstly, the compound 159 was coupled with 3,5-
dinitrobenzoic acid (175) using EDCI/HOBT-coupling reagents (Scheme 2.24).  
The same reaction conditions gave the product 176 with a similar impurity to 
those of the coupling reactions with radical species (a identified by TLC).  The 
coupled compound was not isolated further.  
 
Scheme 2.24: Synthesis of 3,5-dinitrobenzoic acid-coupled adenosine analogue possessing a substituted 
aniline linker moiety (176) Reagents and conditions: (i) EDCI/HOBt, DMF, DIPEA 25 °C. 
We next performed another experiment by assuming that the impurity may have 
formed because of a side reaction or decomposition of the starting material 159 
(Scheme 2.25).  This assumption is confirmed by stirring the aniline linked 
adenosine compound 159 under the same reaction conditions and without any 
carboxy acid starting material.  However, no change was observed on TLC, 
after three days of continued stirring at room temperature and starting 
compound 159 was recovered.   
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Scheme 2.25: Reaction of coupling reagents with adenosine analogue possessing a substituted aniline 
linker, Reagents and conditions: (i) EDCI/HOBt, DMF, DIPEA 25 °C. 
From this experiment, it was confirmed that the unknown compound impurity 
was arising from the other starting material the carboxy nitroxide. After analysis, 
it was found that the impurity interferring in this reaction was the dimer 
compound (anhydried) formed from two CTMIO molecules.   
2.3 Synthesis of C2-substituted CTEMPO adenosine analogues 
possessing substituent attached to ‘aminoethylaniline 
linker’ moiety (164) 
Compound 159 was coupled with commercially available 4-carboxy- 2,2,6,6 -
tetramethylpiperidine-1-yloxyl (CTEMPO) (116) using the EDCI/HOBT amide 
coupling reagent to give the novel compound 2-(-2-(4-N-(4-carboxy-2,2,6,6 
tetramethylpieridine-2-yloxyl)aminophenyl))ethylamino-2,3-O-
isopropylideneadenosine-5-N-ethylcarboxamide (163) in 60% yield (Scheme 
2.26).   
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Scheme 2.26: Synthesis of TEMPO-substituted adenosine analogue possessing a substituted aniline 
linker moiety (164), Reagents and conditions: (i) EDCI/HOBt, DMF, DIPEA 25 °C; (ii) 1 M HCl solution, 
MeCN, 55–60 °C, 5 h.  
The reaction was carried out in freshly distilled DMF under an argon 
atmosphere at room temperature.  The reaction went to completion in 3 days 
(as identified by TLC). 
 
The reaction of 116 with 159 produced two products (as identified by TLC) 
which were isolated and purified twice by MPLC, as the two components ran 
very close to each other.  In the 1H spectrum of the reaction product 163, 
paramagnetic broadening by the nitroxide radical resulted in some peaks not 
being detected or giving poor integration. However, the signal of the aniline 
linker and adenosine moieties could be detected.  The results of HRMS of the 
isolated compound were consistent and supported the structure of 163, which 
showed the expected molecular ion of M+H at 665.3658 m/z, (EI+ HRMS 
showed a deviation of 0.0018 ppm from the calc. mass of C33H47N9O6).  A purity 
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of 99.4% was found using analytical HPLC in an 80% methanol/20% water 
system.  The melting point of compound 163 was measured as 148–150 °C.  
The second spot isolated was found to be the mass corresponding to the 
anhydride of the CTEMPO (116), which was found according to the mass 
analysis.  
  
Deprotection of the isopropylidene group from compound 163 was achieved 
using similar procedure as used for synthesis of compound 162 by employing 1 
M HCl at elevated temperatures to give the novel target compound 2-(2-(4-N-(4-
carboxy-2,2,6,6-tetramethylpieridine-1-
yloxyl)aminophenyl))ethylaminoadenosine-5-N-ethylcarboxamide (164) 
(Scheme 2.26).  The reaction went to completion in 5.0 h at 55–60 °C. 
 
The reaction gave a single reaction product (as identified on TLC) with an Rf 
value of 0.43 in (8:2) IPA: MeOH, and which was purified using MPLC and 
partial crystallisation using a 75% methanol/25% water system to give 164 in 
70% yield.  The melting point of 211-213 °C (decomp) was obtained for the 
isolated product 164.  The structure of 164 was supported by HRMS, which 
showed the expected molecular ion of [M+H]: 625.3341 m/z (EI+ HRMS showed 
a deviation of 0.0011 from the calc. mass of C30H43N9O6).  In the 
1H spectrum of 
the reaction product 164, paramagnetic broadening by the nitroxide radical 
resulted in some peaks not being detected or giving poor integration, however 
the signal of the aniline linker and adenosine moieties could be detected.    
104 
 
2.4 Synthesis of C2-substituted CPROXYL adenosine 
analogues possessing substituent attached by 
‘aminoethylaniline linker’ moiety (166). 
The compound 159 was coupled with commercially available 3-carboxy-2,2,5,5-
tetramethylpyrrolidine-1-oxyl (CPROXYL) (117) using similar reaction conditions 
as used to synthesize compound 163 with EDCI/HOBT as the amide coupling 
reagent to give the novel compound 2-(2-(4-N-(3-carboxy-2,2,5,5-
tetramethylpyrrolidine-1-yloxyl)aminophenyl))ethylamino-2,3-O-
isopropylideneadenosine-5-N-ethylcarboxamide (165) in 74% yield (Scheme 
2.27).   
 
Scheme 2.27: Synthesis of the PROXYL-substituted adenosine analogue possessing a substituted aniline 
linker moiety (166) Reagents and conditions: (i) EDCI/HOBt, DMF, DIPEA 25 °C; (ii) 1 M HCl solution, 
MeCN, 55–60 °C, 5 h. 
The reaction was carried out in freshly distilled DMF under an argon 
atmosphere at room temperature.  The reaction went to completion in 24 h (as 
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identified by TLC).  The reaction of 117 with 159 gives two products (as 
identified by TLC), which were subsequently isolated by MPLC in a 75% 
methanol/25% water system.  The results of HRMS of the main component 
isolated were consistent and supported structure of 165, which showed the 
expected molecular ion of M+H at 651.3493 m/z, (EI+ HRMS showed a 
deviation of 0.0003 ppm from the calc. mass of C32H45N9O6).  The melting point 
of the isolated product 165 was found to be 140–142 °C.  The purity was found 
to be 98% by analytical HPLC in a 75% methanol/25% water system.  The 
second component isolated from the reaction mixture was found to be the 
unreacted substrate compound 159 by MS analysis.   
 
The novel compound 2-(2-(4-N-(3-carboxy-2,2,5,5-tetramethylpyrrolidine-1-
yloxyl) aminophenyl)) ethylaminoadenosine-5-N-ethylcarboxamide (166) was 
synthesised by deprotection of the isopropylidene group from compound 165 
using 1 M HCl at 50–60 °C for 5.0 h in 62.5% yield. (Scheme 2.27).   
 
The reaction gave a single reaction product 166 (as identified on TLC), which 
was isolated using MPLC and partial crystallisation using 75% methanol/25% 
water system.  The results of HRMS of the isolated compound were consistent 
with the expected results for 166, which showed the expected molecular ion of 
M+H at 611.3183 m/z, (EI+ HRMS showed a deviation of 0.0001 ppm from the 
calc. mass of C29H41N9O6).  In the 
1H spectrum of the compound 166, 
paramagnetic broadening by the nitroxide radical resulted in some peaks not 
being detected or giving poor integration of compound 166, however signals of 
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the aniline linker and adenosine moieties could be detected.  A melting point of 
176–178 °C (decomp) was measured for the isolated product 166.  The purity 
was found to be >99.9% using analytical HPLC in a 75% methanol/25% water 
system.   
2.5 Synthesis of C2-substituted MCTMIO adenosine analogues 
possessing substituent attached to “aminoethylaniline 
linker” moiety (168) 
A novel adenosine compound was synthesised using a mixture of the one 
carbon extended methylene carboxy isoindoline nitroxide 115, and compound 
106 which was synthesised from compound 102 and obtained from advanced 
stage synthesis in the laboratory.  The compound 159 was coupled with a 
mixture of nitroxide 5-methylenecarboxy-1,1,3,3-tetramethylisoindoline-2-yloxyl 
(MCTMIO, 115) and 106 using EDCI/HOBT as the amide coupling reagent to 
give a mixture of 2-(2-(4-N-(5-methylenecarboxy-1,1,3,3-tetramethylisoindoline-
2-yloxyl)aminophenyl))ethylamino-2,3-O-isopropylideneadenosine-5-N-
ethylcarboxamide (167) and compound 161 (Scheme 2.28).  
  
107 
 
 
Scheme 2.28: Synthesis of MCTEIO-substituted adenosine analogue possessing a substituted aniline 
linker moiety (168). Reagents and conditions: (i) EDCI/HOBt, DMF, DIPEA 25 °C; (ii) 1 M HCl solution, 
MeCN, 55–60 °C, 5 h. 
The reaction was carried out in freshly distilled DMF under an argon 
atmosphere at room temperature.  Addition of the mixture of nitroxides after the 
coupling reagents, improves the reaction completion time from 48 h to 24 h and 
product 167 was obtained in a high yield.  Moreover, complete consumption of 
the starting material was observed.  The addition of EDCI and HOBt first to 
DMF under an argon atmosphere followed by the addition of carboxy nitroxide 
115 and DIPEA, and later the portion-wise addition of the linker amine 159 led 
to completion of the reaction in 24 h instead of 3 days at room temperature (as 
identified by TLC).  The work-up involved filtration of the coupled solid product 
formed at 0 °C after the 30 min reaction, quenching and washing many times 
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with chilled water.  As per TLC analysis, the similar Rf values were observed for 
the mixture of compounds 167 and 161.   
 
The synthesis of the one carbon extended isoindoline nitroxide derivative of 
adenosine compound 167 was attempted by following a similar amide coupling 
procedure used for the synthesis of compound 165.  The reaction of mixture of 
115 and 106 with 159 produced three components (as identified by MPLC), 
however, a TLC analysis shows only two components.  These components was 
firstly purified by using MPLC. The first fraction was found to be unreacted 
starting amine 159, which was isolated from the product.  The second fraction 
isolated from the 300mg reaction by MPLC was 150 mg of a pale yellow 
component.  The second component on TLC, what appeared to be a single new 
product has two close components (as identified by HPLC).  However, it was 
found difficult to isolate these two compounds present in the sample by MPLC 
and therefore, this mixture was used as it is for the next step of deprotection 
reaction.   
 
The mixture was analysed using analytical HPLC in a 75% methanol/25% water 
system and was found to be a 60:40 mixture of compound 167 with compound 
161 respectively.  The results of HRMS of the isolated product were consistent 
with the expected results for 167 and 161, which showed the expected 
molecular ions of M+H at 713.5496 and 699.9465 m/z respectively.  The NMR, 
MS and HPLC analysis revealed that two structures-related isoindoline 
compounds were present and determined that a component had a molecular 
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mass corresponding to the desired MCTMIO adenosine derivative 167 with the 
CTMIO adenosine derivative 161 in a 60:40 mixture.   
 
A mixture of compound 167 and 161 was used as starting material for the 
deprotection reaction.  Deprotection of the isopropylidene group from a mixture 
of compound 167 and compound 161 was achieved using 1 M HCl at elevated 
temperatures (Scheme 2.28).  The reaction went to completion in 5.0 h at 50–
55 °C and produced a mixture of the final target compound 2-(2-(4-N-(5-
methylcarboxy-1,1,3,3-tetramethylisoindoline-2-
yloxyl)aminophenyl))ethylaminoadenosine-5-N-ethylcarboxamide (168) and 
162 as an off-white solid compound. (Note: compound 162 is present because 
the starting material contained two components).  The product was filtered after 
quenching of the reaction using saturated sodium bicarbonate solution at 0 °C 
and was washed with plenty of chilled water.   
The reaction gave a mixture of compounds 168 with 162 (single spot as 
identified on TLC) that was not isolated using MPLC but partially crystallised in 
75% methanol/25% water system.  The results of HRMS of the isolated 
compound were consistent with the expected results for 168 and 162, which 
showed the expected molecular ion of M+2H at 674.6586, and 661.0205 m/z.  
The isolated off-white solid was found to be a 60:40 mixture of compound 168 
with 162 using analytical HPLC in a 75% methanol/25% water mobile-phase 
system.  This compound was analysed by 1H NMR spectroscopy, which 
indicated clearly the absence of the two methyl signals of isopropylidene 
protection.    
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2.6 Synthesis of C2-substituted adenosine analogue 
possessing TEIO nitroxide substituent attached to the 
‘aminoethylaniline linker’ moiety (170). 
2.6.1 Synthesis of carboxy TEIO nitroxide antioxidant 
The stable nitroxide 5-carboxy-1,1,3,3-tetraethylisoindoline-2-yloxyl (CTEIO) 
114 was synthesised in six steps as per the procedure first published by our 
group 102, 275 (Scheme 2.29).   
 
Scheme 2.29: Synthesis of 5-Carboxy-1,1,3,3-tetraethylisoindoline-2-yloxyl (CTEIO) 114.
102
 Reagents and 
conditions: (i) Glacial CH3COOH, reflux 75 min, 80%; (ii) Mg, C2H5I, toluene, reflux 3.0 h, 32%; (iii) 60 psi 
H2, 10% Pd/C catalyst, glacial CH3COOH, 3 h, 92%;  (iv) Na2WO4. 2H2O, H2O2, NaHCO3, stirred 72 h, 
47%; (v) AcCl, Pd/C,Et3N, 99%; (vi) KMnO4 , MgSO4, 78%; (vii) LiOH, 89%. 
Commercially available 5-methyl phthalic anhydride (107) and benzylamine 
were reacted in a nucleophilic acyl substitution to generate 5-methyl-N-benzyl 
phthalimide (108) in 80% yield.  Compound 108 was tetraethylated in a 
Grignard reaction using ethylmagnesium iodide to form 5-methyl-N-benzyl-
1,1,3,3-tetraethylisoindoline (109) in 32% yield.  The 2-benzyl group of 109 was 
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cleaved through hydrogenation of the protected isoindoline in a Parr-apparatus 
using 50 psi H2 gas pressure to generate 5-methyl-1,1,3,3-tetraethylisoindoline 
amine (110) in 92% yield.  The debenzylated amine compound 110 was then 
oxidized304 with 30% H2O2 in the presence of a Na2WO4.2H2O catalyst to form 
the desired nitroxide 5-methyl-1, 1, 3, 3-tetraethylisoindoline-2-yloxyl (111) in 
47% yield.  Compound 111 was subsequently reduced with hydrogen using a 
Pd/C catalyst and then acylated305 with acetyl chloride to form 2-acetoxy-5-
methyl-1,1,3,3-tetraethylisoindoline (112) in 99% yield.102  The methyl group of 
compound 112 was then oxidized using 0.4 M solution of potassium 
permanganate in the presence of magnesium sulfate306 at 70 °C to generate the 
desired carboxylic acid 2-acetoxy-5-carboxy-1,1,3,3-tetraethylisoindoline (113) 
in 78% yield.102  Compound 113 was finally hydrolysed by lithium hydroxide and 
reoxidised by lead oxide to generate the desired nitroxide 5-carboxy-1,1,3,3-
tetraethylisoindoline-2-yloxyl (114) in 89% yield (Scheme 2.29).  The 
characterization of all compounds in this scheme is in agreement with the 
published data.102 
2.6.2 Coupling carboxy TEIO adenosine compound with 
aminoethylaniline linker (170) 
The compound 159 was coupled with a 5-carboxy-1,1,3,3-tetraethylisoindoline-
2-yloxyl (CTEIO) (114) using the EDCI/HOBT as the amide coupling reagent to 
give the novel compound 2-(2-(4-N-(5-carboxy-1,1,3,3-tetraethylisoindoline-2-
yloxyl)aminophenyl))ethylamino-2,3-O-isopropylideneadenosine-5-N-
ethylcarboxamide (169) in 70% yield. (Scheme 2.30)   
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Scheme 2.30: Synthesis of CTEIO-substituted adenosine analogue possessing a substituted aniline linker 
moiety (170). Reagents and conditions: (i) EDCI/HOBt, DMF, DIPEA 25 °C; (ii) 1 M HCl solution, MeCN, 
55–60 °C, 5 h. 
The reaction was carried out in freshly distilled DMF under an argon 
atmosphere at room temperature.  The nitroxide was added after the coupling 
reagents that led to completion of the reaction in 24 h instead of 3 days and 
also produced a better yield of 79%.  Addition of EDCI and HOBt first in DMF in 
an argon atmosphere followed by carboxy nitroxide 114 and DIPEA, and later 
portion-wise addition of the linker amine led to completion of the reaction at 
room temperature (as identified on TLC).  The work-up involved filtration of the 
coupled solid product formed at chilling temperature after 30 min of reaction 
quenching and washing many times with chilled water.   
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The reaction of 114 with 159 produced two products (as identified by TLC), 
which were isolated by MPLC.  HRMS of one isolated product was consistent 
with the expected results for 169, which showed the expected molecular ion of 
M+H at 755.4118 m/z, (EI+ HRMS showed a deviation of 0.0001 ppm from the 
calc. mass of C40H53N9O6).  The purity was found to be 95% by HPLC in a 75% 
methanol/25% water system. The second component isolated was found to be 
starting material. In the1H NMR spectroscopic analysis of compound 169, 
signals of the aniline linker and the adenosine moieties could be detected.   
 
Deprotection of the isopropylidene group from compound 169 was achieved 
using 1 M HCl at elevated temperatures.  The reaction went to completion in 5.0 
h at 50–55 °C, to give the novel target compound 2-(2-(4-N-(5-carboxy-1,1,3,3-
tetraethylisoindoline-2-yloxyl) aminophenyl)) ethylaminoadenosine-5-N-
ethylcarboxamide (170) as a pale yellow solid compound (Scheme 2.30).  The 
product was filtered after quenching of the reaction using saturated sodium 
bicarbonate solution at 0 °C and washed with plenty of chilled water.   
 
The reaction gave a single reaction product 170 (as identified on TLC), which 
was isolated using MPLC and partial crystallisation using 75% methanol/25% 
water system, to give product in 71% yields.  The results of the HRMS of the 
isolated compound were consistent with the expected results for 170, which 
showed the expected molecular ion of M+Na at 737.3506 m/z, (EI+ HRMS 
showed a deviation of 0.0021 ppm from the calc. mass of C37H48NaN9O6).  The 
purity of product 170 was found to be 98.5% using analytical HPLC in a 75% 
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methanol/25% water mobile-phase system.  This compound was analysed by 
1H NMR spectroscopy, which indicated paramagnetic broadening by the 
nitroxide radical resulting in some peaks not being detected or giving poor 
integration, however the signals of the aniline linker and adenosine moieties 
and the disappearance of the two acetal methyl signals at 1.17 and 1.19 ppm 
could be detected.   
2.7 Synthesis of C2-substituted di-tert-butylhydroxycinnamic 
acid adenosine analogues possessing substituent attached 
to ‘aminoethylaniline linker’ moiety (172).   
Phenolic compounds also exhibit antioxidant properties similar to those of 
nitroxides.  In particular, hindered phenolic compounds, including BHT with 
adenosine molecule demonstrated excellent results in the biological analysis.  
Similarly, the phenolic compound hydroxycinnamic acid is also a potent 
antioxidant.  Additionally, this may deliver an excellent antioxidant activity and 
A2AAR selectivity results when attached to the adenosine molecule.   
 
It was speculated that the nitroxide compounds were degrading through out the 
reaction conditions and having low yield using first approach synthesis, 
therefore to confirm this behavoiur the novel hydroxy cinnamic acid based 
adenosine compound 171 was synthesised using two different synthetic 
approaches in a manner similar to synthesise compound 161.  Firstly coupling 
of the antioxidant moiety 118 with the linker amine is performed to form 
compound 133 and then 133 is coupled to the adenosine intermediate 146. 
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2.7.1 Synthesis of di-tert-butylhydroxycinnamic acid possessing 
substituent attached by ‘aminoethylaniline linker’ intermediate (133)  
 
The novel compound N-tert-butoxycarbonyl-2(4-N-(3,5-ditert-butyl-4-
hydroxycinnamic acid)aminophenyl)ethylamine (132) was synthesized from 
compound 125 by amide coupling with 3,5-ditert-butyl-4-hydroxycinnamic acid 
(118) using EDCI in the presence of a catalytic amount of HOBt and DIPEA 
along with using DMF as the basic solvent in 99% yield (Scheme 2.31).   
 
Scheme 2.31: Overview of synthesis of di-tert-butyl-4-Hydroxycinnamic acid coupled 
aminophenylethylamine linker moiety (133). Reagents and conditions: (i) EDCI/HOBt, DMF, DIPEA 25 °C, 
99%; (ii) 1 M HCl solution, MeCN, 55–60 °C, 5 h., 65% . 
Compound 132 was synthesized by following the same amide coupling 
procedure as that used to generate the nitroxide linker compounds.  EDCI was 
used as an acid activating agent, forming a reactive ester intermediate in situ 
with the carboxylic acid of the hydroxy cinnamic acid antioxidant moiety.  This 
carboxylic acid ester has an activated leaving group that is attacked by the 
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nucleophilic amine group from the linker aniline.  A thermodynamically stable 
urea is released to give the novel desired amide product 132 with the amide 
coupling mechanism explained in Scheme 2.7.  HOBt was used to drive the 
reaction in the desired direction, which limits side reactions and improves yields.   
 
The reaction was run overnight at room temperature.  A workup procedure 
involving pouring the reaction solution into excess water and extracting the 
resulting precipitate with DCM and washing several times with water afforded 
high yields.  The compound 132 was purified by column chromatography using 
a mixture of CHCl3: MeOH: 28% aqueous ammonia solution (7.9:2:0.1), to give 
product 132 in 99% yields on a 50–100 mg scale.  Compound 132 appeared on 
a TLC plate as a single spot.  In the 1H NMR (CDCl3) spectrum of 132, a 
multiplet appeared at 1.4 ppm with an integral corresponding to the eighteen 
protons from the two tert-butyl groups and two triplet appeared at 2.73 and 3.36 
ppm for the four protons of the ethyl linker group from the new aminoethylaniline 
substituent.  An extra two peaks corresponding to the carbons of the ethene 
group also appeared in the 13C NMR spectrum at 117.3 ppm and 136.3 ppm, 
respectively.  The melting point of 126–128 °C of the isolated compound 132 
was consistent and sharp.  The structure of 132 was supported by MS analysis, 
which showed the expected molecular ion of M+Na at 517.3006 m/z (EI+ 
(HRMS) showed a deviation of 0.0034 from the calc. mass of C30H42NaN2O4).   
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The novel target compound primary amine (E)-N-(4-(2-aminoethyl)phenyl)-3-
(3,5-di-tert-butyl-4-hydroxyphenyl)acrylamide (133) was obtained in 65% yield 
from the Boc-protected amine 132 (Scheme 2.31).  Removal of the acid-labile 
Boc-protecting groups of amine 132 can be effected by reaction with 4 M HCl.   
 
By following the same procedure as that used for the deprotection of 169, the 
desired target 133 was obtained from the protected precursor 132.  The 
hydroxycinnamic acid containing linker compound 132 was stirred at 55–60 °C 
for 2–3 h in a mixture of 1,4-dioxane and water with dropwise addition of 4 M 
HCl over ten minutes.  Analysis by TLC indicated consumption of starting 
material, and ninhydrin staining highlighted the reformed primary amine 133 on 
the TLC plate with a strong purple colour with an Rf of 0.13 in 9:1 
chloroform/methanol.  The compound was purified by column chromatography 
to give 65% yield of the deprotected primary amine product 133 with a sharp 
melting point of 130–132 °C.   
 
In the 1H NMR (CDCl3) spectrum of 133, a multiplet appeared at 1.43 ppm with 
an integral corresponding to eighteen protons from two tert-butyl groups and a 
broad singlet appeared at 2.95 ppm for the two primary amine protons.  An 
extra two peaks corresponding to the carbons of the ethene group also 
appeared in the 13C NMR spectrum at 125.0 ppm and 136.6 ppm, respectively.  
The structure of 133 was supported by MS, which showed the expected 
molecular ion of M+H at 395.2651 m/z (EI+ (HRMS) showed a deviation of 
0.0048 from the calc. mass of C25H35N2O2).    
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2.7.2 Synthesis of C2-substituted di-tert-butylhydroxycinnamic acid 
adenosine analogue possessing substituent attached by 
‘aminoethylaniline linker’ moiety (171) (Approach 1)  
Coupling of the antioxidant linker with the functionalized adenosine was the next 
step in the process towards target compound 2-(2-(4-N-(3,5-di-tert-butyl-4-
hydroxyphenyl)acrylamido)aminophenyl))ethylamino-2,3,-O-
isopropylideneadenosine-5-N-ethylcarboxamide (171).  In this work, a novel 
C2-substituted adenosine analogue 171 was synthesised through the reaction 
of 2-fluoro adenosine intermediate (146) with the isoindoline nitroxide 
substituted aminoethylaniline linker moiety (133) (Scheme 2.32) by following the 
Olsson synthetic procedure and as per mechanism explained in Scheme 2.20.   
 
Scheme 2.32: Overview of coupling of di-tert-butylhydroxycinnamic acid with linker to adenosine (171) 
(approach 1) Reagents and conditions: (i) DIPEA 75-80 °C, 7 days, 51%. 
Synthesis of compound 171 was achieved by a coupling reaction in ethanol 
using Hunig’s base DIPEA at 75–80 °C for 7 days.  The reaction of 146 and 133 
gives a single product (as identified on TLC).  The compound was purified by 
119 
 
column chromatography using ethyl acetate and ammonia solvent system in 
50% yield.   
 
The structure of the hydroxycinnamic acid-coupled adenosine compound 171 
was supported by MS, which showed the expected molecular ion of M+H at 
741.4490 m/z by the HRMS (EI+ HRMS showed a deviation of 0.040 ppm from 
the calc. mass of C40H53N8O6).  The consistent sharp melting point of 138–140 
°C supported the synthesis of the isolated compound 171.   
 
Similarly, to the nitroxide possessing adenosine analogues the hydroxycinnamic 
acid coupling reaction with approach 1 only gives moderate yields (50%).  The 
reaction conditions were very harsh.  As this approach required harsh reaction 
conditions and extended reaction times (7 days) an alternative approach 
(approach 2) was explored.  As the amine linkers could be sourced in large 
scale, greater efficiency for the synthesis was thought to be possible through 
first coupling the adenosine intermediate 146 with excess amine 124 and then 
coupling this system to the hydroxycinnamic acid 118.  Moreover, the number of 
steps are also reduced by using adenosine intermediate 159 as the starting 
material. 
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2.7.3 Synthesis of C2-substituted di-tert-butylhydroxycinnamic acid 
adenosine analogues possessing substituent attached by 
‘aminoethylaniline linker’ moiety (172) (Approach 2): 
Compound 159 was coupled with 3, 5-di tert-butyl-4-hydroxycinnamic acid (118) 
using EDCI/HOBt amide coupling reagent and DIPEA in dry DMF to give a 
novel compound 2-(2-(4-N-(3,5-di-tert-butyl-4-
hydroxyphenyl)acrylamido)aminophenyl))ethylamino-2,3,-O-
isopropylideneadenosine-5-N-ethylcarboxamide (171) in 85% yield (Scheme 
2.33).   
 
Scheme 2.33: Synthesis of di-tert-butylhydroxycinnamic acid adenosine analogue possessing a 
substituted aniline linker moiety (172) (Approach 2). Reagents and conditions: (i) EDCI/HOBt, DMF, DIPEA 
25 °C; (ii) 1 M HCl solution, MeCN, 55–60 °C, 5 h. 
The reaction of 159 with 118 gave a single reaction product (as identified by 
TLC), which was purified by using column chromatography to give 171 in 85% 
121 
 
yield.  In the 1H NMR (CD3OD) spectrum, of the product 171, two alkene 
protons appeared at 7.27 and 6.65 ppm as doublets and the phenolic hydroxy 
proton appeared as a broad singlet at 5.57 ppm.  Two multiplets at 2.77 ppm 
with an integral corresponding to two protons and a triplet appeared at 0.59 
ppm with an integral corresponding to three ethyl group protons from the ribose 
amide moiety.  An extra two peaks corresponding to the carbon of the ethene 
group also appeared in the 13C NMR spectrum at 117 ppm and 138 ppm, 
respectively.   
 
The structure of 171 was supported by high-resolution mass spectrometry, 
which showed the expected molecular ion of M+H at 741.4490 m/z (EI+ HRMS 
showed a deviation of 0.040 ppm from the calc. mass of C40H53N8O6).  The 
melting point of 138–140 °C of the isolated compound 171 was sharp.  The 
purity of compound 171 was found to be >99.9% by analytical high-pressure 
liquid chromatography (HPLC).   
 
Deprotection of the isopropylidene group from compound 171 was achieved 
using 1 M HCl at at 55–60 °C. in 4.0 h to give 2-(2-(4-N-(3,5-di-tert-butyl-4-
hydroxyphenyl)acrylamido)phenyl))ethylamino)adenosine-5-N-
ethylcarboxamide (172) in 70% yield (Scheme 2.33).   
 
The deprotection reaction gave a single reaction product 172 (as identified on 
TLC), which was isolated and purified using column chromatography and partial 
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crystallisation with 75% methanol/ 25% water system.  In the 1H NMR 
(CD3COCD3) spectrum of 172, a doublet of two alkene protons appeared at 
7.24 and 5.92 ppm and the phenolic hydroxy proton appeared as a broad 
singlet at 5.59 ppm.  Two multiplets at 3.07 and 3.36 ppm with an integral 
corresponding to two protons and a triplet appeared at 1.03 ppm with an 
integral corresponding to three protons for the ethyl group from the ribose 
amide substituent.  An extra two peaks corresponding to the carbon of the ethyl 
group linker also appeared in the 13C NMR spectrum (CD3OD) at 34.1 ppm and 
42.5 ppm, respectively and two ethene group carbons appears at 117.2 and 
142.6 ppm.  The structure of the deprotected product 172 was supported by 
MS, which showed the expected molecular ion of M+H at 701.4096 m/z, (EI+ 
HRMS showed a deviation of 0.032 ppm from the calc. mass of C37H49N8O6).  
The melting point of 241–243 °C (decomposed) of isolated compound 172 was 
sharp.  The purity of compound 172 was found to be >99.9% using analytical 
HPLC.   
 
All the novel C2-substituted para-aminoethylaniline linked adenosine analogues 
joined with antioxidant moieties were found to be difficult to purify and isolate by 
column chromatography.  The main products generated have close Rf values 
similar to starting materials and a byproduct.  The use of medium pressure 
chromatography (MPLC) was found to be a better technique to purify those 
components. 
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2.8 Result of biological testing of adenosine analogues 
2.8.1  Adenosine receptor-binding assay 
A number of C2-modified nitroxide adenosine compounds with various linker 
groups were successfully synthesised.  The potency and agonist activity (rather 
than antagonists or inverse agonists) of each adenosine analogues was 
assessed with a functional cAMP assay using transfected Chinese Hamster 
Ovary (CHO) cell lines, in which cells overexpress one of the relevant human 
A1, A2A, A2B, and A3 adenosine receptor subtypes. This analysis was undertaken 
at the Monash Pharmaceutical Institute, Melbourne. 
 
These functional assays provide an indication of the physiologically-relevant 
mode of interaction between test compounds and the target receptor 
subtypes307 and determination of the agonist activity of the compound in this 
case at human adenosine receptor subtypes (hAXAR, X=1, 2A, 3). Functional 
assays that measure a cAMP production were used to assess the (A1, A2A, A2B, 
and A3) receptor binding affinity for each of the novel compounds.   
 
This assay is based on a competition between cAMP attached to special 
fluorescence material present in the test well with the test cells, and the 
stimulation or inhibition of intracellular cAMP production by receptor agonism.  
The generation of fluorescent material is relative to the total amount of cAMP at 
the end of the experiment, and is measured by photo-stimulating the fluorescent 
material and measuring the degree of fluorescence. 
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The potency for the A2AAR, and A2BAR is measured by pEC50, which is the 
logarithmic value of concentration at which exactly half of the receptor 
population is in a fully-activated state (i.e. the concentration of an agonists that 
produces a 50% of physiological response).  The A1AR and A3AR data is 
reported as a pIC50 value, which is also a measure of potency, but more 
commonly used for antagonists (this is because A1AR and A3AR act 
biochemically in opposition to the A2AAR) and therefore the assay reports the 
inverse of the pEC50 for the A1AR and A3AR.
121  In this case, both assays are 
equivalent measures of relative agonist activity at the adenosine receptor 
subtype in question, and are expressed here in nanomoles (nM).   
 
Next, the activity of a compound can be compared to that of other compounds 
for each of the adenosine receptor subtypes assayed.  The values are an 
indication of relative functional selectivity and are expressed as a unitless ratio.  
Functional selectivity ratios are calculated simply by dividing the pEC50 of the 
compound at A2AAR by the pIC50 of the compound at the A1AR (or A3AR) 
subtype.  The value is an indication of how much more functionally active the 
compound is at A2AAR than the other receptor subtypes (i.e. a value of A2A/ A1 
of 100 means the compound is 100 times more potent in terms of functional 
selectivity at A2AAR than A1AR).  Desirable figures of this measure tend towards 
more than a thousand fold in favour of the target receptor subtype relative to all 
other receptor subtypes.  The assays were conducted upon all three structural 
classes of compounds at A1AR, A2AAR, A2BAR and A3AR receptor subtypes, 
and the results are presented in Table 1. 
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cAMP Accumulation Assay.  Adenosine is found naturally in nanomolar 
concentrations in human interstitial fluid, and this level is essential for any 
potential drug acting at the adenosine receptor.  However, in this work, 
compounds that exhibited nanomolar pEC50 and pIC50 values were described 
here, which could act as desirable targets for further development as 
cardioprotective agents.   
 
The receptor binding results generated by the adenosine compounds from this 
structural class are listed in Table 1.    
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Table 2.1: cAMP analysis of aminoethylaniline linked adenosine compounds (pEC50 and pIC50) in nM. 
No. Compound Structure pIC50 - A1R 
pEC50 - 
A2AR 
pEC50 - 
A2BR 
pIC50 - A3R A2A/A1 A2A/A3 A2A/A2B 
162 
 
5.2 ± 0.3 8.1 ± 0.2 7.4 ± 0.3 7.3 ± 0.2 794 6.3 5 
164 
 
5.7 ± 0.2 8.1 ± 0.1 7.8 ± 0.3 7.0 ± 0.2 251 13 2 
166 
 
5.5 ± 0.2 8.7 ± 0.3 7.7± 0.2 6.9 ± 0.3 1585 63 10 
168 
 
5.5 ±0.3 8.0 ± 0.2 6.4 ± 0.5 7.1 ± 0.1 316 8 40 
170 
 
N.D.(< 5) 8.2 ± 0.1 7.7 ± 0.1 7.7 ± 0.3 <1585 3 3 
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The dual action of adenosine agonist compounds possessing effective radical 
scavenger nitroxide moieties and the C2-binding domain of A2AAR selective 
compounds has not been explored to date.  To investigate such selectivity, a 
number of C2-modified nitroxide adenosine compounds were synthesised with 
various linker groups.  The potency and agonist activity (rather than antagonists 
or inverse agonists) of the adenosine analogues was assessed with a this type 
of downstream cAMP assay using transfected CHO lines.  These cells 
overexpress one of the human A1, A2A, A2B, and A3 adenosine receptor 
subtypes.  In general the C2-substituted nitroxides with 4-(2-aminoethyl)aniline 
linked N6-aminoadenosine-5-N-ethylcarboxamide compounds (162-172) have 
shown a good A2AAR affinity.  
 
It is well known that the C2-binding domain with particular linkers can 
accommodate a wide range of aryl and cycloalkyl groups. The incorporation of 
very bulky tetramethylisoindoline-2-yloxyl, tetraethylisoindoline-2-yloxyl, 
tetramethylpiperidine-1-yloxyl, and tetramethylpyrrolidine-1-yloxyl nitroxide 
groups in this position afforded agonists with excellent affinity for the A2AAR.  In 
order to improve receptor affinity, the antioxidant nitroxide moiety was attached 
via an aminoethylaniline linker.  Linkers of this type have previously proven to 
be effective in connecting adenosine receptor agonists with antioxidant moieties 
(compounds 48 and 49).121   
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In some cases, large selectivity increases were seen with C2-substituted 
nitroxides possessing (4-aminophenyl) ethylaminoadenosine-5-N-
ethylcarboxamide (namely compounds 162, 164, 166, 168 and 170) showing 
more than 200-fold selectivity for the A2AAR over A1AR and reasonable 
selectivity over A3AR.   
 
All adenosine compounds in the first structural class with aminoethylaniline 
linked series are potent A2AAR agonists with pEC50 values ranging from 8.0-8.7.  
Compound 166 is marginally the most potent adenosine analogue with pEC50 
value of 8.7.  These compounds also showed good selectivity versus A1AR (251 
to 1585) and modest selectivity versus A3AR (up to 63 fold).  Similarly, these 
compounds also have modest selectivity versus A2BAR (2 to 40 fold).  
 
In a comparison of structurally related antioxidant groups in the first structural 
class with aminoethylaniline linked series series, structural modification has 
limited effect on the A2AAR selectivity.  For example the tetramethylisoindoline 
nitroxide 162 has a pEC50 of 8.1 at the A2AAR.  The incorporation of a 
methylene spacer in compound 168 has no (statistically significant) effect on 
A2AAR activity (168; pEC50 of 8.0 ± 0.2).  Likewise, tetraethyl substitution had no 
statistical effect on A2A potency (cf. 162 v 170 with pEC50 values of 8.1 ± 0.2 
and 8.2 ± 0.1, respectively).  The above facts support the concept that the 
antioxidant group is protruding into the extracellular space when the agonist is 
bound to the A2AAR.   
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2.8.2 Simulated Ischemia Assay121.   
A number of potent and selective C2-modified aminoethylaniline linked nitroxide 
adenosine agonists were successfully assessed with this type of simulated 
ischaemia assay.  This assay is one measure of investigating cardioprotective 
action of agonists.  This ischaemia assay was conducted using a previously 
reported cell culture hypoxia model to determine cell protection in the ischemic 
induced rat arterial cardiomyoblast cell line H9c2.258, 308-310  This cell line cells 
are incubating in hypoxic simulated ischaemia.  This analysis was undertaken at 
the Monash Pharmaceutical Institute, Melbourne.   
 
The assay was conducted using the most potent and selective dual functionality 
adenosine compounds 162, 164, 166, and 170 along with known compound 
VCP874 (49) for further analysis.  All compounds possess antioxidant moieties 
combined with aminoethylaniline linked adenosine analogues.  These 
antioxidants possessing aminoethylaniline linked adenosine compounds have 
good A2AAR selectivity (with pEC50 values of 8.0-8.7 nM) and have 
demonstrated positive control in the study of ischemic cell protection as shown 
in Figure 2.3 (panel A).   
 
Specifically, the adenosine compounds 162 and 170 were selected for further 
examination in an ischemic cell culture hypoxia assay.  These compounds were 
analysed by combining with a known A2AAR antagonist SCH442415, to observe 
the effect of the antioxidants.  This study shows that these dual acting ligands 
gave significant cardioprotective effects, however, these effects were largely 
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inhibited by A2AAR antagonist SCH442415.  This means that these effects were 
primarily mediated by A2AAR activation and a limited effect by the nitroxide 
antioxidant species was evident.  There were some additional cardioprotective 
effects observed at the highest concentration in the presence of antagonist.  
These results may indicate that the antioxidant activity makes some contribution 
in cardioprotection at that point of high concentration as shown in Figure 2.3 
(panel B).   
                            A                                                                    B 
 
Figure 2.3: Dual acting A2AAR agonists - antioxidants decrease cell death within an in vitro model of 
simulated ischemia. A) 162 (), 164 (), 166 () and 170 () stimulate an equivalent, concentration-
dependent, decrease in cell death to the reference ligand VCP874 (). B) The decrease in cell death 
mediated by 162 () and 170 () was inhibited in the presence of the A2AAR antagonist, SCH442415 ( 
162 + 100 nM SCH442415; 170 + 100 nM SCH442415). Cell death was assessed by determining the 
proportion of non-viable, propidium iodide positive, cells; N=2-4. 
The smaller ring nitroxide adenosine compounds linked with the 
aminoethylaniline linker group were found to be more potent and selective to 
the adenosine receptors than other larger nitroxides containing adenosine 
analogues.  Furthermore, tetraethyl modified nitroxide adenosine compounds 
also have better adenosine agonist activity.  However, these compounds have 
no major differences in the selectivities to the particular adenosine receptors.  In 
addition, side chains do not limit binding and are not detrimental to bioassays.  
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This means that even small or large group modifications are also tolerated in 
the adenosine receptor selectivity; therefore, a small spacer linker group such 
as alkynyl-linked nitroxide possessing adenosine compounds were synthesised.  
In addition, it has been previously reported that the alkyne containing 
compounds at adenosine C2-position are selective to the A2AAR.  In order to 
expand the possible side chain variations all of which still possess a nitroxide or 
phenolic antioxidant, a further target of ethynyl-linked extended groups were 
developed.  
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Compounds having groups linked by an alkyne joined at the C2-position of the 
adenosine are reported to be selective adenosine receptor agonists.  A series of 
2-alkynyl-5-N-ethylcarboxamide compounds were previously synthesised.311  
These compounds were studied for the binding and functional assays to assess 
their potencies for the A2AR compared to the A1AR.  These compounds are 
known to have desirable effects on vasorelaxation without impacting on heart 
rate.  C2-alkynyl-5-N-ethylcarboxamide compounds were found to be selective 
A2AR agonists
243 (Figure 3.1).  Moreover, some of these alkynyl-linked 
compounds were also found to possess good A1AR/A2AR affinity.  Some of the 
hydroxy alkynyl adenosine derivatives are potent inhibitors of platelet 
aggregation and could be beneficial in the treatment of cardiovascular 
disorders.311 
 
Figure 3.1: Candidate moieties and their actions in the second structural class of target adenosine 
analogues. 
The alkynyl linker was intended to promote specific receptor recognition.  
Binding studies312 have shown that the presence of a phenylethynyl group in the 
134 
 
C2-position of adenosine 65 (Figure 3.2) favoured the interaction with A3AR, 
with the resulting compounds displaying high affinity and selectivity for the 
adenosine A3AR.  Additional substitution at the N
6- and C4-positions interact 
with the hydrophilic pocket on the adenosine receptor to increase both the A3AR 
agonists affinity and also the H-bonding at the 3- and 5-positions which are 
required for A3AR agonism.
313-315   
 
Figure 3.2: Adenosine A3AR agonists (PENECA) 65 
The initial adenosine synthetic targets of this work can be synthesised from the 
adenosine intermediate 2-iodo-2,3-O-isopropylideneadenosine-5-N-
ethylcarboxamide (149) by coupling with the appropriate alkyne isoindoline 
nitroxide (120, and 122) or non-nitroxide moiety.  The published methodology 
for achieving these targets involves the Sonogashira coupling reaction.  
3.1 Synthesis of C2-substituted TMIO adenosine analogues 
possessing substituents attached by an ‘ethynyl 
linker’moiety (178)  
3.1.1 Synthesis of the 2-iodo-2,3-O-isopropylideneadenosine-5-N-
ethylcarboxamide intermediate (149) 
Functional group interconversion of the C2-amine of O6-(benzotriazol-1-yl)-2,3-
O-isopropylideneadenosine-5-N-ethylcarboxamide (144) to the nucleophilic 
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aromatic substitution-promoting iodine was accomplished using the method of 
Kim273 (Scheme 3.1) The reaction proceeded smoothly achieving 2-iodo-O6-
(benzotriazol-1-yl)-2,3-O-isopropylideneadenosine-5-N-ethylcarboxamide 
(148) in 86% yield on a scale ranging from 50-200 mg.  
 
Scheme 3.1: Overview of synthesis of C2-iodo adenosine intermediate (149) Reagents and conditions: (i) 
CH2I2, t-BuONO, in MeCN, 68 %. (ii) 28% aq. ammonia MeCN. 
The reaction conditions were reasonably harsh because diiodomethane was 
used as an iodination agent and MeCN as the solvent, and the reaction was 
carried out at a temperature of 65–70 °C.  The solvent and excess of 
diiodomethane was removed by evaporating the reaction mixture under vacuum 
for a long time.  The impurity was successfully removed by excessive washing 
with ethyl acetate.  The Rf value for the product 148 was 0.42 in 1:4 
DCM/MeOH and was distinguishable from 144 by TLC, (Rf. 0.37 for the C2-
amino compound 144).  These values indicates that the polarity of the molecule 
slightly decreased with the introduction of the electronegative iodine atom and 
the removal of the amine. 
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In the 1H NMR spectrum (d6-DMSO), the broad singlet at 6.67 ppm 
corresponding to the heteroaromatic amino at C2-position of compound 144 
was not present.  The C8-proton appeared to be a sharp singlet.  This singlet 
was shifted to the more deshielded region from 8.04 to the 8.19 ppm for the 
iodo substituted adenosine compound 148.  In the 13C NMR spectrum, a peak 
for the C2-carbon of the purine ring appeared at 144.0 ppm.  Additionally, there 
was a signal at 168 ppm which was assigned to the amide carbonyl carbon.  
The melting point of 194–196 °C for the product 148 was sharp.  The structure 
of deprotected product 148 was supported by HRMS, which showed the 
expected molecular ion of M+Na at 615.0808 m/z, (EI+ HRMS showed a 
deviation of 0.0371 ppm from the calc. mass of C21H21INaN8O5)   
 
Ammonia solution was used to displace the more labile benzotriazolyl leaving 
group from compound 148 with nucleophilic amines262, 282 and form a 6-amino 
product 2-iodo-2,3-O-isopropylideneadenosine-5-N-ethylcarboxamide (149) 
(Scheme 3.1).  This SNAr reaction proceeded smoothly in acetonitrile at room 
temperature overnight.  Purification via column chromatography gave good 
yields between 70–80% of an off-white solid on a 250 mg to 1 g scale.  A 
second component separated by column chromatography was identified as a 
small amount of amino-substituted product at the C2-position.   
 
As expected, the Rf value of 149 on TLC decreased as the benzotriazolyl group 
was lost and the polarity increased slightly.  The Rf value was measured at 0.62 
using 7:3 ethyl acetate/MeOH.  In d6-DMSO, the major features of the 
1H NMR 
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spectrum of 149 were the absence of signals from the benzotriazolyl aromatic 
protons and the broad singlet signal which appeared at 7.85 ppm with an 
integral corresponding to two N6-protons.  Signals from the 2- and 3-protons 
coalesced completely from two resolved doublets to a singlet peak at 5.35 ppm 
with an integral corresponding to two protons.  Similarly, in the 13C NMR 
spectrum, signals from the benzotriazolyl aromatic carbons disappeared.  
Furthermore, the signals for the 2- and 3-carbons coalesced to give two 
identifiable signals separated by 0.03 ppm.  The melting point of 196–198 °C of 
the product 149 was sharp.  The structure of the product 149 was supported by 
MS, which showed the expected molecular ion of M+H at 497.0390 m/z, (EI+ 
HRMS showed a deviation of 0.0030 ppm from the calc. mass of 
C15H19INaN6O4).  The purity of product 149 was found to be 99.99% by 
analytical HPLC in a 80% methanol/20% water system.   
A number of adenosine molecules were generated with either tetramethyl and 
tetraethyl nitroxide or a phenyl side chain joined by with an ethynyl linker by 
modification of adenosine at the C2-position and with 5-N-ethylcarboxamide 
modification of the ribose ring.   
3.1.2 Synthesis of ethynyl TMIO (ETMIO) intermediate (120) 
In this synthesis, firstly the nitroxide moiety 5-ethynyl-1,1,3,3-
tetramethylisoindoline-2-yloxyl (ETMIO) nitroxide 120 was synthesised from 5-
bromo-tetramethylisoindoline (102) according to the procedure reported in the 
literature316 (Scheme 3.2).  
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Scheme 3.2: Synthesis of 5-ethynyl-1,1,3,3-tetraethylisoindoline-2-yloxyl (ETMIO) (120) 
316
. Reagents and 
conditions: (i) I2, n-BuLi, H2O2, Stir 30 min, 69% (ii) Na2WO4.2H2O,H2O2,NaHCO3, Stir 72 h. 79%. (iii) 
DABCO, Pd(OAc)2, 2-methyl-3-butyn-2-ol, MeCN, 80 %; (iv) KOH, Toluene, 90 %. 
5-Bromo-1,1,3,3-tetramethylisoindoline (102) was reacted with n-BuLi in dry 
THF and then quenched with iodine to obtain a di-iodo intermediate, in which 
iodination occurred on the ring as well as on the nitrogen atom.  This product 
was subsequently treated with H2O2 to generate a mono-iodo compound 5-iodo-
1,1,3,3-tetramethylisoindoline (104) in 69% yield.  Compound 104 was then 
oxidised by 30% H2O2 in the presence of the Na2WO4.2H2O catalyst in MeCN to 
give 5-iodo-1,1,3,3-tetramethylisoindoline-2-yloxyl (105) in 79% yield.  The 
compound 105 was then coupled with 2-methyl-3-butyne-2-ol (160) using 
palladium diacetate (Pd(OAc)2) in the presence of 1,4-diazabicyclo(2.2.2) 
octane (DABCO) as a base using triethylamine as a solvent to obtain 5-(2-
methyl-3-butyne-2-ol)-1,1,3,3-tetramethylisoindoline-2-yloxyl (119)316 in 80% 
yield.   
 
The reaction mechanism of alkyne coupling with the palladium reagent is 
detailed in Scheme 3.3.  Deprotection of the dimethylpropanol group from 
compound 119 with solid KOH in refluxing MeCN resulted in the formation of E-
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TMIO 120 in 90% yield (Scheme 3.2).  The melting point of 96–98 °C of the 
recrystallised product was consistent and in agreement with the published 
values316 for the desired product 120.   
3.1.3 Coupling of E-TMIO with iodo-adenosine intermediate (178)   
The ethynyl isoindoline nitroxides and phenyl acetylene were then coupled in 
separate reactions with the adenosine iodo intermediate under Sonogashira 
coupling conditions to achieve coupling products 177, 181 and 185.  The details 
of the reaction mechanisms are explained as follows. 
 
The palladium-catalysed alkynylation called the Sonogashira reaction is a 
convenient method to synthesise aryl and other acetylene-substituted 
compounds.  This methodology was first discovered in 1975 by Cassar,317 
Dieck, Heck318 and Sonogashira et al.319  The method used was an 
amalgamation of the Castro–Stephens reaction320, 321, involving Cu-promoted 
alkynylation and alkyne implementation of the Heck reaction.  Sonogashira et 
al. used Cu (I) in the presence of the Pd (0) catalyst, which favours the alkynyl 
transformation at room temperature. The reaction was achieved under much 
milder conditions and is now commonly referred to as the Sonogshira coupling 
reaction.   
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Scheme 3.3: Sonogshira coupling reaction mechanism. 
This coupling of terminal alkynes with aryl halides typically proceeds with two 
catalysts, palladium (0) (Pd(PPh3)2Cl2) and copper (I) co-catalyst (CuI) using 
triethylamine as base.  This reaction requires anhydrous conditions; however 
newer techniques have recently been developed, where these restrictions are 
not required.322  Reactions can be carried out under mild conditions using 
mixtures of solvents at room temperature.  The aryl halide first forms a complex 
with the palladium catalyst by oxidative addition.  The presence of base results 
in the formation of an alkyne π-complex, which makes the terminal carbon of 
the alkyne more acidic and leads to the formation of a copper-acetylide 
complex.  Trans-metalation with palladium and the copper acetylide along with 
leaving of the halide ion leads to the formation of an alkyne palladium complex, 
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which can undergo reductive elimination to give rise to the desired C–C 
coupling product (Scheme 3.3).   
 
Using this approach 5-iodo-2,3-O-isopropylideneadenosine-5-N-
ethylcarboxamide 149 was coupled with 5-ethynyl-1,1,3,3-
tetramethylisoindoline-2-yloxyl (E-TMIO) 120. This reaction was carried out 
using Pd(PPh3)2Cl2 and copper iodide as the Sonogashira coupling reagent 
along with a catalytic amount triethylamine in dry DMF.  The reaction gave the 
novel compound 2-(1,1,3,3-tetramethylisoindoline-2-yloxyl-5-ethynyl)-2,3-O-
isopropylideneadenosine-5-N-ethylcarboxamide (177) in 76% yield (Scheme 
3.4) .   
 
Scheme 3.4: Synthesis of ETMIO-substituted adenosine analogue (178) Reagents and conditions: (i) Pd 
(PPh3)2Cl2, CuI, TEA in DCM/MeCN, 76%. (ii) 1 M HCl in MeCN 55-60 °C, 98%.  
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The reaction was carried out in a mixture of freshly distilled DCM and dry MeCN 
under an argon atmosphere at room temperature.  The reaction was followed by 
TLC and went to completion in 20 h with a product Rf value of 0.64 in 
chloroform: ammonia solution (9.8:0.2) as the mobile phase solvent system.   
 
The reaction of 120 with 149 produced a single adduct 177 along with some 
alkyne nitroxide starting material (<5%) (as identified by TLC).  The product was 
isolated and purified by column chromatography using ethyl acetate and 
aqueous ammonia solution (9.8:0.2) as the mobile phase.  In the 1H NMR 
spectrum, paramagnetic broadening was observed as expected due to the 
nitroxide radical. This broadening resulted in some peaks not being detected 
and giving poor integration.  However, the signal of the adenosine moieties 
could be detected.  The synthesis of product 177 was supported by HRMS, 
which showed the expected molecular ion of M+H at 561.2682 m/z, (EI+ HRMS 
showed a deviation of 0.0018 ppm from the calc. mass of C29H35N7O5).  The 
melting point of 146–148 °C of the isolated compound 177 was sharp.  The 
purity of product 177 was found to be 97.4% by analytical HPLC in an 80% 
methanol/20% water system.   
 
Deprotection of the isopropylidene group from compound 177 was achieved 
using 1 M HCl at 55–60 °C in 8.0 h. The reaction gave the novel target 
compound 2-(1,1,3,3-tetramethylisoindoline-2-yloxyl-5-ethynyl)-adenosine-5-N-
ethylcarboxamide 178 in 98% yield (Scheme 3.4).   
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The deprotection reaction gave a single product 178 (as identified on TLC), 
which was isolated by column chromatography using (9.8:0.2) chloroform and 
aqueous ammonia solution as the mobile phase. In the 1H NMR spectrum, 
paramagnetic broadening was observed as expected due to the nitroxide 
radical. This broadening resulted in some peaks not being detected and giving 
poor integration.  However, the signal of the adenosine moieties could be 
detected.  The synthesis of product 178 was supported by HRMS, which 
showed the expected molecular ion of M+Na at 543.2281 m/z, (EI+ HRMS 
showed a deviation of 0.0075 ppm from the calc. mass of C26H30NaN7O5).  The 
melting point of 261 °C (decomp) for the isolated compound 178 was sharp.  
The purity of product 178 was found to be 99.9% using analytical HPLC in an 
80% methanol/20% water system.   
3.2 Synthesis of C2-substituted TEIO adenosine analogues 
possessing substituents attached by an ‘ethynyl linker’ 
moiety (182) 
A novel compound 5-ethynyl-1,1,3,3-tetraethylisoindoline-2-yloxyl (E-TEIO) 122, 
which was synthesized from compound 105 and obtained from advanced stage 
synthesis in the laboratory.  Compound 149 was coupled with compound 122 
using Pd(PPh3)2Cl2 and copper iodide as the coupling reagents.  The reaction is 
employed a catalytic amount of triethylamine in dry DMF to produce a novel 
compound 2-(1,1,3,3-tetraethylisoindoline-2-yloxyl-5-ethynyl)-2,3-O-
isopropylideneadenosine-5-N-ethylcarboxamide (181) in 83% yield (Scheme 
3.5).    
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Scheme 3.5: Synthesis of ETEIO-substituted adenosine analogue (182) ,Reagents and conditions: (i) Pd 
(PPh3)2Cl2, CuI, TEA in DCM/MeCN, 83%. (ii) 1 M HCl in MeCN 55-60 °C, 88%. 
 
The reaction was carried out with a mixture of freshly distilled DCM and dry 
MeCN under an argon atmosphere at room temperature.  The reaction went to 
completion in 20 h (as identified by TLC) with Rf value of product 0.47 in (DCM / 
MeOH, 9:1). 
 
The reaction of 122 with 149 produced a single product 181 along with some 
alkynyl nitroxide starting material (<5%) (as identified by TLC).  The product 
was isolated and purified by column chromatography in 83% yield.  In the 1H 
NMR spectrum, paramagnetic broadening was observed as expected due to the 
nitroxide radical.  This broadening resulted in some peaks not being detected 
and giving poor integration.  However, the signal of the adenosine moieties 
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could be detected.  The synthesis of product 181 was supported by HRMS, 
which showed the expected molecular ion of M+H at 617.3296 m/z, (EI+ HRMS 
showed a deviation of 0.0030 ppm from the calc. mass of C33H43N7O5).  The 
melting point of 188–190 °C of the isolated compound 181 was sharp.  The 
purity of the product 181 was found to be 97.4% using analytical HPLC in an 
80% methanol/20% water system.   
 
The deprotection of isopropylidene group from compound 181 was achieved 
using 1 M HCl at 55–60 °C in 8.0 h.  The reaction generated the novel target 
compound 2-(1,1,3,3-tetraethylisoindoline-2-yloxyl-5-ethynyl)-adenosine-5-N-
ethylcarboxamide (182) (Scheme 3.5).   
 
The deprotection reaction of 181 gave a single product 182 (as identified on 
TLC), which was purified by column chromatography to give product 182 in 88% 
yield.  In the 1H NMR spectra, paramagnetic broadening was observed as 
expected due to the nitroxide radical that resulted in some peaks not being 
detected and giving poor integration.  However, signals of the adenosine moiety 
could be detected.  The synthesis of product 182 was supported by HRMS, 
which showed the expected molecular ion of M+Na at 577.3012 m/z, (EI+ 
HRMS showed a deviation of 0.0001 ppm from the calc. mass of C30H39N7O5).  
The melting point of 196–198 °C (decomp) of the isolated compound 182 was 
sharp.  The purity of the product 182 was found to be 99.9% using analytical 
HPLC in an 80% methanol/20% water system.    
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3.3 Synthesis of C2-substituted non-nitroxide phenyl 
adenosine analogues possessing substituents attached by 
an ‘ethynyl linker’ moiety (185)  
The compound 149 was coupled with phenylacetylene (123) using Pd(PPh3)2Cl2 
and copper iodide as the coupling reagent as well as a catalytic amount of 
triethylamine in dry DMF.  The coupling reaction produced the expected product 
2-(2-phenylethynyl)-2,3-O-isopropylideneadenosine-5-N-ethylcarboxamide 
(185) in 97% yield (Scheme 3.6).   
 
Scheme 3.6: Synthesis of the phenylacetylene-substituted adenosine analogue (185). Reagents and 
conditions: (i) Pd (PPh3)2Cl2, CuI, TEA in DCM/MeCN, 97%.  
The reaction was carried out with a mixture of freshly distilled DCM and dry 
MeCN under an argon atmosphere.  The reaction went to completion in 15 h (as 
identified by TLC) at room temperature.   
 
The reaction of 149 with 123 produced a single adduct 185 along with some 
detectable alkyne nitroxide starting material (< 5%) (as identified by TLC).  The 
product was isolated and purified by column chromatography using100% 
chloroform.  In the 1H NMR spectrum, a new peak appeared in the aromatic 
region as a multiplet for three protons from the phenyl group at 7.35–7.40 ppm 
along with one multiplet for two aromatic protons which appeared at 7.58 ppm.  
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In the 13C NMR spectrum, three additional signals appeared as strong peaks 
corresponding to the aromatic phenyl carbons at 128.4, 129.5 and 132.3 ppm.  
The other signals appeared at 84.9 and 114.9 ppm for the alkyne carbons.  The 
synthesis of product 185 was supported by HRMS, which showed the expected 
molecular ion of M+H at 449.1881 m/z, (EI+ HRMS showed a deviation of 
0.0057 ppm from the calc. mass of C23H25N6O4).  The melting point of 174–176 
°C of the isolated compound 185 was sharp.  The purity of product 185 was 
found to be 99.9% using analytical HPLC in a 80% methanol/20% water 
system.   
 
3.4 Results of biological testing of adenosine analogues 
3.4.1 Adenosine receptor binding assays 
A number of C2-modified nitroxide adenosine compounds were synthesised 
with ethynyl linker groups.  The potency and agonist activity (rather than 
antagonists or inverse agonists) of the adenosine analogues were assessed 
with this type of downstream cAMP assay.  This test was implemented using 
transfected CHO lines in which cells overexpress one of the human A1, A2A, A2B, 
and A3 adenosine receptor subtypes.  This assay was carried out by our 
collaborators at the Monash University Melbourne.  
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Table 3.1: cAMP analysis of ethynyl linked adenosine compounds(pEC50 and pIC50) in nM 
No. Compound Structure 
pIC50 - 
A1R 
pEC50 - 
A2AR 
pEC50 - 
A2BR 
pIC50 - 
A3R 
A2A/A1 A2A/A3 A2A/A2B A2B/A1 A2B/A3 A2B/A2A 
178 
 
6.6 ± 0.2 6.2 ± 0.2 7.0 ± 0.4 6.5 ± 0.1 0.4 0.5 0.5 3 3 6 
182 
 
6.3± 0.2 5.6 ± 0.2 7.0 ± 0.7 N.D.(< 5) 0.2 4 0.5 5 100 25 
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The molecules from this series of adenosine linked nitroxide were found to have 
low A2AAR selectivity with pEC50 values ranging from 5.6-6.2 nM.  The alkyne 
(ethynyl) linked tetramethylisoindoline-2-yloxyl nitroxide adenosine compounds 
(178; pEC50 of 6.2 ± 0.2) and tetraethylisoindoline-2-yloxyl nitroxide adenosine 
(182; pEC50 of 5.6 ± 0.2) were significantly less selective for A2AAR over the 
other receptor subtypes.   
 
However, this structural class of nitroxide linked with ethynyl moieties to 
adenosine displayed a slightly higher selectivity for A2BAR with pEC50 values 
(178; pEC50 of 7.0 ± 0.4) and (182; pEC50 of 7.0 ± 0.7) respectively.  The above 
results indicate that the nitroxide adenosine compounds with two carbon 
(ethynyl) linker are better in A2BAR potency and selectivity than the non-
nitroxide adenosine compounds.   
 
These analogues demonstrate slightly higher selectivity for the adenosine 
A2BAR over the other adenosine receptor subtypes.  Specifically, the adenosine 
analogue 178 shows 6 fold better selectivity for A2BAR over A2AAR and 3 fold 
better selectivity over other receptor subtypes.  Adenosine analogue 182 shows 
25 fold selectivity for adenosine A2BAR over A2AAR and 5 and 100 fold 
selectivity over adenosine A1AR and A3AR subtypes respectively ( Table 3.1). 
 
These ethynyl linked nitroxide adenosine compounds synthesised have no 
significant impact on the affinity of the A2AAR.  However, these modified 
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adenosine analogues were found to be selective for the A2BAR.  This 
modification shows the promising characteristics to develop the new A2BAR 
selective compounds.  It was postulated that the flexible chain linker might 
increase the selectivity for the A2AAR agonists.  To find out the effect of 
flexibility on the adenosine receptor selectivity, it was decided to reduce the 
ethynyl triple bond between the adenosine and antioxidant nitroxide moiety in 
order to generate a new class of compounds.   
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 Results and Discussion Part C: Adenosine 4
analogues with ethyl linker possessing 
antioxidant moieties 
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The adenosine synthetic targets of this work have been synthesised starting 
from adenosine-5-N-ethylcarboxamide coupled with nitroxides and non-
nitroxide compounds joined by an ethynyl linker chain to generate nitroxides 
and non-nitroxides possessing ethyl linked adenosine compounds.  These 
ethylene-linked adenosine targets possessing nitroxide antioxidant moieties 
were expected to be highly selective towards the A2AR.  This selectivity is 
expected to arise based on previous reports showing that A2AR selectivity is 
provided through the incorporation of 2 (or 3) atom chain spacers connected to 
the adenosine C2-position.  In this project, a number of nitroxide and non-
nitroxide compounds possessing a 5-amide group (the 5-NECA modification) 
were synthesised by modification of the C2-position using a two methylene 
carbon linkage, with no polar atoms attached.  It was expected that this would 
provide good A2AR specificity whilst allowing a range of structurally-diverse 
antioxidant groups to be incorporated (Figure 4.1). 
 
Figure 4.1: Candidate moieties and their actions in the third structural class of target adenosine 
analogues. 
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A number of adenosine molecules were generated with tetramethyl and 
tetraethylisoindoline nitroxides as well as a phenyl group as the non-radical, 
non-antioxidant analogue and each was joined to adenosine at the adenosine 
C2-position by an ethyl linker were achieved by the reaction of the appropriate 
alkyne at the adenosine C2-position.  These compounds also possesse the 5-
N-ethylcarboxamide modification to enhance receptor subtype specificity.   
 
In this approach, the alkynyl linked nitroxides and non-nitroxide adenosine 
compounds were reacted further with palladium on carbon under hydrogen gas 
at room temperature in methanol to reduce the triple bond and afford the 
‘saturated-linker’ adenosine compounds.   
4.1 Synthesis of C2-substituted TMIO adenosine analogues 
possessing substituents attached by an ‘ethyl linker’ 
moiety (180) 
2-(1,1,3,3-Tetramethylisoindoline-2-yloxyl-5-ethynyl)-2,3-
isopropylideneadenosine-5-N-ethylcarboxamide (177) was reacted with 
palladium on carbon under a hydrogen atmosphere at room temperature to 
afford the novel reduced compound 2-(1,1,3,3-tetramethylisoindoline-2-yloxyl-5-
ethyl)-2,3-isopropylideneadenosine-5-N-ethylcarboxamide (179) in 84% yield 
(Scheme 4.1).    
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Scheme 4.1: Overview the synthesis of the TMIO-nitroxide with ethyl linked adenosine compound 
(180),Reagents and conditions: (i) 10% Pd/C, H2, MeOH, 84%. (ii) PbO2 , MeOH.(iii)1 M HCl, MeCN, 55–60 
°C, 79%.  
The reaction went to completion in methanol in 12 h (as identified on TLC).  The 
Rf value of the product 179 was 0.023 in 1:4 DCM/MeOH (Rf. = 0.37 for the C2-
amino compound 177), indicating that the polarity of the molecule had 
decreased markedly by reduction of the triple bond.   
 
The reduction reaction of 177 produced a single product (as identified by TLC).  
In this reaction, the nitroxide radical was also hydrogenated to form the N-
hydroxy compound.  This hydroxy compound was not isolated or characterised 
(Scheme 4.1).  The crude mixture was subjected to reoxidation using lead oxide 
(PbO2) in methanol to regenerate the nitroxide radical compound 179.  The 
product 179 was isolated and purified by column chromatography using a 
mixture of CHCl3: MeOH (9:1) mobile phase.  In the 
1H NMR spectrum, 
paramagnetic broadening was observed as expected due to the nitroxide 
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radical which resulted in some peaks not being detected and giving poor 
integration, however the signal of the adenosine moieties could be detected.  
The synthesis of product 179 was supported by HRMS, which showed the 
expected molecular ion of M+H at 564.3276 m/z, (EI+ HRMS showed a 
deviation of 0.033 ppm from the calc. mass of C29H38N7O5).  The melting point 
of 108–110 °C of the isolated compound 179 was sharp.  The purity of the 
product 179 was found to be 96.7% using analytical HPLC in an 80% 
methanol/20% water system.   
 
Deprotection of the isopropylidene group from compound 179 was achieved 
using 1 M HCl at 55–60 °C in 8.0 h and generated the novel target compound 2-
(1,1,3,3-tetramethylisoindoline-2-yloxyl)-5-ethyl)-adenosine-5-N-
ethylcarboxamide (180) in 79% yield (Scheme 4.1).   
 
The deprotection of compound 179 produced a single product 180 (as identified 
by TLC).  The Rf value of the product 180 was 0.16 in CHCl3/MeOH (8:2).  The 
product was isolated and purified by column chromatography using a mixture of 
CHCl3: MeOH (9:1) mobile phase.  In the 
1H NMR spectra, paramagnetic 
broadening was observed as expected due to the nitroxide radical which 
resulted in some peaks not being detected and giving poor integration, however 
the signal of the adenosine moieties could be detected.  The synthesis of 
product 180 was supported by HRMS, which showed the expected molecular 
ion of M+H at 525.2833 m/z, (EI+ HRMS showed a deviation of 0.013 ppm from 
the calc. mass of C26H35N7O5).  The melting point of 122–124 °C of the isolated 
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compound 180 was sharp.  The purity of product 180 was found to be 99.9% 
using analytical HPLC in a 80% methanol/20% water system.   
4.2 Synthesis of C2-substituted TEIO adenosine analogues 
possessing substituents attached by ‘ethyl linker’ moiety 
(184).   
2-(2-(1,1,3,3-Tetraethylisoindoline-2-yloxyl)-5-ethynyl)-2,3-
isopropylideneadenosine-5-N-ethylcarboxamide (181) was reacted with 
palladium on carbon under hydrogen atmosphere using a hydrogen gas balloon 
at room temperature afford the novel reduced compound 2-(1,1,3,3-
tetraethylisoindoline-2-yloxyl-5-ethyl)-2,3-isopropylideneadenosine-5-N-
ethylcarboxamide (183) in 97% yield (Scheme 4.2).  
 
Scheme 4.2: Overview synthesis of TEIO-nitroxide with ethyl linked adenosine compound (184) Reagents 
and conditions: (i) 10% Pd/C, H2, MeOH, 97%. (ii) PbO2 , MeOH. (iii) 1 M HCl, MeCN, 55–60 °C, 70%. 
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The reaction was carried out in a mixture of methanol with 10% palladium on 
carbon as the solvent under a hydrogen atmosphere at room temperature.  The 
reaction went to completion in 12 h (as identified on TLC).  The Rf value of 
product 183 was 0.023 in a mixture of DCM/MeOH (1:4), indicating that the 
polarity of the molecule was decreased markedly by reduction of the triple bond.   
 
The reduction of compound 181 produced a single component (as identified by 
TLC).  In this reaction, the nitroxide radical also hydrogenated to form N-
hydroxy compound.  This hydroxy compound was not isolated or characterised 
(Scheme 4.2).  The crude mixture was subjected to reoxidation using lead oxide 
(PbO2) in methanol to regenerate the nitroxide radical product 183.  The product 
183 was isolated and purified by column chromatography using DCM/MeOH 
(9:1) mobile phase.  In the 1H NMR spectrum, paramagnetic broadening was 
observed as expected due to the nitroxide radical which resulted in some peaks 
not being detected and giving poor integration, however the signal of the 
adenosine moieties could be detected.  The synthesis of product 183 was 
supported by HRMS, which showed the expected molecular ion of M+H at 
621.3630 m/z, (EI+ HRMS showed a deviation of 0.0009 ppm from the calc. 
mass of C33H47N7O5).  The melting point of 88–90 °C of the isolated compound 
183 was sharp.  The purity of product 183 was found to be 89% using analytical 
HPLC in an 80% methanol/20% water system.   
 
Deprotection of the isopropylidene group from compound 183 was achieved 
using 1 M HCl at 55–60 °C in 8.0 h and generated a novel target compound 2-
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(1,1,3,3-tetraethylisoindoline-2-yloxyl-5-ethyl)adenosine-5-N-ethylcarboxamide 
(184) in 70 % yield (Scheme 4.2).   
 
The deprotection of compound 183 produced a single product 184 (as identified 
by TLC).  The Rf value of the product 184 was 0.69 in DCM/MeOH (9:1).  The 
product was isolated and purified by column chromatography using (100%) 
chloroform as mobile phase.  In the 1H NMR spectra, paramagnetic broadening 
was observed as expected due to the nitroxide radical which resulted in some 
peaks not being detected and giving poor integration, however the signal of the 
adenosine moieties could be detected.  The synthesis of product 184 was 
supported by HRMS, which showed the expected molecular ion of M+H at 
581.3277 m/z, (EI+ HRMS showed a deviation of 0.0049 ppm from the calc. 
mass of C30H43N7O5).  The melting point of 138–140 °C of the isolated 
compound 184 was consistent.  The purity of product 184 was found to be 
>99.9% using analytical HPLC in 80% methanol/20% water system.   
4.3 Synthesis of C2-substituted non-nitroxide phenyl 
adenosine analogues possessing substituents attached by 
an ‘ethyl linker’ moiety (188). 
2-(2-Phenylethynyl)-2,3-isopropylideneadenosine-5-N-ethylcarboxamide (185) 
was reacted with palladium on carbon under hydrogen atmosphere at room 
temperature to afford the novel reduced compound 2-(2-phenylethyl)-2,3-
isopropylideneadenosine-5-N-ethylcarboxamide (187) in 93% yield (Scheme 
4.3).  
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Scheme 4.3: Overview of synthesis of the non-nitroxide phenyl ethyl linker to the adenosine compound 
(188) Reagents and conditions: (i) 10% Pd/C, H2, 93% MeOH. (ii) 1 M HCl, MeCN, 55–60 °C, 94%. 
The reaction was carried out at room temperature in a mixture of methanol with 
10% palladium on carbon under hydrogen atmosphere at room temperature.  
The reaction went to completion in 12 h (as identified on TLC).  The Rf value of 
the product 187 was 0.023 in DCM/MeOH (9:1), indicating that the polarity of 
the molecule was decreased markedly compared to starting material by 
reduction of the triple bond.   
 
The reduction reaction of 185 produced a single product 187 (as identified by 
TLC), which was purified and isolated twice by column chromatography using 
DCM/MeOH (9:1) mobile phase.  In CDCl3, the major features of the 
1H NMR 
spectrum of the hydrogenated adenosine analogue 187 was the appearance at 
3.05-3.11 ppm a multiplet integrating for four protons corresponding to the two 
methylene groups, as well as the signal for the methyl group from the acetal 
protection appeared at the 1.37 and 1.58 ppm.  Likewise, in the 13C NMR 
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spectrum, two methylene carbon signals appeared at 33.7 and 40.5 ppm. The 
synthesis of the product 187 was supported by HRMS, which showed the 
expected molecular ion of M+H at 453.2243 m/z, (EI+ HRMS showed a 
deviation of 0.0007 ppm from the calc. mass of C23H29N6O4).  The melting point 
of 70–72 °C of the isolated compound 187 was sharp.  The purity of the product 
187 was found to be 98% using analytical HPLC in an 80% methanol/20% 
water system.   
 
Deprotection of the isopropylidene group from compound 187 was achieved 
using 1 M HCl at 55–60 °C in 8 h and generated the novel target compound 2-
(2-phenylethyl)adenosine-5-N-ethylcarboxamide (188) in 94% yield (Scheme 
4.3).  The deprotection of compound 187 produced a single product 188 (as 
identified by TLC).  The Rf value of the product 188 was 0.69 in DCM/MeOH 
(1:4), The product was purified and isolated by column chromatography using 
100% chloroform as the mobile phase.  In CDCl3, the major features of the 
1H 
NMR spectrum of deprotected adenosine analogue 188 were the 
disappearance of the methyl signals from the acetal protection at the 1.37 and 
1.58 ppm.  Likewise, in the 13C NMR spectrum, two methylene carbon signals 
disappeared at 25.2 and 26.9 ppm. The synthesis of the product 188 was 
supported by HRMS, which showed the expected molecular ion of M+H at 
413.2019 m/z, (EI+ HRMS showed a deviation of 0.0082 ppm from the calc. 
mass of C20H25N6O4).  The melting point of 216–217 °C (decomp). of the 
isolated compound 188 was sharp.  The purity of the product 188 was found to 
be >99.9% using analytical HPLC in an 80% methanol/ 20% water system.    
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4.4 Results of Biological testing of adenosine analogues 
A number of C2-modified nitroxide adenosine analogues were synthesised with 
ethyl linker groups.  The potency and agonist activity (rather than antagonists or 
inverse agonists) of the adenosine analogues was assessed with a downstream 
cAMP assay using transfected CHO lines.  These cells overexpress one of the 
human A1, A2A, A2B, and A3 adenosine receptor subtypes.  The details about the 
cAMP Accumulation Assay have recently been described.121  This assay was 
carried out at Monash University in Melbourne. 
 
The tetraethylisoindoline-2-yloxyl nitroxide adenosine analogue 184 possessing 
a two carbon chain (ethyl) linker moiety showed less A2AAR affinity (184; pEC50 
of 5.2 ± 0.2) than non-nitroxide species (188; pEC50 of 6.0 ± 0.1) when 
compared to all other receptors subtypes.  The compound 188 with ethylene 
linked phenyl was prepared in this structural class of comppounds is to compare 
the effect of radical and non-radical species on adenosine receptors.  The 
compound 180 with tetramethyl isoindoline nitroxide linker was not tested for 
cAMP assay because it was synthesised after the last batch of compounds was 
tested.  
 
All compounds in the final series are less-potent A2AAR agonists with pEC50 
values ranging from 5.2–6.0.  However, compound 184 is a slightly higher 
potent adenosine analogue for A2BAR with pEC50 of 7.0 ± 0.5) compared to 
other receptor subtypes.  The non-nitroxide adenosine analogue also showed 
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somewhat good selectivity for A1AR and A3AR (pEC50 of 7.1± 0.2 and 7.0± 0.2) 
respectively, compared to other adenosine receptor subtypes.  
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Table 4.1: cAMP analysis of ethyl linked adenosine compounds (pEC50 and pIC50 values in nM. 
No. Compound Structure 
pIC50 - 
A1R 
pEC50 - 
A2AR 
pEC50 - 
A2BR 
pIC50 - 
A3R 
A2A/A1 A2A/A3 
A2A/A2
B 
A2B/A1 A2B/A3 
A2B/
A2A 
184 
 
6.0± 0.2 5.2± 0.2 7.0± 0.5 N.D.(< 5) 0.2 <2 <2 10 100 63 
188 
 
7.1± 0.2 6.0± 0.1 6.3± 0.6 7.0 ± 0.2 0.08 0.1 0.1 
A1/A2B 
13 
A3/A2B 
10 
- 
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Specifically, radical species (TEIO nitroxide) possessing adenosine analogue 
184 with an ethyl linker moiety has been demonstrated to have 63 fold better 
selectivity at the adenosine A2BAR over the adenosine A2AAR subtype.  
However, it was 10 and 100 fold selective for the A1AR and A3AR subtype 
respectively.  Non-radical, non-nitroxide species (phenyl group) possessing 
ethyl linked adenosine derivative 188, exhibited slightly increased selectivity 
towards the adenosine A1AR and A3AR subtypes (10–13 fold), over the 
adenosine A2AAR and A2BAR subtypes. 
 
However, it was confirmed that the nitroxide possessing adenosine compounds 
with ethyl linkers also have the similar receptor subtype affinity and selectivity at 
A2BAR as the ethyne linked nitroxide adenosine compounds from the previous 
chapter.  In addition, it was also confirmed that flexibility of the linker chain has 
no significant impact on receptor-binding .  
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5.1 Synthetic chemistry  
This project focused on the design, synthesis and biological evaluation of novel 
adenosine compounds that incorporate radical antioxidant species.  These 
hybrid analogues are designed to act potentially as selective adenosine 
receptor agonists.  They are specifically designed to target the A2A adenosine 
receptors.  The A2A adenosine receptors are one of the primary drug targets in 
the management of ischaemia reperfusion injury.  It has previously been 
reported that having a potent antioxidant molecule within a molecular framework 
of A2AAR agonists significantly increases their therapeutic efficacy.  Therefore, 
this work was based on linking/combining antioxidant molecules with known 
adenosine receptor agonists.  The main classes of antioxidant molecules 
explored are nitroxides and phenolic compounds.  These compounds were 
linked via enzymatically cleavable (esters, amides) and non-clevable 
(aminoethylaniline, ethynyl, ethyl) bonds. 
 
Facilitating this approach, three structural classes of adenosine analogues were 
designed and synthesised using a linear methodology.  In total, twelve novel 
hybrid adenosine compounds were synthesised in nine to twelve synthetic 
steps.  In eleven of those new adenosine analogues, the antioxidant moieties 
were incorporated at the C2-position of the adenosine skeleton.  These 
analogues were designed to act as bifunctional ligands at the adenosine A2AAR 
subtype.  In the twelveth adenosine compound, the C2-position was modified 
with a phenyl group instead of an antioxidant.  This was intended to act as a 
control to compare the effect of the presence of an antioxidant moiety.  
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5.1.1 Adenosine based antioxidant compounds with para-
aminoethylaniline linkers 
In the first set of antioxidant-linked adenosine analogues, the C2-position of the 
adenosine intermediate 146 was functionalised with a series of sterically 
hindered antioxidant nitroxides via a para-aminoethylaniline linker.  Different 
ring classes of nitroxides, having tetramethyl substitution predominantly at the 
α-carbon (some with tetraethyl substituent), were used.  Adenosine intermediate 
146 was synthesised in high yield from commercially available guanosine 138 in 
seven steps.  The key step in the synthesis of adenosine N-ethylcarboxamide 
(NECA) 146 involves the generation of 143 which was achieved through the 
synthesis of a novel guanosine-5-ethyl ester analogue 142.  The synthesis of 
143 was accomplished successfully in high yield by the esterification of 
appropriately substituted guanosine-5-carboxylic acid 140.   
 
Addition rate and addition sequence of the reagents and reactants make a 
significant difference in the time span in completion of the amide coupling 
reaction.  The amide coupling reaction was complete in 21 h compared to 48 h, 
when the carboxy nitroxide reactant was added after the addition of the other 
coupling reagents to give the C2-substituted adenosine analogue in reduced 
time.   
 
The deprotection of the isopropylidene group was carried out using dilute 
hydrochloric acid (HCl).  Using this easier and cheaper deprotection reagent 
gave better yields and compared to the reported resin mediated isopropylidene 
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deprotection.323  However, the isopropylidene deprotection of adenosine 
derivatives with dilute HCl gave the deprotected adenosine analogues in (50–
71%) moderate yields.  These moderate yields were attributed to the low 
solubility of the deprotected adenosine analogues.  The synthesis of the target 
adenosine analogues was achieved in a with ten step reaction scheme starting 
from guanosine and achieved in an overall yield of 9–12%. 
 
Purification and isolation of the novel antioxidant possessing aminoethylaniline 
linked adenosine analogues was found to be difficult using silica gel column 
chromatography.  The product generated has an Rf value close to the starting 
materials and a byproduct.  The use of medium pressure chromatography 
(MPLC) with a reverse phase column was found to be a better technique to 
purify those components.  All the adenosine were analogues generated in > 
98% pure and all the novel target adenosine analogues were isolated with > 
99.9% purity (as analysed by HPLC).   
5.1.2 Adenosine based antioxidant compounds with ethynyl linkers 
In a second structural class of adenosine compounds, two novel alkynyl 
(ethynyl) linked adenosine analogues were successfully synthesised 
possessing sterically bulky isoindoline nitroxide substituents attached at the C2-
position of the adenosine skeleton.  In this synthesis, the key step was the 
formation of the ethynyl coupled product between the 2-iodo adenosine 149 and 
the appropriate terminal alkyne functionality of 120 and 122 and 123.  This 
synthesis was achieved using the Sonogshira coupling procedure under mild 
reaction conditions.  The ethynyl linked adenosine product was successfully 
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synthesised in good overall yields of 53% and by 58% respectively.  All the 
novel target adenosine analogues were isolated in this class were > 99.9% 
purity (as analysed by HPLC). 
5.1.3 Adenosine based antioxidant compounds with ethyl linkers 
In a third structural class of adenosine compound, three novel adenosine 
analogues were successfully synthesised possessing ethyl linked sterically 
bulky isoindoline nitroxides and a phenyl group substituents at the C2-position 
of the adenosine skeleton.  In this project, a four-stage reaction scheme was 
employed to synthesise the target adenosine analogues.  The isoindoline 
nitroxide possessing ethynyl linked adenosine analogues 177 and 181 and 185 
(from the chapter 3) were the key materials used as starting compounds.  The 
target adenosine analogues were achieved in excellent overall yields of 62% 
and 64% respectively.  In addition, a single non-nitroxide ethyl linked adenosine 
derivative was synthesised using a three-step reaction scheme from the iodo 
adenosine intermediate 149 in a high overall yield of 74%.  All the novel target 
adenosine analogues isolated in this class were > 99.9% purity (as analysed by 
HPLC). 
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5.2 Biological Testing 
In this project, three structural classes comprising of twelve novel hybrid 
adenosine compounds were synthesised.  In eleven of those novel compounds, 
an antioxidant functionality was incorporated into the adenosine framework to 
generate the bifunctional compounds.  Each structural class of adenosine 
analogue was tested for the adenosine agonist activity and selectivity at A1AR, 
A2AAR, A2BAR, and A3AR.  All three structural classes of adenosine analogues 
were found to act as adenosine agonists to all adenosine receptor subtypes.   
5.2.1 Adenosine based antioxidant compounds with para-
aminoethylaniline linkers 
In this work, seven novel antioxidants possessing aminoethylaniline linked 
adenosine analogues were found to be selective as the human adenosine 
receptor agonists.  Specifically, these adenosine analogues are acted as 
selective bifunctional ligands at the adenosine A2AAR subtype.  The adenosine 
A2AARs are one of the primary drug targets in the pathophysiology of 
cardiovascular diseases.  The activation of adenosine A2AAR is required to 
achieve higher cardioprotection via ischemic preconditioning.  In addition, these 
receptor subtype are strongly involved in anti-ischemic action to avoid damage 
induced by reperfusion injury.  In this regard, all these synthesised adenosine 
analogues were shown to have very promising characteristics and may be 
implicated in potential cardiac treatments.   
 
The nitroxide radical functionality and the ring size of the cyclic nitroxide moiety 
have no significant difference in the receptor-binding ability at any of the four 
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adenosine receptor subtypes.  From this, it can be postulated that the nitroxide 
functionality of the five compounds did not interact in any great extent within the 
binding pocket of the adenosine receptors.   
 
However, all these adenosine derivatives retained more than 200-fold selectivity 
to adenosine A2AAR over the A1AR subtype.  Specifically, the adenosine 
analogue possessing PROXYL nitroxide (166) and TEIO nitroxide (170) 
substituents being displayed more than 800 fold selectivity for the A2AAR over 
the A1AR.  These compounds have low selectivity versus A2BAR (3 and 10 fold).  
In addition, these analogues demonstrate modest selectivity for A2AAR over the 
A3AR (63 and three fold).  Therefore, it is beneficial to implicate some of these 
adenosine A2AAR selective analogues in further ischemic evaluations.   
 
All the adenosine analogues from this first structural class were analysed in the 
further cardioprotection testing by using cell-based simulated ischemia assay.  
All compounds have demonstrated positive control in the study of an ischaemia 
cell protection assay.  The test indicates that, the positive cardioprotective effect 
is primarily mediated by A2AAR activation.  Furthermore, additional 
cardioprotective effects were observed at the highest concentration is may be 
due to the contribution of antioxidant activity.  However, it can be said with 
confidence that the incorporation of antioxidant functionality does not have a 
measurable adverse effect on selectivity as adenosine A2AAR agonists.  It is 
reemphasized here that selectivity at the receptor subtype is an equally 
important characteristic than compounds potency.  This feature justifies the 
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original hypothesis that the C2-binding domain can accommodate sufficient 
structural variations.  This property makes feasible the design and application of 
bifunctional compounds of this nature in the cardioprotection. 
5.2.2 Adenosine based antioxidant compounds with ethynyl linkers 
Compounds from a second structural class include antioxidant linked adenosine 
analogues with ethynyl linkers.  These adenosine analogues demonstrated no 
significant impact on selectivity at adenosine A2AAR.  However, these 
analogues show slightly higher selectivity for the adenosine A2BAR over the 
other adenosine receptor subtypes.  This characteristic activity of these 
analogues as a selective adenosine A2BAR agonists may be implicated in their 
therapeutic applications. 
5.2.3 Adenosine based antioxidant compounds with ethyl linkers 
Compounds from a third structural class include two adenosine analogues 
possessing various antioxidant isoindoline nitroxides linked with two carbon 
chain (ethyl) linker moieties.  Similarly, to the second class nitroxide adenosine 
compounds, these nitroxide compounds exhibit high selectivity at A2BAR over 
the other receptor subtypes.  However, no significant selectivity at A2AAR was 
observed.  
 
However, non-nitroxide phenyl group possessing ethyl linked adenosine 
derivative 188, exhibited slightly increased selectivity towards the adenosine 
A1AR and A3AR subtypes over the adenosine A2AAR and A2BAR subtypes.  
There is no significant difference in selectivities of non-nitroxide adenosine 
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analogues with an ethynyl or ethyl linkers, all are selective at adenosine A1AR 
and A3AR subtypes. 
 
In this structural class of compounds, the comparison between adenosine 
compounds possessing antioxidant groups with non-antioxidant groups was 
found to have significant effect on the selectivity of particular adenosine 
receptor subtypes.  The adenosine compound possessing antioxidant groups 
has higher selectivity at the adenosine A2BAR subtype.  However, the 
adenosine compound possessing non-antioxidant groups has greater selectivity 
at the A1AR and A3AR subtypes compared to other receptor subtypes.  In this 
regard, the characteristics of this adenosine analogues possessing nitroxide 
antioxidant moiety as A2BAR selective analogues may be implicated in the 
further testing in the potential treatment as coronary vasodilator or 
antihypertensive agents.   
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No further pharmacological testing of the adenosine compounds was able to be 
conducted within the time frame of the project and this remains an missing 
piece of this work.  While the functional data has confirmed that the compounds 
possess agonists function, testing for compound antioxidant efficacy remains to 
be performed.  
 
The functional efficacy of the antioxidant combined adenosine analogues would 
be more challenging to effectively measure.  The work described in this thesis 
has been an initial exploration into the concept of ligands for selective 
adenosine receptors that also possess an antioxidant species.  No further 
pharmacological testing was conducted within the time frame of this project.  
Although this research has resulted in the synthesis of compounds that are 
potent adenosine agonists ligands, there are three main areas that can be 
identified where there is opportunity for further development of the concept of 
dual action adenosine receptor ligands.  These areas are i) Synthesis of novel 
adenosine compounds that are designed to be selective adenosine A2AAR 
agonists with propynyl linkers linked to nitroxide antioxidant capabilities.  This 
joining of three carbon distance with a triple bond (alkyne) compounds 
increases the selectivity for A2AAR and antioxidant function will also have 
additional effects.  ii) Synthesis of tetraethyl modified smaller ring nitroxides with 
aminoethylaniline linked adenosine compounds will increase the selectivity for 
A2AAR.  The nitroxide functionality will be blocked at some extent by more 
hindered tetraethyl group.  This phenomenon will achieve better 
cardioprotection.  iii) More extensive biological evaluation of the novel 
compounds synthesised in this work remained to be performed, as the 
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functional data have confirmed that the compounds possess agonist function, 
testing for compound antioxidant efficacy remains to be performed.  
 
More extensive biological testing of the novel adenosine derivatives described 
in this work is required in order to measure their potential as cardioprotective 
treatments.  Although the antioxidant activity of both BHT and TMIO and other 
nitroxide functional groups are mentioned in the literature, the novel compounds 
synthesised in this work have not yet been tested for the comprehensive 
assessment of antioxidant activity.  In vitro, evaluation of the antioxidant 
capabilities of these antioxidant coupled adenosine analogues should be 
performed.  In addition, the further biological assay should be performed in a 
more complex biological system such as isolated perfused rat hearts 
(Langendorff heart assay) and live animal models which stimulate heart attack 
and ischaemia-reperfusion injury.  However, only after the biological evaluation 
of these compounds in a more complex system, their viability can be assessed 
as a potential cardioprotective treatment.   
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7.1 General Experimental 
All starting materials and required chemicals were purchased from Sigma-
Aldrich with purities of more than 95% and all solvents used were of analytical 
reagent (AR) grade except for HPLC.  Solvents were dried according the 
appropriate drying procedure under an argon atmosphere.  Solvents used such 
as acetone, tetrahydrofuran (THF), Dichloromethane (DCM), Chloroform 
(CHCl3), and methanol (MeOH), N, N-dimethylformamide (DMF) for air and 
moisture sensitive reactions were distilled under an argon atmosphere.  The 
solvents such as diethyl ether (Et2O), and toluene were dried under sodium wire 
and acetonitrile (MeCN) was dried under predried molecular sieves and used 
absolute ethanol (EtOH) for moisture sensitive reactions.  Demineralised (DM) 
water was used for all reaction work-ups. Thin layer chromatography was 
performed on aluminium backed silica F254 plates with UV light (254 nm) for 
chemical compound detection.  Column chromatography was performed using 
kieselgel 60 silica gel (200- 300 mesh) with eluents.   
 
Nuclear magnetic resonance spectra were recorded on a Bruker Advance 300 
WB (1H at 400 MHz and 13C at 75 MHz) or a Varian (1H NMR at 400 MHz and 
13C NMR at 101 MHz) FT- NMR spectrometer instrument.  NMR spectra are 
reported based on integration, chemical shift (δ ppm) and multiplicity (s = 
singlet, d = doublet, dd = doublets of doublet, t = triplet, q = quartet, m = 
multiplet, br = broad, coupling constant and assignment.  13C NMR spectra are 
reported according to the chemical shift, multiplicity, coupling constant (if 
appropriate) and assignment.  Deuterated solvents acetone (1H NMR 2.05/13C 
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NMR 29.84 ppm), chloroform (1H NMR 7.26/13C NMR 77.16 ppm); DMSO (1H 
NMR 2.50/13C NMR 39.53 ppm) and methanol (1H NMR 3.31/13C NMR 49.00 
ppm) was used for recording nuclear magnetic resonance spectra with their 
respective solvent residual peaks.   
 
High resolution mass analysis were performed on the Micromass platform II 
single quadrupole mass spectrometer equipped with the dual electron spray ion 
source.  Melting points were measured using a Gallenkamp melting point 
apparatus with a calibrated thermometer.  All the target final compounds (161-
174 and 177-188) were purified using a medium pressure liquid 
chromatography (MPLC) instrument using filtered HPLC grade methanol and 
HPLC grade water using C18 reverse phase column with 1 mL/ minute flow rate 
of mobile phase and 264 nM UV detector.  The purities of novel compounds 
(161-174 and 177-188) were analysed using analytical high performance liquid 
chromatography (HPLC) using a C18 reverse phase column with a 1 mL/minute 
flow rate with various solvent (methanol/water) ratios of mobile phase and 264 
nM UV detector. 
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7.2 Synthetic procedure 
7.2.1 Synthesis of 2-benzyl phthalimide (100). 
 
A suspension of phthalic anhydride (98) (20 g, 135 mmol, 1 equiv) in acetic acid 
(93.5 mL) was treated with benzylamine (99) (22.42 mL, 205 mmol, 1.52 equiv).  
The reaction mixture was heated at 120 °C and stirred for 1 h.  The resulting 
solution was poured onto an ice/ water mixture (150 mL) and collect the white 
precipitate by filteration.  The solid was recrystallised from ethanol to give 2-
benzyl phthalimide (100) as a white solid (26.5 g, 83%).  Rf = 0.83 (EtOAc / 
Hexane, 1:1).  
1H NMR (400 MHz, CDCl3) δ ppm:  4.85 (s, 2 H) 7.29 - 7.35 (m, 3 H) 7.43 (d, 
J=6.99 Hz, 2 H) 7.67 - 7.72 (m, 2 H) 7.84 (dd, J=5.40, 3.06 Hz, 2 H).  
13C NMR (101MHz, CDCl3) δ ppm: 41.6, 123.3, 127.8, 128.6, 128.7, 132.1, 
134.0, 136.3, 168.1. The obtained spectroscopic data was consistent with that 
previously reported.324 
Melting point: 116–118 °C  (lit.325 116 °C).  
HRMS (ESI): m/z calcd for C15H11NNaO2
+ [M+Na]: 260.0687, found: 260.0813 
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7.2.2 Synthesis of 2-benzyl-1,1,3,3-tetramethylisoindoline (101).  
 
A solution of compound 100 (40 g,168 mmol,1.0 equiv) in anhydrous toluene 
(320 mL) was treated with methyl magnesium iodide [freshly prepared from 
methyl iodide (62.75 mL,1008 mmol, 6.0 equiv) and pre-dried magnesium 
turnings (33 g, 1348 mmol, 8.0 equiv) in anhydrous Et2O (400 mL)].  The Et2O 
was distilled off via a Dean-stark.  The reaction mixture was heated to reflux, 
stirred for 3 h and then concentrated to half its volume.  Hexane (600 mL) was 
added, and the resulting mixture was filtered through celite and washed 
thoroughly with extra hexane (600 mL).  The filtrate was passed through a 
column of basic alumina and evaporated under reduced pressure to give a 
colourless oil that solidified at ambient temperature. This solid was 
recrystallised in MeOH to give 2-benzyl-1,1,3,3-tetramethylisoindoline (101) as 
a white crystalline solid (14 g, 31%), Rf = 0.9 (EtOAc / Hexane, 1:1).   
1H NMR (400 MHz, CDCl3) δ ppm: 1.33 (s, 12 H) 4.02 (s, 2 H) 7.16 (dd, J=5.52, 
3.17 Hz, 2 H) 7.26 (br. s., 2 H) 7.27 - 7.34 (m, 3 H) 7.49 (d, J=7.23 Hz, 2 H). 
13C NMR (101 MHz, CDCl3) δ ppm: 28.4, 46.3, 65.2, 120.6, 122.1, 126.0, 127.2, 
127.5, 128.6, 129.0, 143.5 and 147.9. The obtained spectroscopic data was 
consistent with that previously reported.76 
Melting point: 63–65 °C (lit.76 63–64 °C).   
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HRMS (ESI): m/z calcd for C19H24N
+ [M+H]: 266.1909, found: 266.1936. 
7.2.3 Synthesis of 5-bromo-1,1,3,3-tetramethylisoindoline (102)275  
 
A solution of compound 101 (5 g, 18.8 mmol, 1 equiv) in DCM (30 mL) under an 
atmosphere of argon was cooled to 0 °C in an ice bath.  A solution of liquid Br2 
(2.15 mL, 41.47 mmol, 2.2 equiv) in DCM (42 mL) was cautiously added 
followed by the immediate addition of anhydrous AlCl3 (9.5 g, 65.8 mmol, 3.5 
equiv).  The reaction was stirred at 0 °C for 1 h and then poured onto ice (200 
mL) and stirred vigorously for 30 minutes after which time the solution was 
basified with 10 M NaOH solution up to pH 14 and extracted with DCM (3 × 50 
mL).  The combined DCM layers were washed with brine (3 × 50 mL) and 
evaporated under reduced pressure to give 2, 5-dibromoisoindoline as a yellow 
oily residue.   
The residue was dissolved in methanol (30 mL), and NaHCO3 (280 mg) was 
added to the solution.  Aqueous H2O2 (30% aqueous solution, 15 mL) was then 
added slowly until no further effervescence could be detected (ensuring that 
some NaHCO3 remained).  The mixture was acidified with 2 M H2SO4 aqueous 
solution (up to pH 1) and extracted with DCM (3 × 50 mL) to remove the 
benzaldehyde by-product.  The combined organic layers were back extracted 
with 2 M H2SO4 to recover any removed product.  The combined aqueous 
phases were washed with DCM (3 × 50 mL), after which time they were cooled 
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in ice bath, basified with 10 M NaOH aqueous solution (up to pH 14) and 
extracted with DCM (3 × 50 mL).  The combined organic phases were washed 
with brine (3 × 50 mL) and dried (over anhydrous Na2SO4).  The solvent was 
removed under reduced pressure to give a golden oil which immediately 
crystallised to give yellowish-white solid, which was purified by silica gel column 
chromatography using a mixture of DCM: MeOH (8:2) to give 5-bromo-1,1,3,3-
tetramethylisoindoline (102) as a pale yellow solid (3.15 g, 64.5%).  Rf = 0.65 
(EtOAc: Hexane, 1:1). 
1H NMR (400 MHz, CDCl3): δ ppm 1.45 (s, 6 H) 1.47 (s, 6 H) 1.80 (br s, 1 H) 
7.00 (d, J=8.03 Hz, 2 H) 7.25 (d, J=1.58 Hz, 2 H) 7.35 - 7.39 (m, 3 H). 
13C NMR (101 MHz, CDCl3): δ ppm 31.8, 62.7, 120.8, 123.1, 123.2, 124.7, 
147.9, 151.3. (The obtained spectroscopic data was consistent with that 
previously reported)276 
Melting point: 58–60 °C (lit.276 58–60 °C). 
HRMS (ESI): m/z calcd for C12H17NBr
+ [M+H]: 254.0544 and 256.0524, found: 
254.0568 and 256.0549. 
7.2.4 Synthesis of 5-Bromo-1,1,3,3-tetramethylisoindoline-2-yloxyl 
(103)276. 
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To a solution of compound 102 (1.0 g, 3.92 mmol, 1 equiv), NaHCO3 (400 mg, 
4.312 mmol, 1.1 equiv) and Na2WO4.2 H2O (169 mg, 0.78 mmol, 0.2 equiv) in 
methanol (15 mL) was added 30% H2O2 solution (2.7 mL, 28.6 mmol, 7.3 
equiv).  The reaction mixture was stirred for 24 h, after which time added a 
second portion of NaHCO3 (400 mg, 4.312 mmol, 1.1 equiv), Na2WO4.2 H2O 
(169 mg, 0.78 mmol, 0.2 equiv) and 30% H2O2 (2.7 mL, 28.6 mmol, 7.3 equiv) 
were added and stirring was continued for 48 hours.  Water (40 mL) was then 
added into the reaction solution and the resulting mixture was extracted with 
DCM (3× 40 mL).  The combined organic phases were washed with 2 M HCl 
solution (40 mL), brine solution (3 × 40 mL) and dried over anhydrous Na2SO4.  
The solvent was concentrated under reduced pressure.  The residue was 
recrystallised (MeCN) to give 5-bromo-1, 1, 3, 3- tetramethylisoindoline-2-yloxyl 
(103) as a yellowish crystalline solid (1.0 g, 95%), Rf = 0.01 (EtOAc / MeOH, 
8:2). 
Melting point: 108–110 °C (lit.276 109 °C). 
HRMS (ESI): m/z calcd for C12H16NBrO
+ [M+2H]: 270.0494, found: 270.0487. 
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7.2.5 Synthesis of 5-iodo-1,1,3,3- tetramethylisoindoline (104)276. 
 
Compound 102 (300 mg, 1.176 mmol, 1 equiv) was dissolved in dry THF (3.4 
mL) under an atmosphere of argon.  The solution was cooled in a dry ice and 
acetone bath at –78 °C.  A solution of n-BuLi (1.6 M in hexanes, 1.95 mL, 3.22 
mmol, 2.74 equiv) was added dropwise to the stirring mixture, followed by the 
addition of a solution of iodine (0.9 g, 65.8 mmol, 6 equiv) in dry THF (7.5 mL).  
The reaction mixture was cooled to room temperature and then quenched by 
pouring onto an ice water mixture (150 mL).  The mixture was basified with 5 M 
NaOH solution (up to pH 14).  The resulting mixture was extracted with DCM (3 
× 25 mL), the combined organic phases were washed with brine (3 × 25 mL) 
and dried over anhydrous Na2SO4 and the solvent was concentrated under 
reduced pressure to give a yellow oily residue.   
The residue was taken up in MeOH (7.5 mL) and NaHCO3 (37.5 mg) was 
added, followed by the addition of 30% H2O2 solution, until no further 
effervescences could be detected.  The mixture was treated with 2 M H2SO4 (50 
mL) and washed with DCM (3 × 25 mL).  The combined organic layers were 
back extracted with 2 M H2SO4 to recover any removed product.  The combined 
aqueous phases were washed with DCM (25 mL) after which time they were 
cooled in ice bath and basified with 5 M NaOH solution (up to pH 14).  The 
resulting solution was extracted with DCM (3 × 25 mL).  The combined organic 
phases were washed with brine (3 × 25 mL), dried over anhydrous Na2SO4 and 
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the solvent was evaporated under reduced pressure to give a golden oil which 
immediately crystallised to give 5-iodo -1, 1, 3, 3- tetramethylisoindoline (104) 
as a pale yellow solid (243 mg, 69%).  Rf = 0.67 (EtOAc / Hexane, 3:7). 
1H NMR (400 MHz, CDCl3) δ ppm: 1.43 (s, 6 H) 1.44 (s, 6 H) 1.93 (br. s., 1 H) 
6.88 (d, J=7.92 Hz, 1 H) 7.44 (d, J=1.03 Hz, 1 H) 7.56 (dd, J=7.92, 1.22 Hz, 1 
H). 
13C NMR (101 MHz, CDCl3) δ ppm: 31.7, 62.7, 92.2, 123.5, 130.8, 136.1, 148.6, 
and 151.4. (The obtained spectroscopic data was consistent with that previously 
reported)79 
ESMS calcd for C12H17IN
+ [M+H]: 302.0406, found: 302.0400. 
7.2.6 Synthesis of 5-iodo-1,1,3,3-tetramethylisoindoline-2-yloxyl (105)79 
 
To a stirring solution of compound 104 (180 mg, 0.59 mmol, 1 equiv) in MeOH 
(2.7 mL), NaHCO3 (60 mg, 0.705 mmol, 1.195 equiv), Na2WO4.2H2O (25.4 mg, 
0.705 mmol, 0.135 equiv) and 30% H2O2 (0.5 mL, 4.307 mmol, 7.3 equiv) was 
added and the reaction mixture was stirred at room temperature for 24 h.  A 
second portion of NaHCO3 (60 mg, 0.705 mmol, 1.195 equiv), Na2WO4.2H2O 
(25.4 mg, 0.705 mmol, 0.135 equiv) and 30% H2O2 solution (0.5 mL, 4.307 
mmol, 7.3 equiv) was then added.  After 48 h, water (30 mL) was added and the 
resulting mixture was extracted with DCM (3 × 20 mL).  The combined organic 
phases were washed with 2 M HCl solution (25 mL) and brine solution (3 × 25 
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mL) and dried over anhydrous Na2SO4.  The solvent was concentrated under 
reduced pressure to give a yellow crystalline solid and which was recrystallised 
(MeCN) to give 5-iodo-1,1,3,3-tetramethylisoindoline-2-yloxyl (105) as an 
orange crystalline solid (150 mg, 79%).  Rf = 0.71 (EtOAc / Hexane, 3:7). 
Melting point: 133–135 °C (lit.79 133–135 °C).  
ESMS calcd for C12H16INNaO
+ [M+Na]: 339.0096, found: 339.0090. 
7.2.7 Synthesis of 5-carboxy-1,1,3,3-tetramethylisoindoline-2-yloxyl 
(106)275. 
 
A solution of n-BuLi (1.6 M in hexanes, 1.95 mL, 3.22 mmol, 2.74 equiv ) was 
added dropwise to a stirring solution of compound 102 (300 mg, 1.176 mmol, 1 
equiv) in a freshly distilled dry THF (3.4 mL) at –78 °C under an atmosphere of 
argon.  After stirring for 10 min, the solution was added slowly to a mixture of 
crushed dry ice (0.9 g, 65.8 mmol, 6 equiv) in freshly distilled dry THF (7.5 mL).  
The reaction mixture was warmed to room temperature under an atmosphere of 
argon and then concentrated under reduced pressure.  2 M HCl (15 mL) was 
added to the resulting residue and the solution was washed with Et2O (3 × 10 
mL). The combined organic phases were washed with 2 M HCl (15 mL).  The 
combined aqueous phases were neutralised with saturated Na2CO3 solution (15 
mL) and extracted with Et2O (3 × 20 mL).  The ether layers were washed with 
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water (3 × 20 mL) and brine (3 × 20 mL) and dried over anhydrous Na2SO4.  
The solvent was evaporated under reduced pressure to give yellow oily residue.   
The yellow oily residue was dissolved in MeOH (2 mL) at room temperature.  
NaHCO3 (40 mg, 3.92 mmol, 1.1 equiv), Na2WO4.2H2O (24 mg, 0.78 mmol, 0.2 
equiv) and 30% H2O2 solution (0.56 mL, 28.6 mmol, 7.3 equiv) were added and 
the reaction mixture was stirred for 24 h.  A second portion of NaHCO3 (40 mg, 
3.92 mmol, 1.1 equiv), Na2WO4.2 H2O (24 mg, 0.78 mmol, 0.2 equiv) and 30% 
H2O2 (0.56 mL, 28.6 mmol, 7.3 equiv) was added. The reaction mixture was 
stirred again for 48 h, after which time water (30 mL) was added to the reaction 
mixture and the resulting mixture was extracted with DCM (3× 40 mL).  The 
combined organic extracts were washed with 2 M HCl solution (40 mL) and 
brine solution (40 mL) and dried over Na2SO4.  The solvent was concentrated 
under reduced pressure to give a yellow crystalline solid, which was 
recrystallised (MeCN) to give 5-carboxy-1, 1, 3, 3- tetramethylisoindoline-2-
yloxyl (106) as a yellowish crystalline solid (140 mg, 76.5%).  Rf = 0.01 (EtOAc / 
MeOH, 8:2). 
IR: 2977 (alkylCH3)), 1680 (C=O), 1423, 1357 (N-O), 1256, 1160, 908, 840, 
774, 744. 
Melting point: 216–216 °C (lit.275 214–218 °C). 
ESMS calcd for C13H17 NO3
+ [M+H+]: 235.1208, found: 235.1198. 
EPR (methanol): typical 3-line nitroxide signal, g 1.9823, aN 1.5007 mT. 
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7.2.8 Synthesis of 2-benzyl-5-methylphthalimide(108)102. 
 
Benzylamine (20.5 mL, 92.6 mmol, 1.52 equiv) was added to a stirring 
suspension of 5-methylphthalic anhydride (107) (20.0 g, 123 mmol, 1 equiv) in 
acetic acid (94 mL).  The reaction mixture was refluxed at 120 °C for 1 h and 
then poured onto ice/ water mixture (500 mL) and stirred vigorously for 30 
minutes and the obtained white precipitate was filtered.  The residue was 
recrystallised from EtOH to give 2-benzyl-5-methylphthalimide (108) as a white 
solid (24.8g, 80%) Rf = 0.83 (100% EtOAc), 
1H NMR (400 MHz, CDCl3) δ ppm: 2.45 - 2.54 (m, 3 H) 4.83 (s, 2 H) 7.22 - 7.35 
(m, 3 H) 7.39 - 7.51 (m, 3 H) 7.60 - 7.67 (m, 1 H) 7.67 - 7.78 (m, 1 H). 
13C NMR (101 MHz, DMSO- d6) δ ppm: 22.0, 41.5, 123.3, 123.9, 127.7, 128.5, 
128.6, 129.5, 132.9, 134.5, 136.8, 145.3, 168.1 and 168.2. (The obtained 
spectroscopic data were consistent with that previously reported).102 
Melting point:128–130 °C .(lit 102 128–130 °C) 
HRMS (ESI): m/z calcd for C16H14NO2
+ [M+H]: 252.1025, found: 252.1067. 
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7.2.9 Synthesis of 2-benzyl-5-methyl-1,1,3,3-tetraethylisoindoline(109)102.  
 
A solution of compound 108 (10.0 g, 39.8 mmol, 1 equiv) in anhydrous toluene 
(80 mL) was treated with ethyl magnesium iodide [freshly prepared from ethyl 
iodide (19.2 mL, 239 mmol, 6.0 equiv) and pre-dried magnesium turnings (7.78 
g, 318.4 mmol, 8.0 equiv.) in anhydrous Et2O (100 mL)].  The Et2O was distilled 
off via dean-stark.  The reaction mixture was heated to reflux, stirred for 3 h and 
then concentrated to half its volume.  Hexane (4 x 200 mL) was added to the 
reaction mixture.  The resulting mixture was filtered through celite and washed 
thoroughly with extra hexane (600 mL).  The extracted hexane was bubbled 
overnight to dryness.  The residue was dissolved in hexane (600 mL) and 
passed through a column of basic alumina.  The resulting filtrate was 
evaporated under reduced pressure to give 2-benzyl-5-methyl-1,1,3,3-
tetraethylisoindoline (109) as a colourless oil (4.25 g, 32%). Rf = 0.92 (100% 
EtOAc).  
1H NMR (400 MHz, CDCl3) δ ppm: 0.78 (td, J=7.34, 2.93 Hz, 12 H) 1.53 (dd, 
J=13.90, 7.30, 3.30 Hz, 4 H) 1.84 - 1.97 (m, 4 H) 2.38 (s, 3 H) 4.01 (s, 2 H) 6.87 
(s, 1 H) 6.95 (d, J=7.78 Hz, 1 H) 7.00 - 7.06 (m, 1 H) 7.24 (br. s., 1 H) 7.27 - 
7.34 (m, 2 H) 7.46 (d, J=7.04 Hz, 2 H). 
13C NMR (75 MHz, CDCl3) δ: 9.6, 21.5, 30.3, 46.8, 71.0, 71.2, 123.2, 124.0, 
125.3, 126.5, 127.7, 128.2, 129.1, 129.3, 135.0, 141.7, 142.5, and 144.8; (The 
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obtained spectroscopic data was consistent with that previously reported for this 
compound).102 
HRMS (ESI): m/z calcd for C24H34N
+ [M+H]: 336.2691, found: 336.2677. 
7.2.10 Synthesis of 5-methyl-1,1,3,3-tetraethylisoindoline (110). 
 
To a solution of compound 109 (4.2 g, 12.5 mmol, 1.0 equiv) in acetic acid (100 
mL) was added palladium (10% charcoal = 1.0 g).  The reaction mixture was 
shaken under hydrogen pressure (50 psi in Parr apparatus) at room 
temperature for 3 h.  The mixture was filtered through celite and concentrated 
under reduced pressure.  The resulting residue was dissolved in DCM (150 mL) 
and the resulting solution was washed with saturated sodium bicarbonate 
(Na2HCO3) solution (3 x 50 mL).  The organic phase was dried over anhydrous 
Na2SO4 and concentrated under reduced pressure to give 5-methyl-1,1,3,3-
tetraethylisoindoline (110) as a yellow orange oil (2.82 g, 92%).  Rf = 0.92 
(EtOAc: MeOH, 8:2). 
1H NMR (400 MHz, CDCl3) δ ppm: 0.80 - 0.91 (m, 12 H) 1.59 - 1.78 (m, 8 H) 
2.35 (s, 3 H) 3.49 (s, 1 H) 6.86 (s, 1 H) 6.91 - 6.97 (m, 1 H) 7.01 (s, 1 H). 
13C NMR (101 MHz, CDCl3) δ ppm: 9.1, 21.5, 33.9, 47.0, 68.1, 68.2, 122.3, 
123.2, 127.5, 136.2, and 147.9. (The obtained spectroscopic data was 
consistent with that previously reported for this compound)102. 
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HRMS (ESI): m/z calcd for C17H28N
+ [M+H]: 246.2222, found: 246.2226.  
7.2.11 Synthesis of 5-methyl-1,1,3,3-tetraethylisoindoline-2-yloxyl (111). 
 
A solution of compound 110 (2.8 g,11.4 mmol, 1 equiv), NaHCO3 (1.04 g,125 
mmol, 1.1 equiv) and Na2WO4.2 H2O (0.42 g,15.5 mmol, 1.15 equiv) in MeOH 
(80 mL), was added dropwise 30% H2O2 solution (9.2 mL,105 mmol, 7.3 equiv 
).  The reaction mixture was stirred at room temperature for 24 h after which 
time a second portion of NaHCO3 (1.04 g,125 mmol, 1.1 equiv) and Na2WO4.2 
H2O (0.42 g,15.5 mmol, 1.15 equiv) and then 30% H2O2 solution (9.2 mL,105 
mmol, 7.3 equiv) were added and the stirring was continued for an additional 48 
h.  Water (160 mL) was then added to a reaction mixture and the resulting 
mixture was extracted in DCM (3 x 50 mL).  The combined organic phases were 
washed with 2 M H2SO4 solution (3 x 50 mL), brine (3 x 50 mL) solution and 
dried over anhydrous Na2SO4, filtered.  The solvent was evaporated under 
reduced pressure.  The resulting residue was purified by silica gel column 
chromatography (eluent 100 % DCM) to give 5-methyl-1,1,3,3-
tetraethylisoindoline-2-yloxyl (111) as a yellowish orange oil (1.35 g, 47%). Rf = 
0.53 (1:1 DCM/ Hexane). 
HRMS (ESI): m/z calcd for C17H27NaN
+ [M+Na]: 283.191, found: 283.1934. (The 
obtained spectroscopic data was consistent with that previously reported for this 
compound).102  
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7.2.12 Synthesis of 2-acetoxy-5-methyl-1,1,3,3-tetraethylisoindoline (112). 
 
To a stirring solution of compound 111 (1.35 g, 5.17 mmol, 1 equiv) in a dry 
THF (70 mL) was added palladium (10% charcoal, 137 mg).  The reaction 
mixture was stirred under balloon of hydrogen for 1 h.  The reaction mixture was 
cooled at 0 °C in ice bath and, triethylamine (1.44 mL, 10.34 mmol, 2 equiv) and 
acetyl chloride (0.92 mL) were added.  A mixture was allowed to warm up to 25 
°C and stirred for 1 h.  Argon gas bubbled over the mixture for 10 minutes and 
the reaction mixture was filtered through celite and evaporated under reduced 
pressure.  Water was poured onto the residue and the resulting mixture was 
extracted with EtOAc (3 x 50 mL).  The organic extracts were dried over 
anhydrous Na2SO4 and evaporated by distillation under reduced pressure.  The 
resulting residue was purified by silica gel column chromatography (eluent 1:1 
DCM/ Hexane) to give 2-acetoxy-5-methyl-1,1,3,3-tetraethylisoindoline (112) as 
a colourless oil which solidifies upon standing (1.55 g, 99%).  Rf = 0.78 (DCM/ 
Hexane, 1:1). 
1H NMR (400 MHz, CDCl3) δ ppm: 0.79 (br. s., 6 H) 0.95 (d, J=4.70 Hz, 6 H) 
1.60 - 1.80 (m, 4 H) 1.83 - 2.02 (m, 4 H) 2.10 (s, 3 H) 2.36 (s, 3 H) 6.86 (s, 1 H) 
6.94 (d, J=7.63 Hz, 1 H) 7.06 (d, J=7.48 Hz, 1 H). 
13C NMR (101 MHz, CDCl3) δ ppm: 8.7, 9.6, 19.6, 21.7, 29.0, 30.4, 73.7, 73.8, 
123.5, 124.2, 127.6, 136.3, 138.8, 141.9, and 170.7. (The obtained 
194 
 
spectroscopic data was consistent with that previously reported for this 
compound).102  
Melting point: 78–80 °C (Lit102 76–78 °C). 
HRMS (ESI): m/z calcd for C19H30NO2
+ [M+H]: 304.2277, found: 304.2293. 
7.2.13 Synthesis of 2-acetoxy-5-carboxy-1,1,3,3-tetraethylisoindoline(113). 
 
A solution of compound 112 (1.55 g, 5.12 mmol, 1 equiv) in tert-butyl alcohol 
(35 mL) was warmed to 40 °C.  Anhydrous MgSO4 (0.62 g, 5.12 mmol, 1 equiv) 
and potassium permanganate (0.4 M solution in water, 60 mL, 20.68 mmol, and 
4.04 equiv) were added to the solution and heated to 70 °C for 24 h and the 
reaction progress was followed by TLC analysis DCM: EtOAc (6:4).  The 
solution was cooled to 40 °C, was treated with 2-propanol (50 mL) and the 
reaction mixture was stirred at room temperature for 16 h, after which time it 
was filtered through celite.  The filtrate was then evaporated to half its volume 
and acidified with 2 M HCl solution (50 mL) up to pH 2.  Water was added to the 
mixture (50 mL) and extracted with Et2O (4 x 50 mL).  The organic layers were 
dried over anhydrous Na2SO4.  The combined organic phases were evaporated 
under reduced pressure.  The resulting residue was purified by using silica gel 
column chromatography (eluent DCM/ EtOAc, 6:4) to give 2-acetoxy-5-carboxy-
1,1,3,3-tetraethylisoindoline (113) as a white solid (1.32 g, 78%).  
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1H NMR (400 MHz, CDCl3) δ ppm: 0.80 (br. s., 6 H) 0.97 (br. s., 6 H) 1.57 - 1.85 
(m, 4 H) 1.85 - 2.06 (m, 4 H) 2.12 (s, 3 H) 7.17 (d, J=8.07 Hz, 1 H) 7.80 (s, 1 H) 
8.03 (d, J=7.92 Hz, 1 H). 
13C NMR (101 MHz, CDCl3) δ ppm: 8.5, 9.4, 19.3, 28.9, 30.2, 73.7, 74.0, 123.7, 
125.4, 128.0, 128.9, 142.3, 148.1 , 170.3., 170.8 (The obtained spectroscopic 
data was consistent with that previously reported for this compound).102 
Melting point: 168–170 °C. (Lit102 168–170 °C). 
HRMS (ESI): m/z calcd for C19H28NO4
+ [M+H]: 334.2018, found: 334.2042. 
7.2.14 Synthesis of 5-carboxy-1,1,3,3-tetraethylisoindoline-2-yloxyl (114). 
 
Compound 113 (1.3 g, 3.91 mmol, 1 equiv) was suspended in water (26 mL) 
and the mixture was cooled using ice/salt mixture up to 0–5 °C.  Lithium 
hydroxide (LiOH) (0.462 g, 19.47 mmol, 4.98 equiv) was added to the reaction 
mixture and ice bath was removed.  The mixture was stirred at room 
temperature for 20 h and the reaction progress was followed by TLC analysis  
EtOAc: MeOH (8:2) The resulting yellow solution was again cooled in ice bath 
and acidified with 2 M HCl (50 mL) solution and extracted with Et2O (5 x 50 mL).  
The combined ether layers were treated with lead oxide (PbO2) (0.462 g, 1.95 
mmol, 0.5 equiv) and stirred for 30 minutes.  The ether extract was dried using 
anhydrous Na2SO4, filtered.  The filtrate was evaporated under reduced 
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pressure to give yellow oil that solidifies upon standing, which was recrystallised 
(MeCN) to give 5-carboxy-1,1,3,3-tetraethylisoindoline-2-yloxyl (114) as yellow 
crystals. (1.02 g, 89%). 
Melting point: 102–104 °C. (lit.102 97–99 °C) 
HRMS (ESI): m/z calcd for C17H24NNaO3
+ [M+Na]: 313.1654, found: 313.1680. 
EPR (methanol): typical 3-line nitroxide signal, g 1.9928, aN 1.4418 mT. 
7.2.15 Synthesis of 5-(3-hydroxy-3-methyl)butynyl-1,1,3,3-
tetramethylisoindoline-2-yloxyl) (119). 
 
To a solution of compound 105 (770 mg, 2.435 mmol, 1 equiv) in an anhydrous 
triethylamine (15 mL) was added in a stirring solution of Pd(OAc)2 (13 mg, 
0.021 mmol, 0.1 equiv), and DABCO (820 mg, 7.31 mmol, 3 equiv) and 2-
methyl-3-butyne-2-ol (204).  The argon was bubbled for 10 minutes in a mixture.  
The reaction mixture was stirred at 80–85 °C for 3 days and after which time, 
CHCl3 (50 mL) was added to the reaction mixture.  The organic phase was 
washed with water (3 x 50 mL) and brine solution (3 x 50 mL) and dried over 
anhydrous Na2SO4.  The solvent was evaporated under reduced pressure and 
the resulting residue was purified by silica gel column chromatography using a 
mixture of (1:9) EtOAc: Hexanes to give 5-(3-hydroxy-3-methyl)butynyl-1,1,3,3-
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tetramethylisoindoline-2-yloxyl) (119) as a brown-oil (530 mg, 80 %), Rf = 0.71 
(DCM/ Hexanes, 2:8).  
HRMS (ESI): m/z calcd for C17H22NO2
+ [M+]: 272.1651, found: 272.1654. (The 
obtained spectroscopic data was consistent with that previously reported for this 
compound).316 
7.2.16 Synthesis of 5-ethynyl-1,1,3,3-tetramethylisoindoline-2-yloxyl (120). 
 
To a solution of compound 119 (200 mg, 0.734 mmol, 1 equiv), in an anhydrous 
MeCN (15 mL) added solid KOH (330 mg, 5.87 mmol, 8.0 equiv).  The reaction 
mixture was stirred at 80–85 °C for 4 h and after which time water (30 mL) was 
added to the reaction mixture.  The resulting mixture was extracted with EtOAc 
(3 x 50 mL).  The combined organic phases were washed with water (15 mL) 
and brine solution (15 mL) and dried over an anhydrous Na2SO4, filtered.  The 
solvent was evaporated under reduced pressure and the resulting residue was 
purified on silica gel column chromatography using a mixture of DCM: Hexanes 
(9:1) to give 5-ethynyl-1,1,3,3-tetramethylisoindoline-2-yloxyl (120) as a 
yellowish-purple oil (141 mg, 90 %).  Rf = 0.71 (DCM/ Hexanes, 2:8). 
Ʋmax (ATR-FTIR) cm
-1: 3726 (aryl C-H), 3192 (ΞC-H), 3044, 2978 (alkyl CH3), 
2166 (CΞC), 1487 (aryl C-C), and 1428 (N-O).  
Melting point: 96–98 °C (lit).   
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HRMS (ESI): m/z calcd for C14H17NO
+ [M+Na]: 237.1130, found: 237.1126. 
(The obtained spectroscopic data was consistent with that previously reported 
for this compound).316 
EPR (methanol): typical 3-line nitroxide signal, g 1.9908, aN 1.1266 mT. 
7.2.17 Synthesis of N-tert-butoxycarbonyl-2-(4-aminophenyl)ethylamine 
(125)277, 326  
 
A solution of 2-(4-aminophenyl)ethylamine (124) (550 mg, 4.04 mmol, 1 equiv) 
in DCM (50 mL) was cooled to –5 °C and tert-butoxycarbonyl anhydride (882 
mg, 4.04 mmol, 1 equiv) was slowly added.  The reaction mixture was stirred for 
100 minutes at –5 to –10 °C, and the reaction progress was followed by TLC 
analysis using DCM / MeOH (9:1)  and poured onto an ice/ water mixture.  After 
stirring vigorously for 30 minutes, the organic phase was separated and washed 
with water (3 × 25 mL).  The combined aqueous layers were then washed with 
DCM (3 × 25 mL).  The combined organic layers were washed with brine 
solution (3 × 25 mL) and dried, over anhydrous MgSO4, filtered.  The solvent 
was evaporated under reduced pressure and the resulting residue purified by 
silica gel column chromatography to give N-tert-butoxycarbonyl-2-(4-
aminophenyl)ethylamine (125) as an orange solid (847 mg, 88.7%).  Rf = 0.71 
(DCM / MeOH, 9:1).   
Melting point: 56–58 °C (lit.121 55–60 °C).   
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1H NMR (400 MHz, DMSO-d6) δ ppm 1.37 (s, 9 H) 2.95 - 3.07 (m, 2 H) 3.17 (d, 
J=4.36 Hz, 2 H) 4.12 (d, J=5.06 Hz, 1 H) 4.85 (s, 2 H) 6.47 (d, J=8.33 Hz, 2 H) 
6.82 (d, J=8.25 Hz, 2 H). 
13C NMR (101 MHz, CDCl3) δ ppm: 28.4, 35.2, 41.9, 79.1, 115.3, 128.8, 129.6, 
144.7, and 155.9. 
Ʋmax (ATR-FTIR) cm
-1: 3369 (NH2), 3188 (aryl C-H), 2976 (alkyl CH3), 1678 
(NC=OO), 1511 (aryl C-C), 1362 (O-C(CH3)3), 1244 (H-NCOO),  
ESMS calcd for C13H20NaN2O2
+ [M + Na]: 259.1422, found: 259.1433. 
7.2.18 Synthesis of N-tert-butoxycarbonyl-2-(4-N-(5-carboxy-1,1,3,3-
tetramethylisoindoline-2-yloxyl)aminophenyl)ethylamine (126). 
 
Compound 125 (244 mg, 1.03 mmol, 1.21 equiv) was added to a solution 
containing 5-carboxy-1,1,3,3-tetramethylisoindoline-2-yloxyl (106) (200 mg, 
0.853 mmol, 1 equiv), EDCI (174 mg, 0.904 mmol, 1.06 equiv), HOBt (126 mg, 
0.929 mmol, 1.09 equiv), and DIPEA (160 µL, 0.895 mmol, 1.05 equiv) in dry 
DMF (10 mL).  The reaction mixture was stirred at room temperature for 16 h 
and the reaction progress was followed by TLC analysis using (DCM / EtOAc, 
7:3).  The solution was quenched using water (30 mL) at 0–5 °C and the oily 
reaction mixture was extracted in EtOAc (3 × 25 mL).  The combined extracts 
were washed with water (30 mL) and brine solution (30 mL) and dried over 
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anhydrous MgSO4.  The solvent was evaporated under reduced pressure and 
the resulting residue purified by silica gel column chromatography using a (8:2) 
mixture of EtOAc and petroleum ether to give N-tert-butoxycarbonyl-2-(4-N-(5-
carboxy-1,1,3,3-tetramethylisoindoline-2-yloxyl)aminophenyl)ethylamine (126) 
as a brownish-white solid (220 mg, 57%).  Rf = 0.64 (DCM / EtOAc, 7:3).   
1H NMR (400 MHz, CDCl3) δ ppm 1.47 (br. s., 9 H) 1.57 (br. s., 12 H) 2.82 (br. 
s., 3 H) 3.42 (br. s., 4 H) 4.55 (br. s., 1 H) 7.62 (br. s., 3 H) 7.79 (br. s., 1 H) 
Note that paramagnetic broadening by the nitroxide radical results in some 
peaks not being detected or giving poor integration in the proton NMR 
spectrum.   
Melting point: 158–160 °C. 
ESMS calcd for C26H34NaN3O4
+ [M+Na]: 475.2440, found: 475.2450. 
Elemental analysis: found C 68.58, H 7.51, N 8.88, expected C 69.00, H 7.57, 
and N 9.28. 
HPLC: 91% 
Ʋmax (ATR-FTIR) cm
-1: 3360 (NH), 3289 (NH), 2969 (alkylCH3); 2929 (aryl CH), 
1689 (NC=O), 1662, 1599 (amide C=O), 1514 (H-NCOO), 1359 (O-C(CH3)3), 
1319 and 1356 (NO), 1276-1248 (N-CO-O), 1168 (H-NCOO). 
EPR (methanol): typical 3-line nitroxide signal g 1.9922, aN 1.4875 mT. 
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7.2.19 Synthesis of 2-(4-N-(5-carboxy-1,1,3,3-tetramethylisoindoline-2-
yloxyl) aminophenyl) ethylamine (127). 
 
4 M HCl (0.75 mL) was added to a solution of compound 126 (100 mg, 0.94 
mmol, 1.0 equiv) in a (1:1) mixture of 1, 4–dioxane (4.3 mL) and water (4.3 mL).  
The reaction mixture was stirred for 2 h at 55–60 °C and the reaction progress 
was followed by TLC analysis using DCM / EtOAc (7:3).  Upon completion, the 
solution was evaporated to half its volume under reduced pressure.  Water (30 
mL) was added and the resulting solution was basified with 28% aqueous 
ammonia solution and extracted with EtOAc (3 x 25 mL).  The combined 
organic layers were washed with water (30 mL) and brine solution (30 mL), and 
dried over anhydrous MgSO4, filtered.  The filtrate was concentrated under 
reduced pressure and the resulting residue purified by silica gel column 
chromatography using a (8.9:1:0.1) mixture of CHCl3: methanol: 28% aqueous 
ammonia solution to give (127) as a yellowish solid (95 mg, 91%), Rf = 0.26 
(DCM / EtOAc, 7:3).   
1H NMR (400 MHz, CDCl3) δ ppm 0.79 - 0.97 (m, 2 H) 1.28 (br. s., 13 H) 1.38 - 
1.63 (m, 12 H) 2.06 (s, 2 H) 2.62 (s, 1 H) 2.68 - 2.86 (m, 3 H) 3.17 (br. s., 1 H) 
3.81 (br. s., 2 H) 4.14 (d, J=6.90 Hz, 1 H) 7.21 (br. s., 3 H) 7.61 (br. s., 4 H). 
Note that paramagnetic broadening by the nitroxide radical results in some 
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peaks not being detected or giving poor integration in the proton NMR 
spectrum.  
Ʋmax (ATR-FTIR) cm
-1: 3285 (NH2), 2972 (alkylCH3); 2921(aryl CH), 1654 
(C=O), 1598 and 1574 (H-NCO), 1514 (aryl C-C), 1356, and 1316 and (NO). 
Melting point: 176–178 °C. 
ESMS calcd for C21H27N3O2
+ [M + H]: 353.2100, found: 353.2110. 
EPR (methanol): typical 3-line nitroxide signal, g 1.9924, aN 1.4738 mT.. 
HPLC:  97% 
7.2.20 Synthesis of (E)-tert-4-(3-(3,5-di-tert-butyl-4-
hydroxyphenyl)acrylamide)phenethylcarbamate (132). 
 
3, 5-di tert-butyl-4-hydroxycinnamic acid (118) (135 mg, 0.486 mmol, 1.15 
equiv) was added to a mixture of EDCI (93.5 mg, 0.486 mmol, 1.15 equiv), 
HOBt (65.6 mg, 0.486 mmol, 1.15 equiv), DIPEA (85 µL, 0.486 mmol, 1.15 
equiv), and compound 125 (100 mg, 0.423 mmol, 1 equiv) in anhydrous DMF (2 
mL).  The reaction mixture was stirred to room temperature for 21 h and the 
reaction progress was followed by TLC analysis in IPA/ MeOH (8:2).  DCM was 
added in to the reaction mixture and the solution was quenched by using water 
(30 mL) at 0–5 °C.  The resulting mixture was extracted in DCM (3 × 25 mL).  
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The combined extracts were washed with water (3 × 25 mL) and brine solution 
(2 × 25 mL) and dried over anhydrous MgSO4, filtered.  The solvent was 
evaporated under reduced pressure and the oily residue was purified by silica 
gel column chromatography using a (8:2) mixture of isopropanol: methanol to 
give (E)-tert-4-(3-(3,5-di-tert-butyl-4-
hydroxyphenyl)acrylamide)phenethylcarbamate (132) as a brownish-oil (208 
mg, 99.5 %), Rf = 0.78 (CHCl3/ MeOH, 8:2),  
1H NMR (400 MHz, CDCl3) δ ppm: 1.40 - 1.50 (m, 18 H) 1.60 (br. s., 9H) 2.73 - 
2.81 (m, 2 H) 3.36 (d, J=5.53 Hz, 2 H) 5.30 (s, 1 H) 5.49 (s, 1 H) 6.39 (d, 
J=15.41 Hz, 1 H) 7.17 (d, J=8.27 Hz, 2 H) 7.29 (s, 1 H) 7.39 (s, 2 H) 7.55 (d, 
J=8.17 Hz, 1 H) 7.70 (d, J=15.41 Hz, 1 H). 
13C NMR (101 MHz, CDCl3) δ ppm: 28.4, 30.2, 34.3, 35.6, 41.8, 117.3, 120.1, 
125.3, 125.9, 129.4, 136.3, 143.4, and 155.9. 
Ʋmax (ATR-FTIR) cm
-1: 3624 (NH2), 3282 (OH), 2956 (alkyl CH3), 1690 (NC=O), 
1619 (C=C), 1511, 1425 (aryl C-C), 1390, 1365 (tBu-O), 1238 (H-NCO), 1168, 
978, 849. 
Melting Point: 126–128°C. 
HRMS (ESI): m/z calcd for C30H42NaN2O4
+ [M+Na]: 517.3042, found: 517.3006. 
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7.2.21 Synthesis of (E)-N-(4-(2-aminoethyl)phenyl)-3-(3,5-di-tert-butyl-4-
hydroxyphenyl)acrylamide (133). 
 
4 M HCl (2 mL) was slowly added to a stirring solution of compound 33 (205 
mg, 0.414 mmol, 1 equiv) in a (1:1) mixture of 1, 4-dioxane (9 mL) and water (9 
mL).  The solution was stirred for 2 h at 55–60 °C and the reaction progress 
was followed by TLC analysis in CHCl3/ MeOH (8:2).  Upon completion, the 
solution was treated with water (25 mL) and basified up to pH 14 by using 28% 
aqueous ammonia solution.  The resulting mixture was extracted with EtOAc (3 
x 25 mL).  The combined organic phases were washed with water (3 x 25 mL) 
and brine solution (2 x 25 mL) and dried over anhydrous Na2SO4, filtered.  The 
filtrate was evaporated under reduced pressure and the resulting residue was 
purified by silica gel column chromatography using a mixture of CHCl3: MeOH: 
28% aqueous ammonia (7.9:2:0.1) solution to give (E)-N-(4-(2-
aminoethyl)phenyl)-3-(3,5-di-tert-butyl-4-hydroxyphenyl)acrylamide (133) as a 
yellowish-green solid (105 mg, 65%), Rf = 0.13 (CHCl3/ MeOH, 8:2). 
1H NMR (400 MHz, CDCl3) δ ppm: 1.43 (s, 18 H) 2.70 - 2.74 (m, 2 H) 2.95 (br. 
s., 2 H) 5.30 (s, 1 H) 6.48 (d, J=15.41 Hz, 1 H) 7.11 (d, J=7.24 Hz, 2 H) 7.37 (s, 
2 H) 7.49 (d, J=6.94 Hz, 2 H) 7.70 (d, J=15.36 Hz, 1 H). 
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13C NMR (101 MHz, CDCl3): δ ppm: 30.1, 34.3, 55.9, 63.9, 125.0, 125.3, 126.0, 
129.2, 136.2, 136.6 137.9, 143.2 146.2, 153.5 and 155.8.  
Ʋmax (ATR-FTIR) cm
-1: 3624 (NH2), 2955 (alkyl CH3), 1660 (NC=O), 1617 
(C=C), 1513, 1421 (aryl C-C), 1237 (H-NCO), 1174, 979, 848, 771, 565, 508. 
Melting point: 130–132 °C. 
HRMS (ESI): m/z calcd for C25H35N2O2
+ [M+H]: 395.2699, found: 395.2651. 
7.2.22 Synthesis of 2,3-O-isopropylideneguanosine (139).288 
 
Guanosine 138 (10.00 g, 35.3 mmol, 1.0 equiv) and para-toluenesulfonic acid 
monohydrate (6.72 g, 35.3 mmol, 1.0 equiv) were added to a stirring solution of 
acetone (350 mL) and 2, 2-dimethoxypropane (88.7 mL, 723 mmol, 20.5 equiv). 
The reaction was stirred overnight at 25 °C.  The reaction mixture was 
evaporated to dryness and water (250 mL) and saturated NaHCO3 solution (70 
mL) was added.  The mixture was stirred for a further 1 h.  The resulting 
suspension was filtered and washed with cold water (250 mL) to give 2,3-O-
isopropylideneguanosine (139) as a white solid (8.6 g, 75%), Rf = 0.72 (EtOAc / 
MeOH, 7:3).   
1H NMR (400 MHz, DMSO-d6) δ ppm:1.34 (s, 3 H) 1.49 (s, 3 H) 3.49- 3.55 (m, 
2H) 4.10- 4.15 (m, 1 H) 4.97 (dd, J=6.31, 3.08, 1 H) 5.05 (br. s., 1 H) 5.19(dd, 
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J=6.24, 2.86 Hz, 1 H)  5.93 (d, J=2.79, 1 H) 6.52 (s, 2 H) 7.92 (s, 1 H) 10.70 (s, 
1 H). 
13C NMR (101 MHz, DMSO-d6) δ ppm: 25.2, 27.0, 62.1, 81.2, 83.6, 86.6, 88.4, 
113.0, 116.7, 135.8, 150.7, 153.7, 156.7.  
Melting point: 260–262 °C (lit.259 260–262 °C) 
HRMS (ESI): m/z calcd for C13H18N5O5+ [M + H]: 324.1300, found: 324.1286. 
(The obtained spectroscopic data was consistent with that previously reported 
for this compound).259 
7.2.23 Synthesis of 2,3-O-isopropylideneguanosine-5-carboxylic acid 
(140).259 
 
Compound 139 (6.7 g, 21 mmol, 1 equiv), TEMPO (809 mg, 5.25 mmol, 0.25 
equiv) and bis (acetoxy) iodobenzene (BAIB) (13.5 g, 42 mmol, 2.25 equiv) 
were combined in MeCN/ water (1:1, 88 mL).  The reaction mixture was stirred 
overnight at 25 °C and the reaction progress was followed by TLC analysis 
using a EtOAc / MeOH (4:1).  After which time, acetone (160 mL) was added 
and the solution was stirred for 1 h.  The solution was poured into a well-stirred 
volume of Et2O (930 mL) and the mixture was stirred for a further 1 h.  The 
resulting precipitate was filtered to give 2,3-O-isopropylideneguanosine-5-
carboxylic acid (140) as a pale orange solid (5.5 g, 78.8%).  Rf = 0.16 (4:1 
EtOAc / MeOH).  
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1H NMR (400 MHz, DMSO- d6) δ ppm: 1.34 (s, 3 H) 1.49 (s, 3 H) 4.61 (s, 1 H) 
5.31 (d, J=6.02 Hz, 1 H) 5.56 (d, J=6.02 Hz, 1 H) 6.10 (s, 1 H) 6.46 (br. s., 2 H) 
7.80 (s, 1 H) 10.68 (s, 1 H). 
13C NMR (101 MHz, DMSO- d6) δ ppm: 25.4, 26.9, 84.0, 84.2, 85.9, 89.5, 
112.9, 116.9, 137.1, 151.3, 153.8, 157.2, and 171.4.  
Melting point: 210–212 °C (lit.259 210–212 °C). 
HRMS (ESI): m/z calcd for C13H16N5O6
+ [M + H]: 338.1101, found: 338.1134. 
(The obtained spectroscopic data was consistent with that previously reported 
for this compound).259 
7.2.24 Synthesis of 2,3-O-isopropylideneguanosine-5-ethylcarboxylate 
(142). 
 
A suspension of 140 (5 g, 15.7 mmol, 1 equiv) in EtOH (500 mL) was stirred at 
0 °C for 30 minutes.  SOCl2 (4.5 mL, 67.6 mmol, 4.3 equiv) was slowly added.  
The reaction mixture was warmed to room temperature and stirred overnight 
and the reaction progress was followed by TLC analysis using (7:3) EtOAc / 
MeOH.  The reaction mixture was basified up to pH 8 by adding saturated 
NaHCO3 solution and the resulting mixture was filtered.  The filtrate was 
evaporated under reduced pressure.  The resulting residue was purified by 
silica gel column chromatography using a mixture of EtOAc / MeOH (7:3)  to 
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give 2,3-O-isopropylideneguanosine-5-ethylcarboxylate (142) as an off-white 
solid (4.5 g, 84%).  Rf = 0.71 (7:3 EtOAc / MeOH). 
1H NMR (400 MHz, DMSO-d6) δ ppm: 0.98 (t, J=7.19 Hz, 3 H) 1.35 (s, 3 H) 1.49 
(s, 3 H) 3.71 - 3.81 (m, 1 H) 3.82 - 3.91 (m, 1 H) 4.74 (s, 1 H) 5.34 (d, J=6.02 
Hz, 1 H) 5.72 (d, J=5.87 Hz, 1 H) 6.18 (s, 1 H) 6.43 (br. s., 2 H) 7.78 (s, 1 H) 
10.69 (br. s., 1 H). 
13C NMR (101 MHz, DMSO-d6) δ ppm: 13.8, 25.3, 26.7, 61.1, 83.9, 84.8, 86.3, 
89.9, 112.7, 117.1, 137.7, 151.1, 153.7, 157.2 and 169.8.  
Ʋmax (ATR-FTIR) cm
-1: 3413 (NH2), 3162 (NH), 2731 (alkyl CH3), 1696 (OC=O), 
1628, 1596 (aryl C-N), 1540, 1488 (aryl C-C), 1382 (Et-O), 1271, 1205, 1157, 
1057 (C-O-C), 866, 782. 
Melting point:  272–274 °C. 
HRMS (ESI): m/z calcd for C15H20N5O6
+ [M + H]: 366.1414, found: 366.1449. 
HPLC purity: - 99.99 %. 
Elemental analysis: found C 49.30, H 5.17, and N 19.06. Expected C 49.31, H 
5.24, and N 19.17  
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7.2.25 Synthesis of 2,3-O-isopropylideneguanosine-5-N-
ethylcarboxamide (143)259. 
 
Compound 142 (774 mg, 2.12 mmol, 1 equiv) and ethylamine (22 mL) were 
stirred at 0 to –20 °C for 3 h.  The reaction progress was followed by TLC 
analysis using (8:2 DCM: MeOH) and after which time the solution was allowed 
to warm to room temperature and stirred overnight and the reaction progress 
was followed by TLC analysis using a DCM / MeOH (7:3).  The reaction mixture 
was added to a stirring Et2O (50 mL) and the resulting mixture was stirred for 1 
h, after which time the obtained precipitate was filtered and washed with Et2O 
(25 mL).  The resulting residue was purified by silica gel column 
chromatography using a mixture of Pet Spirits/ EtOAc (2:8) to give 2,3-O-
isopropylideneguanosine-5-N-ethylcarboxamide (143) as a bluish-white solid 
(725 mg, 94%), Rf = 0.85 (DCM / MeOH, 8:2). 
1H NMR (400 MHz, DMSO-d6) δ ppm: 0.75 (t, J=7.19 Hz, 3 H) 1.33 (s, 3 H) 1.51 
(s, 3 H) 2.78 - 2.90 (m, 1 H) 2.90 - 3.01 (m, 1 H) 4.47 (d, J=2.20 Hz, 1 H) 5.27 
(dd, J=6.09, 1.25 Hz, 3 H) 5.44 (dd, J=6.09, 2.27 Hz, 3 H) 6.13 (s, 1 H) 6.42 (br. 
s., 2 H) 7.37 (t, J=5.80 Hz, 1 H) 7.81 (s, 3 H) 10.65 (br s, 2 H). 
13C NMR (101 MHz, DMSO-d6) δ ppm: 14.7, 15.8, 17.5, 25.4, 75.9, 76.0, 80.1, 
82.9, 105.1, 108.6, 130.3, 142.8, 145.6, 149.9, and 162.5.  
Melting point: 278–280 °C (lit.259 199–200 °C).  
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HRMS (ESI): m/z calcd for C15H21N6O5
+ [M + H]: 365.1573, found: 365.1574. 
(The obtained spectroscopic data was consistent with that previously reported 
for this compound).259 
7.2.26 Synthesis of O6-(benzotriazol-1-yl)-2′,3′-O-isopropylideneguanosine-
5′-N-ethylcarboxamide (144).259 
 
Compound 143 (285 mg, 0.78 mmol, 1 equiv) was suspended in MeCN (27 
mL).and BOP (554 mg, 1.25 mmol, 1.6 equiv) and DBU (187 µL, 1.25 mmol, 1.6 
equiv) were added.  The reaction mixture was stirred at room temperature for 
20 h and the reaction progress was followed by TLC analysis using (Pet Spirits: 
EtOAc, 1:4).  The reaction mixture was diluted with EtOAc (90 mL) and the 
resulting solution was washed with water (3 x 90 mL) and brine solution (90 
mL).  The EtOAc layer was filtered and dried over anhydrous MgSO4.  The 
solvent was evaporated under reduced pressure and the resulting residue was 
purified via silica gel column chromatography using a gradient from (1:1) 
petroleum spirits/ EtOAc to (1:4) petroleum spirits/ EtOAc to give O6-
(benzotriazol-1-yl)-2′,3′-O-isopropylideneguanosine-5′-N-ethylcarboxamide 
(144) as a pale yellow solid (500 mg, 98%), Rf = 0.95 (Pet Spirits / EtOAc, 1:4). 
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1H NMR (400 MHz, DMSO-d6): δ ppm 0.67 (t, J=7.19 Hz, 3 H) 1.35 (s, 3 H) 1.52 
(s, 3 H) 2.71 - 2.98 (m, 2 H) 4.53 (s, 1 H) 5.40 (d, J=6.16 Hz, 1 H) 5.52 (d, 
J=6.02 Hz, 1 H) 6.29 (s, 1 H) 6.68 (s, 2 H) 7.48 (t, J=5.72 Hz, 1 H) 7.51 - 7.58 
(m, 1 H) 7.66 (d, J=3.81 Hz, 2 H) 8.18 (d, J=8.51 Hz, 1 H) 8.21 (s, 1 H). 
13C NMR (101 MHz, DMSO-d6) δ ppm: 14.4, 25.4, 27.0, 33.5, 83.6, 87.0, 90.5, 
109.5, 113.4, 120.6, 126.1, 128.6, 130.2, 143.1, 147.4, 155.0, 156.1, 156.2, 
159.8, 160.0 and 168.4. 
Melting point: 140–142 °C (lit.259 140–141 °C). 
HRMS (ESI): m/z calcd for C21H24N9O5
+ [M+H]: 482.1900, found: 482.1898. 
(The obtained spectroscopic data was consistent with that previously reported 
for this compound)259. 
7.2.27 Synthesis of 2-fluoro-O6-benzotriazole-1-yl-2,3-O-
isopropylideneguanosine-5-N-ethylcarboxamide (145).259  
 
Pyridine (2.0 mL) was cooled to –50 °C and 70% HF in pyridine (6.5 mL) was 
added slowly followed by compound 144 (1 g, 2.08 mmol, 1 equiv) with vigorous 
stirring.  The temperature was allowed to rise up to –30 °C and the reaction 
mixture was stirred to dissolve all solid.  Tert-butylnitrite (2.1 mL, 17.68 mmol, 
8.5 equiv) was added dropwise into the reaction mixture and the mixture was 
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stirred at –30 °C for a further 15 minutes.  The reaction progress was followed 
by TLC analysis using (2:8 Pet Spirits: EtOAc).  The reaction mixture was 
poured onto iced water (200 mL) and stirred for 30 minutes.  The resulting 
suspension was extracted in DCM (3 x 50 mL) and the combined DCM extracts 
were washed with water (3 x 50 mL) and brine solution (3 x 50 mL).  The DCM 
extract was dried over anhydrous MgSO4, filtered.  The filtrate was evaporated 
under reduced pressure and the resulting residue was purified by silica gel 
column chromatography using a mixture of Pet Spirits / EtOAc (2:8) to give 2-
fluoro-O6-benzotriazole-1-yl-2,3-O-isopropylideneguanosine-5-N-
ethylcarboxamide (145) as an off-white solid (0.68 g, 68%).  Rf = 0.52 (2:8 Pet 
Spirits / EtOAc). 
1H NMR (400 MHz, DMSO-d6): δ ppm 0.65 (t, J=7.12 Hz, 3 H) 1.36 (s, 3 H) 1.54 
(s, 3 H) 2.66 - 2.98 (m, 2 H) 4.65 (s, 1 H) 5.38 (d, J=4.40 Hz, 1 H) 5.45 (d, 
J=5.87 Hz, 1 H) 6.46 (s, 1 H) 7.59 (t, J=6.0 Hz, 1 H) 7.66 - 7.82 (m, 3 H) 8.24 
(d, J=8.36 Hz, 1 H) 8.78 (s, 1 H). 
13C NMR (101 MHz, DMSO-d6) δ ppm: 14.4, 25.5, 27.0, 33.5, 83.7, 87.1, 90.6, 
109.6, 113.5, 118.2, 120.6, 126.1, 128.7, 130.2, 143.2, 147.5, 155.0, 157.1, 
159.9, 168.4.  
Melting point: 145–147 °C (decomp) (lit.259 140–141 °C). 
HRMS (ESI): m/z calcd for C21H22FN8O5
+ [M+H]: 485.1692, found: 485.1699. 
(The obtained spectroscopic data was consistent with that previously reported 
for this compound).259 
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7.2.28 Synthesis of 2-fluoro-2,3-O-isopropylideneadenosine-5-N-
ethylcarboxamide (146).259 
 
A solution of compound 145 (700 mg, 1.24 mmol. 1 equiv)) in MeCN (9 mL) was 
cooled at 0 °C in ice bath and 28% ammonia solution (500 µL) was cautiously 
added to the stirring solution.  The reaction mixture was allowed to rise to room 
temperature and the stirring was continued for 2 h and the reaction progress 
was followed by TLC analysis using EtOAc: MeOH (7:3).  The reaction mass 
was partitioned between water (50 mL) and EtOAc (50 mL).  The aqueous 
phase was extracted with EtOAc (3 x 30 mL) and the combined organic phases 
were washed with water (3 x 50 mL) and brine solution (3 x 50 mL) and dried 
over anhydrous MgSO4, filtered.  The filtrate was evaporated under reduced 
pressure.  The resulting residue was purified by silica gel column 
chromatography using EtOAc as the eluent to give 2-fluoro-2,3-O-
isopropylideneadenosine-5-N-ethylcarboxamide (146) as a pale yellow solid 
(450 mg, 85%).  Rf = 0.63 (EtOAc / MeOH, 7:3).   
1H NMR (400 MHz, DMSO-d6): δ ppm 0.66 (t, J=7.19 Hz, 3 H) 1.34 (s, 3 H) 1.53 
(s, 3 H) 2.72 - 2.97 (m, 2 H) 4.54 (s, 1 H) 5.36 (br s, 2 H) 6.27 (s, 1 H) 7.55 (t, 
J=5.58 Hz, 1 H) 7.75 (br s, 2 H) 8.23 (s, 1 H).  
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13C NMR (101 MHz, DMSO-d6) δ ppm: 14.4, 25.5, 27.1, 33.5, 83.5, 83.7, 86.5, 
89.8, 113.3, 117.9, 141.0, and 150.6 (d, J = 20.1 Hz), 158.0 (d, J = 21.1 Hz), 
158.2, 168.5.  
Melting point: 194–196 °C (lit 259 194–196 °C).   
HRMS (ESI): m/z calcd for C15H19FN6O4
+ [M+]: 366.1500, found: 366.1451. (The 
obtained spectroscopic data was consistent with that previously reported for this 
compound).259 
7.2.29 Synthesis of 2-iodo-O6-benzotriazole-1-yl-2,3-O-
isopropylideneguanosine-5-N-ethylcarboxamide (148)259. 
 
Tert-butylnitrite (0.2 mL, 10.39 mmol, 4 equiv) was added to a mixture of 
compound 144 (200 mg, 0.415 mmol, 1 equiv) and diiodomethane (1 mL, 49.92 
mmol, 30 equiv) in MeCN (3 mL).  The reaction mixture was vigorously stirred at 
65–70 °C for 4 h under argon atmosphere and the reaction progress was 
followed by TLC analysis using DCM: MeOH (9:1).  The reaction solution was 
diluted with EtOAc (50 mL), and washed with water (3 x 50 mL), and brine 
solution (3 x 50 mL) and dried over anhydrous MgSO4.  The filtrate solvent was 
evaporated under reduced pressure and the resulting residue was purified by 
silica gel column chromatography using a mixture of DCM and MeOH (9:1) to 
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give 2-iodo-O6-benzotriazole-1-yl-2,3-O-isopropylideneguanosine-5-N-
ethylcarboxamide (148) as a brown solid (212 mg, 86%).  Rf = 0.42 (DCM / 
MeOH, 9:1). 
1H NMR (400 MHz, DMSO-d6) δ ppm: 0.64 (t, J=7.19 Hz, 3 H) 1.33 (s, 3 H) 1.50 
(s, 3 H) 2.54 - 2.59 (m, 2 H) 4.58 (d, J=2.20 Hz, 1 H) 5.38 (m, 2 H) 6.44 (br. s., 1 
H)  7.53 - 7.57 (m, 2 H) 7.64 - 7.67 (m, 2 H) 8.17- 8.20 (m, 1 H) 8.63 (s, 1 H). 
13C NMR (101 MHz, DMSO-d6) δ ppm: 14.7, 25.1, 27.0, 30.9, 34.2, 82.9, 83.2, 
86.3, 91.6, 108.3, 114.9, 116.3, 120.0, 120.7, 125.0, 128.6, 129.0, 143.4, 143.9, 
154.2, 157.9 and 167.8.  
Melting point: 194–196 °C (lit 259 195–196 °C). 
HRMS (ESI): m/z calcd for C21H21INaN8O5
+ [M+Na]: 615.0577, found: 
615.0808. (The obtained spectroscopic data was consistent with that previously 
reported for this compound).259  
7.2.30 Synthesis of 2-iodo-2,3-O-isopropylideneadenosine-5-N-
ethylcarboxamide (149).259 
 
An aqueous ammonia (28%) solution (1.1 mL) was added to the solution of 
compound 148 (652 mg, 1.1 mmol, 1 equiv) in MeCN (52 mL) at 25 °C.  The 
solution was stirred for three days at room temperature, and the reaction 
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progress was followed by TLC analysis using EtOAc: MeOH (7:3).  After which 
time, the reaction mass was partitioned between water (50 mL) and EtOAc (50 
mL).  The aqueous phase was extracted with EtOAc (4 x 70 mL).  The 
combined organic phases were washed with water (3 x 50 mL), and brine 
solution (4 x 50 mL) and dried over anhydrous MgSO4.  The organic phase was 
filtered, and the solvent was evaporated under reduced pressure.  The resulting 
residue was purified by silica gel column chromatography using 100% EtOAc to 
give 2-iodo-2,3-O-isopropylideneadenosine-5-N-ethylcarboxamide (149) as a 
pale yellow solid (400 mg, 77%), Rf = 0.63 (EtOAc / MeOH, 7:3). 
1H NMR (400 MHz, CDCl3) δ ppm 0.92 (t, J=7.24 Hz, 3 H) 1.37 (s, 3 H) 1.59 (s, 
3 H) 3.11 - 3.35 (m, 2 H) 4.66 (d, J=1.81 Hz, 2 H) 5.27 (d, J=2.74 Hz, 1 H) 5.28 
(d, J=2.64 Hz, 1 H) 5.32 (d, J=1.96 Hz, 1 H) 5.33 (d, J=2.01 Hz, 1 H) 6.00 (d, 
J=2.69 Hz, 2 H) 6.02 (br. s., 2 H) 6.48 (br. s., 1 H) 7.74 (s, 1 H).  
13C NMR (101 MHz, CDCl3) δ ppm: 14.7, 25.2, 27.1, 30.9, 34.3, 82.6, 83.4, 
85.9, 91.5, 114.7, 120.1, 139.8, 149.7, 155.2, and 168.2.  
Ʋmax (ATR-FTIR) cm
-1: 3390 (NH2), 3308 (NH), 3168, 3079 (aryl C-H), 2982 
(alkyl C-H), 1647 (NC=O), 1586 (aryl C-N), 1520 (aryl C-C), 1456 (N-CO), 1256 
(H-NCO) 1183, 1091 (C-O-C), 1052. 
Melting point: 196–198 °C(lit 259 196–198 °C). 
HRMS (ESI):  m/z calcd for C15H19INaN6O4
+ [M+Na]: 497.0410, found: 
497.0390.  
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7.2.31 Synthesis of 2-(2-(4-aminophenyl))ethylamino-2,3-O-
isopropylideneadenosine -5-N-ethylcarboxamide (159). 
 
Approach 1 
Compound 146 (150 mg, 0.41 mmol, 1 equiv) was combined with compound 
124 (93 mg, 0.389 mmol, 1.25 equiv), and DIPEA (1.1 mL) in absolute EtOH 
(3.0 mL).  The reaction mixture was stirred at 70–75 °C for 7 days, after which 
time the reaction mixture was treated with DM water at 0–5 °C.  The resulting 
oily reaction mixture was extracted in DCM (4 x 30 mL), and the combined DCM 
extract was washed with water (50 mL), saturated NaHCO3 solution (50 mL) 
and brine solution (50 mL).  The solvent was dried over anhydrous MgSO4 and 
evaporated under reduced pressure.  The resulting residue was purified by 
silica gel column chromatography using a mixture of 75% MeOH and 25% 
water, to give 2-(2-(4-aminophenyl))ethylamino-2,3-O-
isopropylideneadenosine-5-N-ethylcarboxamide (159) as a yellowish solid. 
 
Approach 2 
Compound 146 (400 mg, 0.33 mmol, 1 equiv), 4-(2-aminoethyl)anilne 124 (83 
mg, 0.69 mmol, 2 equiv), and DIPEA (1.5 mL) in MeCN (36 mL) was stirred in a 
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sealed reaction vessel at 180 °C in microwave conditions for 7 h.  The reaction 
progress was followed by TLC analysis in a mixture of (9.9:0.1) EtOAc and 28% 
aqueous ammonia solution.  After which time, the reaction mixture was 
evaporated under reduced pressure.  The resulting residue was purified by 
silica gel column chromatography using a mixture of (9.9:0.1) EtOAc and 28% 
aqueous ammonia solution to give 2-(2-(4-aminophenyl))ethylamino-2,3-O-
isopropylideneadenosine-5-N-ethylcarboxamide (159) as a yellowish solid (510 
mg, 97%), Rf = 0.32 (EtOAc/ 28% NH3 solution, 9.5:0.5).   
1H NMR (400 MHz, CDCl3) :δ ppm 0.71 (t, J=7.26 Hz, 3 H) 1.40 (s, 3 H) 1.62 ( 
s., 3 H) 2.82 (t, J=6.82 Hz, 2 H) 2.86 - 3.08 (m, 2 H) 3.45 - 3.61 (m, 1 H) 3.62 - 
3.72 (m, 1 H) 4.68 (s, 1 H) 4.85 (br. s., 1 H) 5.26 (br. s., 2 H) 5.54 (d, J=6 Hz, 1 
H) 5.63 (d, J=4.84 Hz, 1 H) 6.04 (br. s., 2 H) 6.67 (d, J=8.22 Hz, 2 H) 7.06 (d, 
J=8.07 Hz, 2 H) 7.53 (s, 1 H).  
13C NMR (101 MHz, CDCl3) δ ppm: 13.9, 20.1, 25.0, 26.7, 33.8, 34.8, 83.3, 
84.0, 87.7, 91.4, 105.7, 113.7, 115.4, 129.3, 129.6, 137.0, 144.7, 151.3, 155.6, 
159.5 and 168.9.  
Ʋmax (ATR-FTIR) cm
-1: 3350 (NH2), 3292 (NH), 2968 (alkyl CH3), 1689 (NC=O), 
1662, 1602 (aryl C-N), 1513 (aryl C-C), 1437 (N-CO), 1364, 1253 (H-NCO), 
1170 (C-O-C). 
Melting point: 150–152 °C (lit 121 95–104 °C). 
HRMS (ESI): m/z calcd for C23H31N8O4+ [M+H]: 483.2460, found: 483.2482. 
(The obtained spectroscopic data was consistent with that previously reported 
for this compound).121 
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7.2.32 Synthesis of 2-(2-(4-N-(5-carboxy-1,1,3,3-tetramethylisoindoline-2-
yloxyl)aminophenyl))ethylamino-2,3-O-isopropylideneadenosine -
5-N-ethylcarboxamide (161). 
 
Approach 1  
Compound 146 (25 mg, 0.068 mmol, 1 equiv) was combined with compound 
127 (51 mg, 0.143 mmol, 2.1 equiv), and DIPEA (75 µL) in absolute EtOH (1.5 
mL).  The reaction mixture was stirred at 70–75 °C for 7 days.  The reaction 
mixture was cooled to 0–5 °C and treated with DM water, and the resulting oily 
mixture was extracted in DCM (4 x 30 mL).  The combined organic layer was 
washed with water (30 mL) and saturated NaHCO3 solution (30 mL) and brine 
solution (30 mL).  The solvent was dried over anhydrous MgSO4 and 
evaporated under reduced pressure.  The resulting residue was purified by 
MPLC instrument using a mixture of 75% MeOH and 25% water, to give 2-(2-(4-
N-(5-carboxy-1,1,3,3-tetramethylisoindoline-2-yloxyl)aminophenyl))ethylamino-
2,3-O-isopropylideneadenosine-5-N-ethylcarboxamide (161) as a pale yellow 
solid (40 mg, 58%). 
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Approach 2  
Compound 159 (143 mg, 0.311mmol, 1 equiv) was added to a mixture 
containing 5-carboxy-1,1,3,3-tetramethylisoindoline-1-yloxyl 106 (88 mg, 0.37 
mmol, 1.25 equiv), EDCI (96 mg, 0.356 mmol, 1.2 equiv), HOBt (100 mg, 0.356 
mmol, 1.2 equiv), and DIPEA (1 mL) were combined in dry DMF (3 mL) under 
argon atmosphere.  The reaction mixture was stirred at room temperature for 2 
days.  The solution was quenched by using water (30 mL) at 0–5 °C and the 
resulting oily reaction mixture was extracted in DCM (4 x 30 mL).  The 
combined DCM extract was washed with water (30 mL), saturated NaHCO3 
solution (30 mL) and brine solution (30 mL).  The solvent was evaporated under 
reduced pressure and the resulting residue was purified by MPLC instrument 
using a mixture of 75% MeOH and 25% water to give 2-(2-(4-N-(5-carboxy-
1,1,3,3-tetramethylisoindoline-2-yloxyl)aminophenyl))ethylamino-2,3-O-
isopropylideneadenosine-5-N-ethylcarboxamide (161) as a pale yellow solid 
(168 mg, 81%), Rf = 0.48 (DCM / IPA/ MeOH, 4.5:4.5:1). 
1H NMR (400 MHz, CDCl3) δ ppm: 0.71 (t, 3 H) 1.23 (d, J=6.13 Hz, 12 H) 1.42 
(s, 3 H) 1.62 (s, 3 H) 2.91 (s, 2 H) 2.98 (s, 2 H) 4.69 - 4.70 (m, 1 H) 5.32 (s, 1 H) 
6.05 - 6.07 (m, 1 H) 6.24 - 6.26 (m, 1 H) 7.00 - 7.03 (m, 1 H) 7.55 (s, 1 H) 8.03 - 
8.05 (m, 1 H) Note that paramagnetic broadening by the nitroxide radical results 
in some peaks not being detected or giving poor integration in the proton NMR 
spectrum. 
Melting point: 66–68 °C (decomp.) 
HRMS (ESI): m/z calcd for C36H45N9O6
+ [M + H]: 699.3493, found: 699.3506. 
EPR (methanol): typical 3-line nitroxide signal, g 1.9823, aN 1.4871 mT. 
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HPLC purity- 97.64%. 
7.2.33 Synthesis of 2-(2-(4-N-(5-carboxy-1,1,3,3-tetramethylisoindoline-1-
yloxyl)aminophenyl))ethylaminoadenosine-5-N-ethylcarboxamide 
(162). 
 
1 M HCl (3.3 mL) was added to a solution of compound 161 (101 mg, 0.94 
mmol) in MeCN (8.0 mL).  The solution was stirred for 4 h at 55–60 °C, and the 
reaction progress was followed by TLC.  Upon completion, the reaction mixture 
was basified with saturated NaHCO3 solution up to pH 8 at 0–5 °C, the resulting 
precipitate was extracted with EtOAc (3 x 25 mL).  The combined organic phase 
was washed with water (3 x 25 mL), brine solution (3 x 25 mL) and dried over 
anhydrous MgSO4.  The solvent was filtered and evaporated under reduced 
pressure.  The resulting residue was purified by MPLC instrument using a 
mixture of 80% MeOH and 20% water with partial crystallisation to give 2-(2-(4-
N-(5-carboxy-1,1,3,3-tetramethylisoindoline-1-
yloxyl)aminophenyl))ethylaminoadenosine-5-N-ethylcarboxamide (162) as a 
pale yellow solid (66 mg, 69.5%), Rf = 0.65 (EtOAc: MeOH, 8:2). 
1H NMR (400 MHz, MeOH-d4) δ ppm: 1.00 - 1.12 (m, 3 H) 1.27 (s, 2 H) 2.12 - 
2.25 (m, 1 H) 2.61 - 2.69 (m, 1 H) 2.86 - 3.00 (m, 1 H) 3.09 - 3.22 (m, 1 H) 3.33 
(br. s., 20 H) 3.46 - 3.61 (m, 1 H) 3.63 - 3.77 (m, 1 H) 4.36 - 4.47 (m, 1 H) 4.49 - 
4.55 (m, 1 H) 4.58 - 4.72 (m, 1 H) 4.87 (s, 74 H) 5.01 - 5.09 (m, 1 H) 5.90 - 6.02 
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(m, 1 H) 7.54 - 7.75 (m, 1 H) 7.93 - 8.04 (m, 1 H) 8.05 - 8.12 (m, 1 H) Note that 
paramagnetic broadening by the nitroxide radical results in some peaks not 
being detected or giving poor integration in the proton NMR spectra. 
Ʋmax (ATR-FTIR) cm
-1: 3400-3000 (NH2, NH, OH), 2926 (alkyl CH3), 1691 
(NC=O), 1597 (aryl C-N), 1529 (aryl C-C), 1408 (OC-N), 1258 (H-NCO), 1044 
(C-O-C). 
Melting point: 241-243 °C (decomp).  
HRMS (ESI): m/z calcd for C33H41N9O6
+ [M+H]: 659.318, found: 659.3197. 
EPR (methanol): typical 3-line nitroxide signal, g 1.9950, aN 1.4928 mT. 
HPLC purity: >99.9 %. 
Elemental analysis: found C 57.64, H 6.10, N 17.91. Expected C 60.17, H 6.12, 
N 19.14 
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7.2.34 Synthesis of 2-(2-(4-N-(4-carboxy-2,2,6,6-tetramethylpiperidine-1-
yloxyl)aminophenyl))ethylamino-2,3,-O-isopropylidineadenosine-
5-N-ethylcarboxamide (163). 
 
Compound 159 (300 mg, 0.622 mmol, 1 equiv), was added to a mixture 
containing 4-carboxy-TEMPO-1-yloxyl 116(156 mg, 0.7789 mmol, 1.25 equiv), 
EDCI (179 mg, 0.933 mmol, 1.5 equiv), and HOBt (101 mg, 0.746 mmol, 1.2 
equiv), and DIPEA (2 mL) in dry DMF (10 mL) under argon atmosphere.  The 
resulting reaction mixture was stirred at room temperature for two days.  The 
solution was quenched by adding water (30 mL) at 0–5 °C and the resulting oily 
mixture was extracted in DCM (3 x 30 mL).  The combined extracts were 
washed with water (2 x 30 mL), and saturated NaHCO3 solution (2 x 30 mL) and 
brine solution (2 x 30 mL) and dried over anhydrous MgSO4.  The solvent was 
evaporated under reduced pressure. The resulting brownish residue was 
purified by MPLC instrument using a mixture of 75% MeOH and 25% water to 
give 2-(2-(4-N-(4-carboxy-2,2,6,6-tetramethylpiperidine-1-
yloxyl)aminophenyl))ethylamino-2,3,-O-isopropylidineadenosine-5-N-
ethylcarboxamide (163) as a yellowish solid (346 mg, 82%).  Rf = 0.43 (IPA: 
MeOH, 8:2).  
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Ʋmax (ATR-FTIR) cm
-1: 3400-3000 (NH, NH2), 2976 (alkyl CH3), 1655 (NC=O), 
1596 (aryl C-N), 1530 (aryl C-C), 1411 (N-CO), 1326 (N-O), 1239 (H-NCO) 
1087 (C-O-C), 789.  
Melting point: 148–150 °C decomp.  
HRMS (ESI): m/z calcd for C33H47N9O6+ [M + H]: 665.364, found: 665.3658.  
EPR (methanol): typical 3-line nitroxide signal, g 1.9823, aN 1.4871 mT. 
HPLC purity: 99.38%. 
Elemental analysis: found: C 59.58, H 7.35, and N 18.43. Expected: C 59.62, H 
6.97, and N 18.96. 
7.2.35 Synthesis of 2-(2-(4-N -(4- carboxy-2,2,6,6-tetramethylpiperidine-1-
yloxyl)aminophenyl))ethylaminoadenosine-5-N-ethylcarboxamide 
(164). 
 
1 M HCl (11 mL) was slowly added to a solution of compound 163 (177 mg, 
0.267 mmol, 1 equiv) in MeCN (6.0 mL).  The reaction mixture was stirred for 5 
h at 55–60 °C, and the reaction progress was followed by TLC in IPA: MeOH 
(8:2).  Upon completion, the solution was basified up to pH 8 by adding 
saturated NaHCO3 solution at 0–5 °C, and the resulting precipitate was 
extracted with EtOAc (3 x 20 mL).  The combined organic phase was washed 
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with water (3 x 20 mL), brine solution (3 x 20 mL) and dried over anhydrous 
MgSO4, filtered.  The solvent was evaporated under reduced pressure and the 
resulting residue was purified by MPLC instrument using a mixture of 70% 
MeOH and 30% water with a partial crystallisation to give 2-(2-(4-N-(4-carboxy-
2,2,6,6-tetramethylpiperidine-1-yloxyl)aminophenyl))ethylaminoadenosine-5-N-
ethylcarboxamide (164) as a pale yellow solid (100 mg, 60 %).  Rf = 0.43 (IPA: 
MeOH, 8:2). 
Ʋmax (ATR-FTIR) cm
-1: 3400-3100 (NH2, NH, OH), 2926 (alkyl CH3), 1691 
(NC=O), 1650, 1600 (aryl C-N), 1532 (aryl C-C), 1411 (OC-N), 1240 (H-NCO), 
1324 (N-O), 1044 (C-O-C). 
Melting point: 211-213°C (decomp). 
HRMS (ESI): m/z calcd for C30H43N9O6
+ [M+H]: 625.333, found: 625.3341. 
EPR (methanol): typical 3-line nitroxide signal, g 1.9893, aN 1.6011 mT. 
HPLC Purity – <99.9 %. 
Elemental analysis: found C 59.79, H 7.25, and N 19.32. Expected C 57.68, H 
6.78, and N 20.18. 
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7.2.36 Synthesis of 2-(2-(4-N-(3-carboxy-2,2,5,5-tetramethylpyrrolidine-1-
yloxyl) aminophenyl)) ethylamino-2,3,-O-isopropylidineadenosine-
5-N-ethylcarboxamide (165). 
 
3-Carboxy-PROXYL 117(145 mg, 0.778 mmol, 1.25 equiv) was added to a 
stirring solution containing compound 159 (300 mg, 0.622 mmol, 1 equiv), EDCI 
(179 mg, 0.933 mmol, 1.5 equiv), HOBt (101 mg, 0.746 mmol, 1.2 equiv), and 
DIPEA (2 mL) were combined in dry DMF (10.5 mL) under argon atmosphere.  
The reaction mixture was stirred at room temperature for two days.  The 
resulting solution was quenched by adding water (20 mL) at 0–5 °C and the 
resulting oily reaction mixture was extracted in DCM (3 x 20 mL).  The 
combined extracts were washed with water (3 x 25 mL) and saturated NaHCO3 
solution (3 x 25 mL) and brine solution (3 x 25 mL) and dried over anhydrous 
MgSO4.  The solvent was evaporated under reduced pressure and the resulting 
residue was purified by MPLC instrument using a mixture of 75% MeOH and 
25% water to give 2-(2-(4-N-(3-carboxy-2,2,5,5-tetramethylpyrrolidine-1-
yloxyl)aminophenyl))ethylamino-2,3,-O-isopropylidineadenosine-5-N-
ethylcarboxamide (165) as a yellowish-white solid (300 mg, 74 %), Rf = 0.29 
(IPA / MeOH, 9:1). 
Ʋmax (ATR-FTIR) cm
-1: 3500-3000 (OH, NH, NH2), 2923 (alkyl CH3), 1670 
(NC=O), 1600 (aryl C-N), 1532 (aryl C-C), 1411 (N-CO), 1356-1320 (N-O), 
1195, 1087 (C-O-C), 789. 
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Melting point: 140–142 °C. 
HRMS (ESI): m/z calcd for C32H45N9O6+ [M + H]: 651.349, found: 651.3493, 
EPR (methanol): typical 3-line nitroxide signal, g 1.9808, aN 1.5239 mT. 
HPLC purity- 97.96 %. 
Elemental analysis: found C 59.57, H 7.30, and N 19.08. Expected C 59.06, H 
6.82, and N 19.37. 
7.2.37 Synthesis of 2-(2-(4-N -(3-carboxy-2,2,5,5-tetramethylpyrrolidine-1-
yloxyl) aminophenyl))ethylaminoadenosine-5-N-ethylcarboxamide 
(166). 
 
1 M HCl (3.3 mL) was added to a stirring solution of compound 165 (101 mg, 
0.94 mmol, 1 equiv) in MeCN (8.0 mL).  The reaction mixture was stirred for 4 h 
at 55–60 °C, and the reaction progress was followed by TLC analysis using 
(DCM: IPA: MeOH, 4:5:1).  Upon completion, the solution was basified by using 
saturated NaHCO3 solution up to pH 8 at 0–5 °C and the resulting precipitate 
was extracted with EtOAc (4 x 20 mL).  The organic phases were washed with 
water (3 x 20 mL) and brine solution (3 x 20 mL) and dried over anhydrous 
MgSO4, filtered.  The solvent was evaporated under reduced pressure and the 
resulting residue was purified by MPLC instrument using a mixture of 70% 
methanol and 30% water with a partial crystallisation of solid to give 2-(2-(4-N-
(3-carboxy-2,2,5,5-tetramethylpyrrolidine-1-
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yloxyl)aminophenyl))ethylaminoadenosine-5-N-ethylcarboxamide(166) as a 
brownish white solid (65 mg, 62.5 %), Rf = 0.10 (DCM: IPA: MeOH, 4:5:1). 
1H NMR (400 MHz, CD3OD) δ ppm: 0.97 - 1.11 (m, 3 H) 2.17 (s, 1 H) 2.82 - 
3.01 (m, 1 H) 3.05 - 3.19 (m, 1 H) 3.33 (d, J=1.47 Hz, 18 H) 3.46 - 3.59 (m, 1 H) 
3.61 - 3.74 (m, 1 H) 4.37 - 4.54 (m, 1 H) 4.97 - 5.12 (m, 1 H) 5.87 - 5.99 (m, 1 
H) 7.14 - 7.33 (m, 1 H) 7.38 - 7.61 (m, 1 H) 7.91 - 8.04 (s, 1 H). Note that 
paramagnetic broadening by the nitroxide radical results in some peaks not 
being detected or giving poor integration in the proton NMR spectrum. 
Ʋmax (ATR-FTIR) cm
-1: 3322-3000 (OH, NH, NH2), 2926 (alkyl CH3), 1634 
(NC=O), 1597 (aryl C-N), 1538 (aryl C-C), 1411 (N-CO), 1354 (N-O), 1255 (H-
NCO), 1048 (C-O-C). 
Melting point: 176–178 °C (decomp). 
HRMS (ESI): m/z calcd for C29H41N9O6
+ [M+H]: 611.3184, found: 611.3183. 
EPR (methanol): typical 3-line nitroxide signal, g 1.9939, aN 1.5006 mT. 
HPLC purity- >99.9%  
Elemental analysis: found C 56.40, H 7.19, and N 19.22. Expected C 57.04, H 
6.60, and N 20.64. 
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.  
7.2.38 .Synthesis of 2-(2-(4-N-(5-methylcarboxy-1,1,3,3-
tetramethylisoindoline-2-yloxyl)aminophenyl))ethylamino-2,3-O-
isopropylideneadenosine -5-N-ethylcarboxamide (167). 
 
Compound 159 (100 mg, 0.207 mmol, 1 equiv), was added in a stirring mixture 
of (60:40) 5-methylcarboxy-1,1,3,3-tetramethylisoindoline-2-yloxyl (115) and 
compound 8 (65 mg, 0.259 mmol, 1.25 equiv), EDCI (64 mg, 0.33 mmol, 
1.6equiv), HOBt (35 mg, 0.259 mmol, 1.25 equiv), and DIPEA (1.4 mL) in 
anhydrous DMF (8 mL).  The reaction mixture was stirred at room temperature 
for 4 days and the reaction progress was followed by TLC analysis (EtOAc: 
MeOH, 8:2).  The solution was quenched by adding of water (50 mL) at 0–5 °C 
and the oily reaction mixture was extracted in DCM (3 x 50 mL).  The combined 
extracts were washed with water (3 x 50 mL) and brine solution (3 x 50 mL).  
The solvent was evaporated under reduced pressure.  The resulting residue 
was purified by MPLC instrument using a mixture of 75% MeOH and 25% water 
to give a (60:40) mixture of 2-(2-(4-N-(5-methylcarboxy-1,1,3,3-
tetramethylisoindoline-2-yloxyl)aminophenyl))ethylamino-2,3-O-
isopropylideneadenosine-5-N-ethylcarboxamide (167) and compound (161) as 
a pale yellow solid (150 mg, 71% w/w) 
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Melting point: 175–180 °C (decomp). 
HRMS (ESI): m/z calcd for C37H47N9O6+ [M + H] 713.3649 and C36H45N9O6+: 
699.3493, found: 713.5496 and 699.9465. 
HPLC purity: 60:40 mixtures of compound 167 and 161 
EPR (methanol): typical 3-line nitroxide signal, g 1.9912, aN 1.5084 mT. 
(This mixture was hard to separate so taken as it is for further for next reaction) 
7.2.39 Synthesis of 2-(2-(4-N-(methylcarboxy-1,1,3,3-
tetramethylisoindoline-2-
yloxyl)aminophenyl))ethylaminoadenosine-5-N-ethylcarboxamide 
(168).  
 
1 M HCl (3.3 mL) was added slowly in to a mixture of compound 167 and 161 
(86 mg, 0.94 mmol, 1 equiv)) in MeCN (8.0 ml).  The solution was stirred for 9 h 
at 55–60 °C, and the reaction progress was followed by TLC analysis in (DCM: 
IPA: MeOH, 4:5:1).  Upon completion, the solution was basified up to pH 8 by 
slow adding saturated NaHCO3 solution and, the resulting mixture was 
extracted with EtOAc (5 x 50 mL).  The EtOAc layers were washed with water 
(3 x 25 mL) and brine solution (3 x 25 mL), and dried over anhydrous MgSO4, 
filtered.  The filtrate was evaporated under reduced pressure and the resulting 
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residue was purified by MPLC instrument using 70% MeOH and 30% water to 
give a mixture of 2-(2-(4-N-(methylcarboxy-1,1,3,3-tetramethylisoindoline-2-
yloxyl)aminophenyl))ethylaminoadenosine-5-N-ethylcarboxamide (168) and 
compound (162) as an off-white solid (74 mg,).  Rf = 0.37 (DCM: MeOH, 9:1).   
Ʋmax (ATR-FTIR) cm
-1: 3400-3117 (OH, NH, NH2), 2973 (alkyl CH3), 2927, 1656 
(NC=O), 1599 (aryl C-N), 1409 (N-CO), 1355 (N-O), 1256 (H-NCO), 1045 (C-O-
C). 
Melting point: 175–180 °C (decomp). 
HRMS (ESI): m/z calcd for C34H43N9O6
+ and C33H41N9O6
+ [M+2H]: 673.3336 
and 659 56 found: 674.6586.and 661.0205. 
HPLC purity: 60:40 mixture. 
EPR (methanol): typical 3-line nitroxide signal, g 1.9928, aN 1.4952 mT. 
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7.2.40 Synthesis of 2-(2-(4-N-(5-carboxy-1,1,3,3-tetraethylisoindoline-2-
yloxyl) aminophenyl)) ethylaminoadenosine-5-N-ethylcarboxamide 
(169). 
 
Compound 159 (150 mg, 0.311 mmol, 1 equiv) was added in a mixture 
containing 5-carboxy-1, 1, 3, 3-tetraethylisoindoline-2-yloxyl (114) (113 mg, 
0.389 mmol, 1.25 equiv), EDCI (95.4 mg, 0.498 mmol, 1.6 equiv), HOBt (53 mg, 
0.389 mmol, 1.25 equiv), and DIPEA (1.2 mL) were combined in anhydrous 
DMF (10 mL). The reaction mixture was stirred at room temperature for 19 h 
and the reaction progress was followed by TLC analysis (DCM: MeOH, 9:1).  
The solution was quenched by adding water at 0–5 °C and the resulting oily 
reaction mixture was extracted in DCM (5 x 50 mL).  The combined DCM 
extracts were washed with water (3 x 25 mL) and saturated NaHCO3 solution (3 
x 25 mL) and brine solution (2 x 25 mL) and dried over anhydrous MgSO4, 
filtered.  The solvent was evaporated under reduced pressure. The resulting 
residue was purified by MPLC instrument using a mixture of 75% MeOH and 
25% water to give 2-(2-(4-N-(5-carboxy-1,1,3,3-tetraethylisoindoline-2-
yloxyl)aminophenyl))ethylaminoadenosine-5-N-ethylcarboxamide (169) as a 
pale yellow solid (101 mg, 65%).   
Rf = 0.80 (DCM / MeOH, 9:1). 
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1H NMR (400 MHz, METHANOL-d4) δ ppm 0.54 - 0.68 (t, 3 H) 1.17 - 1.19 (d, 6 
H) 1.53 - 1.63 (m, 1 H) 2.71 - 2.86 (m, 1 H) 2.86 - 3.03 (m, 1 H) 3.44 - 3.58 (m, 
1 H) 3.67 - 3.82 (m, 1 H) 5.56 - 5.64 (m, 1 H) 5.73 - 5.81 (m, 1 H) 6.20 - 6.27 
(m, 1 H) 7.29 - 7.39 (m, 1 H) 7.59 - 7.73 (m, 1 H) 7.83 - 7.90 (m, 1 H) Note that 
paramagnetic broadening by the nitroxide radical results in some peaks not 
being detected or giving poor integration in the proton NMR spectrum.   
Ʋmax (ATR-FTIR) cm
-1:3400-3000 (NH2 and NH), 2924 (alkyl CH3), 1645 
(NC=O), 1593 (C-N), 1528 (aryl C-C), 1409 (OC-N), 1256 (H-NCO), 1088 (C-O-
C). 
Melting point: 138–140 °C dec; 
HRMS (ESI): m/z calcd for C40H53N9O6
+ [M + H]: 755.4119, found: 755.4118. 
HPLC purity – <95%. 
EPR (methanol): typical 3-line nitroxide signal, g 2.0288, aN 1.4456 mT. 
Elemental analysis: found C 66.59, H 8.03, and N 15.97. Expected C 63.64, H 
6.94, and N 16.70. 
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7.2.41 Synthesis of 2-(2-(4-N-(5-carboxy-1,1,3,3-tetraethylisoindoline-2-
yloxyl)aminophenyl))ethylaminoadenosine-5-N-ethylcarboxamide 
(170). 
 
1M HCl (6.5 mL) added slowly in to a stirring solution of compound 169 (100 
mg, 0.132 mmol, 1 equiv) in MeCN (3.0 mL).  The solution was stirred for 5 h at 
55–60 °C and the reaction progress was followed by TLC analysis (EtOAc: 
MeOH, 8:2) indicated that all starting material had been consumed.  Upon 
completion, the solution was basified up to pH 8 with saturated NaHCO3 
solution, and the resulting mixture was extracted with EtOAc (3 x 50 mL).  The 
combined organic phases were washed with water (3 x 25 mL) and brine 
solution (3 x 25 mL) and dried over anhydrous MgSO4, filtered.  The filtrate was 
evaporated under reduced pressure. The resulting residue was purified by 
MPLC instrument using a mixture of 75% MeOH and 25% water as the eluent to 
give 2-(2-(4-N-(5-carboxy-1,1,3,3-tetraethylisoindoline-2-yloxyl) 
aminophenyl))ethylaminoadenosine-5-N-ethylcarboxamide (170) as a pale 
yellow solid (67 mg, 71%), Rf = 0.48 (EtOAc: MeOH, 8:2). 
1H NMR (400 MHz, METHANOL-d4) δ ppm 1.00 - 1.20 (m, 12 H) 2.95 (br. s., 8 
H) 3.22 (br. s., 4 H) 3.56 - 3.84 (m, 7 H) 4.47 (br. s., 9 H) 5.99 (br. s., 4 H) 7.31 
(br. s., 8 H) 7.67 (br. s., 7 H) 8.11 (br. s., 3 H) Note that paramagnetic 
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broadening by the nitroxide radical results in some peaks not being detected or 
giving poor integration in the proton NMR spectrum. 
Melting point: 175–180 °C (decomp). 
Ʋmax (ATR-FTIR) cm
-1: 3286-3000 (OH, NH, NH2), 2962 and 2926 (alkyl CH3), 
1622 (NC=O), 1591 (aryl C-N), 1515 (aryl C-C), 1407 (OC-N), 1320 (N-O), 1050 
(C-O-C). 
HRMS (ESI): m/z calcd for C37H48NaN9O6
+ [M+ Na]: 737.3625, found: 
737.3883. 
HPLC purity- 98.5%. 
EPR (methanol): typical 3-line nitroxide signal, g 1.9923, aN 1.4380 mT. 
Elemental analysis: found C 59.58, H 7.35, and N 18.43. Expected C 59.62, H 
6.97, and N 18.96. 
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7.2.42 Synthesis of 2-(2-(4-N-(3,5-di-tert-butyl-4-
hydroxyphenyl)acrylamido) phenyl))ethylamino-2,3-O-
isopropylideneadenosine-5-N-ethylcarboxamide(171). 
 
3, 5-di tert-butyl-4-hydroxycinnamic acid (118) (65 mg, 0.486 mmol, 1.2 equiv) 
was added to a mixture of EDCI (85 mg, 0.486 mmol, 1.2 equiv), HOBt (35 mg, 
0.486 mmol, 1.2 equiv), DIPEA (85 µL, 0.486 mmol, 1.2 equiv), and compound 
159 (100 mg, 0.207 mmol, 1 equiv) in anhydrous DMF (2 mL).  The reaction 
mixture was stirred to room temperature for 21 h and the reaction progress was 
followed by TLC analysis in (EtOAc/ Hexanes, 9:1).  DCM was added in to the 
reaction mixture and the solution was quenched by using water (30 mL) at 0–5 
°C.  The resulting mixture was extracted in DCM (3 × 25 mL).  The combined 
extracts were washed with water (3 × 25 mL) and brine solution (2 × 25 mL) and 
dried over anhydrous MgSO4, filtered.  The solvent was evaporated under 
reduced pressure and the oily residue was purified by silica gel column 
chromatography using a (9:1) mixture of EtOAc/ Hexanes to give 2-(2-(4-N-(3,5-
di-tert-butyl-4-hydroxyphenyl)acrylamido) phenyl))ethylamino-2,3-O-
isopropylideneadenosine-5-N-ethylcarboxamide (171) as a brownish-solid (146 
mg, 95%), Rf = 0.54 (IPA/ MeOH, 8:2). 
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1H NMR (400 MHz, CD3OD) δ ppm: 0.59 (t, J=7.21 Hz, 3 H) 0.84 - 0.92 (t, 
J=7.21 Hz, 3 H) 1.28 (s, 6 H) 1.45 (s, 9 H) 1.51 - 1.58 (m, 2 H) 1.97 (s, 1 H) 
2.01 (s, 1 H) 2.13 - 2.20 (m, 1 H) 2.30 (d, J=6.80 Hz, 1 H) 2.62 (s, 1 H) 2.76 (dd, 
J=13.74, 7.14 Hz, 1 H) 2.85 (s, 1 H) 2.87 - 2.95 (m, 1 H) 2.99 (s, 1 H) 3.48 (d, 
J=6.50 Hz, 1 H) 3.66 - 3.76 (m, 1 H) 4.55 - 4.62 (m, 1 H) 5.58 (d, J=5.09 Hz, 1 
H) 5.73 (d, J=5.87 Hz, 1 H) 6.21 (s, 1 H) 6.50 - 6.55 (m, 1 H) 6.63 (d, J=15.80 
Hz, 1 H) 6.95 (s, 1 H) 7.13 (s, 1 H) 7.26 (d, J=7.87 Hz, 1 H) 7.42 (s, 1 H) 7.53 - 
7.63 (m, 1 H) 7.84 (br. s., 1 H) 7.97 (s, 1 H) 
13C NMR (101 MHz, CD3OD) δ ppm 12.5, 23.9, 25.5, 29.2, 29.3, 29.5, 33.4, 
34.1, 83.6, 84.1, 87.9, 91.1, 113.0, 117.2, 119.8, 122.0, 124.6, 126.0, 128.9, 
135.6, 136.9, 138.0, 142.5, 156.2, 159.4, 163.4, 165.9, 170.2 . 
Ʋmax (ATR-FTIR) cm
-1: 3621(NH2), 3500-3200 (NH, OH), 2922 and 2852 (alkyl 
CH3), 1655 (NC=O), 1601 (C=C), 1515 (aryl C-N), 1467 (aryl C-C), 1425 (N-
CO), 1381, 1357, 1207 (H-NCO), 1184, 1118, 1087 (C-O-C). 
Melting point: 138–140 °C.  
HRMS (ESI): m/z calcd for C40H53N8O6
+ [M+H]: 741.4088, found: 741.4490. 
HPLC purity: >99.9%.   
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7.2.43 Synthesis of 2-(2-(4-N-(3,5-di-tert-butyl-4-
hydroxyphenyl)acrylamido) phenyl))ethylaminoadenosine-5-N-
ethylcarboxamide (172) (2VHM162) 
 
1 M HCl (3.3 mL) was added to a solution of compound 171 (121 mg, 0.94 
mmol) in MeCN (8.0 mL).  The solution was stirred for 4 h at 55–60 °C, and the 
reaction progress was followed by TLC.  Upon completion, the reaction mixture 
was basified with saturated NaHCO3 solution up to pH 8 at 0–5 °C, the resulting 
precipitate was extracted with EtOAc (3 x 25 mL).  The combined organic phase 
was washed with water (3 x 25 mL), brine solution (3 x 25 mL) and dried over 
anhydrous MgSO4.  The solvent was filtered and evaporated under reduced 
pressure.  The resulting residue was purified by MPLC instrument using a 
mixture of 80% MeOH and 20% water with partial crystallisation to give 2-(2-(4-
N-(3,5-di-tert-butyl-4-hydroxyphenyl)acrylamido) phenyl))ethylaminoadenosine-
5-N-ethylcarboxamide (172) as a pale yellow solid (46 mg, 50%), Rf = 0.65 
(EtOAc: MeOH, 8:2). 
1H NMR (400 MHz, (CD3)2CO) δ ppm 1.02 (t, J=7.09 Hz, 3 H) 1.23 - 1.34 (m, 9 
H) 1.44 - 1.52 (m, 9 H) 2.05 (d, J=1.03 Hz, 2 H) 3.07 - 3.17 (m, 1 H) 3.26 - 3.36 
(m, 1 H) 3.51 - 3.58 (m, 1 H) 3.59 - 3.69 (m, 1 H) 4.36 (s, 1 H) 4.46 (br, s, 1 H) 
5.02 - 5.09 (m, 2 H) 5.59 - 5.63 (s, 1 H) 5.91 (d, J=6.55 Hz, 1 H) 6.33 (br, s, 1 H) 
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6.69 (d, J=15 Hz, 2 H)) 7.23 (d, J=8.12 Hz, 2 H) 7.38 (s, 1H) 7.45 (s, 2 H) 7.64 
(s, 1 H) 7.69 (s, 1 H) 7.70 (d, J=7.87 Hz, 2 H) 7.87 (s, 1 H) 9.26 (s, 1 H). 
13C NMR (101 MHz, CD3OD) δ ppm 21.4, 29.1, 33.4 , 34.9, 35.5, 42.5, 83.6, 
84.1, 87.9, 91.1, 113.9, 117.2, 119.8, 122.0, 126.0, 128.9, 135.7, 136.8, 137.0, 
138.1, 142.6, 152.4 156.1, 156.2, 159.3, 159.5, 163.5, 165.9, 170.2.  
Ʋmax (ATR-FTIR) cm
-1: 3700-3000 (NH2, NH, OH), 2955 and 2852 (alkyl CH3), 
1620 (C=C), 1596 (NC=O), 1514 (aryl C-N), 1467 (aryl C-C), 1424 (N-CO), 
1356, 1236 (H-NCO), 1206, 1184, 1116 (C-O-C). 
Melting point: 241-243 °C (decomp).  
HRMS (ESI): m/z calcd for C37H49N8O6
+ [M+H]: 701.3775, found: 701.4096. 
HPLC purity: >99.9%.   
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7.2.44 Synthesis of 2-((1,1,3,3-tetramethylisoindoline-2-yloxyl)-5-ethynyl)-
2,3-O-isopropylideneadenosine-5-N-ethylcarboxamide (177). 
 
Compound 149 (190 mg, 0.4 mmol,1 equiv), triethylamine (550 µL), 
Pd(PPh3)2Cl2 (28.5 mg, 0.04 mmol, 0.1 equiv), 5-ethyne-1,1,3,3-
tetramethylisoindoline-2-yloxyl (120) (94.5 mg, 0.44 mmol,1.1 equiv), and 
copper(I)iodide (15.0 mg, 0.08 mmol, 0.2 equiv), were combined in a mixture of 
freshly distilled DCM (8.0 mL) and anhydrous MeCN (4.0 mL) The reaction 
mixture was stirred at room temperature for 20 h.  The reaction mixture was 
quenched by adding chloroform (50 mL) and the organic layer was washed with 
water (3 x 25 mL), brine solution (3 x 25 mL) and dried over anhydrous NaSO4.  
The solvent was evaporated under reduced pressure, and the resulting residue 
was purified by silica gel column chromatography using chloroform: 28% 
aqueous ammonia solution (9.9:0.1) to give 2-((1,1,3,3-tetramethylisoindoline-2-
yloxyl)-5-ethynyl)-2,3-O-isopropylideneadenosine-5-N-ethylcarboxamide (177) 
as a yellowish solid (170 mg, 76%), Rf = 0.57 (chloroform: MeOH, 9:1). 
1H NMR (400 MHz, CDCl3) δ ppm: 1.00 (br. s., 3 H) 1.40 (s, 3 H) 1.65 (s, 3 H) 
2.18 (s, 1 H) 2.63 - 2.65 (m, 1 H) 4.72 (s, 1 H) 5.31 - 5.34 (m, 1 H) 6.05 (br. s., 1 
H) 7.12 - 7.22 (m, 1 H) 7.32 - 7.39 (m, 1 H) 7.40 - 7.44 (m, 1 H) 7.45 - 7.53 (m, 
1 H) 7.84 - 7.89 (m, 1 H) Note that paramagnetic broadening by the   
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nitroxide radical results in some peaks not being detected or giving poor 
integration in the proton NMR spectrum. 
Ʋmax (ATR-FTIR) cm
-1: 3634 (NH2), 3050 (alkyl CH3), 2220 (CΞC), 1668 
(NC=O), 1572 (aryl C-N), 1490 (aryl C-C), 1454 (N-CO), 1377 (N-O), 1206 (H-
NCO), 1084 (C-O-C). 
Melting point: 146–148 °C. 
HRMS (ESI): m/z calcd for C29H35N7O5
+ [M+H]: 561.2700, found: 561.2682. 
HPLC purity: 97.4%. 
EPR (methanol): typical 3-line nitroxide signal, g 1.9919, aN 1.4972 mT. 
7.2.45 Synthesis of 2-((1,1,3,3-tetramethylisoindoline-2-yloxyl)-5-
ethynyl)adenosine-5-N-ethylcarboxamide (178). 
 
1 M HCl solution (3.5 mL) was added slowly in a stirring solution of compound 
177 (55 mg, 0.98 mmol, 1 equiv) in MeCN (3 mL).  The reaction mixture was 
stirred for 8 h at 55–60 °C and the reaction was followed by TLC analysis.in 
(EtOAc: MeOH, 8:2).  Upon completion, the pH of the solution was adjusted up 
to 8 via the slow addition of saturated NaHCO3 solution (25 mL).  The resulting 
mixture was extracted with EtOAc (5 x 50 mL).  The organic phases were 
washed with water (3 x 25 mL), brine solution (3 x 25 mL), and dried over 
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anhydrous Na2SO4.  The solvent was filtered and the filtrate was evaporated 
under reduced pressure to give 2-((1,1,3,3-tetramethylisoindoline-2-yloxyl)-5-
ethynyl)adenosine-5-N-ethylcarboxamide (178) as a pale yellow solid (50 mg, 
98%), Rf = 0.57 (EtOAc: MeOH, 8:2).  
1H NMR (400 MHz, acetone-d6) δ ppm: 1.10 (br. s., 12 H) 4.37 (br. s., 2 H) 4.43 
(s, 3 H) 4.68 - 4.81 (m, 2 H) 4.91 (br. s., 6 H) 6.04 (d, J=6.55 Hz, 3 H) 7.96 - 
7.98 (m, 1 H) 8.31 (s, 3 H) 8.58 - 8.61 (m, 1 H). Note that paramagnetic 
broadening by the nitroxide radical results in some peaks not being detected or 
giving poor integration in the proton NMR spectrum. 
Ʋmax (ATR-FTIR) cm
-1: 3634 (NH2), 3050 (alkyl CH3), 2220 (CΞC), 1668 
(NC=O), 1572 (aryl C-N), 1490 (aryl C-C), 1454 (N-CO), 1377 (N-O), 1206 (H-
NCO), 1084 (C-O-C). 
Melting point: 261 °C (decomp). 
HRMS (ESI): m/z calcd for C26H30NaN7O5
+ [M+Na]: 543.2206, found: 543.2281. 
EPR (methanol): typical 3-line nitroxide signal, g 1.9928, aN 1.4876 mT. 
HPLC purity: 99.99%.   
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7.2.46 Synthesis of 2-((1,1,3,3-tetramethylisoindoline-2-yloxyl)-5-ethyl)-
2,3-O-isopropylideneadenosine-5-N-ethylcarboxamide (179). 
 
Palladium (10% charcoal = 190 mg) was added to a stirring solution of 
compound 177 (190 mg, 0.178 mmol, 1.equiv) in MeOH (50 mL).  The reaction 
mixture was stirred at room temperature using a balloon of H2 gas for 12 h and 
the reaction progress was followed by TLC analysis in (CHCl3: MeOH, 9:1).  
The reaction mixture was filtered through celite and the solvent was evaporated 
under reduced pressure.  The resulting residue was dissolved in MeOH and 
added lead oxide (100 mg).  The mixture was stirred for 1 h at room 
temperature after which time filtered and dried through anhydrous Na2SO4 and 
the solvent was evaporated under reduced pressure.  The resulting residue was 
purified by silica gel column chromatography using CHCl3: MeOH (9:1) to give 
2-((1,1,3,3-tetramethylisoindoline-2-yloxyl)-5-ethyl)-2,3-O-
isopropylideneadenosine-5-N-ethylcarboxamide (179) as an off-white solid (161 
mg, 84%).  Rf = 0.023 (CHCl3: MeOH, 9:1),  
1H NMR (400 MHz, CDCl3) δ ppm 0.67 (t, J=7.29 Hz, 3 H) 1.40 (s, 3 H) 1.60 (s, 
3 H) 1.75 - 1.87 (m, 12 H) 2.75 - 2.87 (m, 1 H) 2.95 - 3.04 (m, 1 H) 3.04 - 3.11 
(m, 2 H) 3.11 - 3.18 (m, 2 H) 3.48 (s, 1 H) 4.69 (d, J=1.37 Hz, 1 H) 5.42 (d, 
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J=6.80 Hz, 1 H) 5.59 - 5.67 (m, 3 H) 6.04 (t, J=5.40 Hz, 1 H) 6.13 (s, 1 H) 7.00 
(s, 1 H) 7.05 (d, J=7.82 Hz, 1 H) 7.29 (s, 1 H) 7.81 (s, 1 H). 
13C NMR (101 MHz, CDCl3) δ ppm 14.1, 25.2, 26.8, 33.7, 34.3, 40.6, 83.4, 83.8, 
87.4, 91.4, 114.0, 121.3 (d, J=5.34 Hz, 1 C) 139.8, 155.2, 168.5. Note that 
paramagnetic broadening by the nitroxide radical results in some peaks not 
being detected or giving poor integration in the NMR spectrum. 
Melting point: 108–110 °C. (Decomp.) 
HRMS (ESI): m/z calcd for C29H38N7O5
+ [M+]: 564.2934, found: 564.3276. 
EPR (methanol): typical 3-line nitroxide signal, g 1.9928, aN 1.5066 mT. 
HPLC purity- 96.72%. 
7.2.47 .Synthesis of 2-((1,1,3,3-tetramethylisoindoline-2-yloxyl)-5-
ethyl)adenosine-5-N-ethylcarboxamide (180). 
 
1 M HCl (10 mL) was slowly added in a stirring solution of compound 179 (150 
mg, 0.155 mmol, 1 equiv) in MeCN (12.0 mL).  The reaction mixture was stirred 
for 5 h at 55–60 °C, and the reaction progress was followed by TLC analysis in 
(CHCl3: MeOH, 8:2).  Upon completion, the solution was basified up to pH 8 by 
slow addition of saturated NaHCO3 solution (50 mL).  The resulting suspension 
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was extracted with EtOAc (5 x 50 mL).  The combined organic layers were 
washed with water (3 x 50 mL) and brine solution (3 x 50 mL) and dried over 
anhydrous Na2SO4, filtered.  The solvent was evaporated under reduced 
pressure to give a tan solid which was recrystallised (MeCN) to give 2-((1,1,3,3-
tetramethylisoindoline-2-yloxyl)-5-ethyl)adenosine-5-N-ethylcarboxamide (180) 
as a pale yellow solid (110 mg, 79%).  Rf = 0.16 (CHCl3: MeOH, 8:2).   
1H NMR (400 MHz, Acetone-d6) δ ppm: 1.08 (t, J=7.16 Hz, 3 H) 1.31 - 1.31 (m, 
1 H) 1.31 - 1.42 (m, 16 H) 2.98 - 3.08 (m, 2 H) 3.08 - 3.16 (m, 2 H) 3.26 (d, 
J=7.09 Hz, 1 H) 3.31 - 3.43 (m, 1 H) 3.55 - 3.61 (m, 1 H) 4.38 - 4.44 (m, 2 H) 
4.88 (dd, J=7.24, 4.60 Hz, 1 H) 6.02 (d, J=7.43 Hz, 1 H) 6.68 (br. s., 1 H) 7.00 
(s, 1 H) 7.04 - 7.09 (m, 1 H) 7.09 - 7.15 (m, 1 H) 8.20 (s, 1 H) 8.23 (br. s., 1 H). 
13C NMR (101 MHz, Acetone-d6) δ ppm: 14.7, 31.5, 31.6, 33.5, 34.7, 41.3, 62.0 
(d, J=13.73 Hz, 1 C) 72.0, 73.7, 84.9, 88.7, 121.2 (d, J=3.05 Hz, 1 C) 127.1, 
140.5, 140.7, 146.6, 149.1, 150.3, 156.2, 164.5, 169.2. Note that paramagnetic 
broadening by the nitroxide radical results in some peaks not being detected or 
giving poor integration in the NMR spectra 
Ʋmax (ATR-FTIR) cm
-1: 3198(OH), 2924 (alkyl CH3), 1636 (NC=O), 1581, 1388 
(N-O), 1120, 1046, 797. 
Melting point: 122-124 °C 
HRMS (ESI): m/z calcd for C26H35N7O5
+ [M+H]: 525.2700, found: 525.2833. 
EPR (methanol): typical 3-line nitroxide signal, g 1.9939, aN 1.5006 mT. 
 HPLC purity- >99.9%. 
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7.2.48 Synthesis of 2-((1,1,3,3-tetraethylisoindoline-2-yloxyl)-5-ethynyl)-
2,3-O-isopropylideneadenosine-5-N-ethylcarboxamide (181). 
 
Compound 149 (100 mg, 0.211 mmol, 1 equiv), 5-ethyne-(1,1,3,3-
tetraethylisoindoline-2-yloxyl (122) (57 mg, 0.211 mmol, 1 equiv), Pd(PPh3)2Cl2 
(15 mg, 0.021 mmol, 0.1 equiv), copper iodide (8 mg, 0.042 mmol, 0.2 equiv), 
and triethylamine (0.25 mL) were combined in a mixture of freshly distilled DCM 
(6 mL) and anhydrous MeCN (3 mL).  Argon was bubbled for 10 min, and the 
reaction mixture was stirred at room temperature for 3 days and the reaction 
progress was followed by TLC analysis using (DCM / MeOH, 9:1).  The 
chloroform (25 mL) was added to the reaction mixture and the organic layer was 
washed with water (3 x 25 mL), and brine solution (3 x 25 mL) and dried over 
anhydrous Na2SO4.  The solvent was evaporated under reduced pressure and 
the resulting residue was purified by silica gel column chromatography using a 
mixture of (9:1) EtOAc: Hexane to give 2-((1,1,3,3-tetraethylisoindoline-2-
yloxyl)-5-ethynyl)-2,3-O-isopropylideneadenosine-5-N-ethylcarboxamide (181) 
as a pale yellow solid (107 mg, 83%), Rf = 0.47 (DCM / MeOH, 9:1). 
1H NMR (400 MHz, CDCl3)(Me trap) δ ppm: 0.58 - 1.05 (m, 5 H) 1.23 (br. s., 8 
H) 1.57 (br. s., 13 H) 1.85 - 2.18 (m, 3 H) 2.97 (s, 5 H) 3.47 (br. s., 1 H) 3.66 (br. 
s., 1 H) 4.63 (br. s., 1 H) 4.89 (br. s., 1 H) 5.60 - 5.92 (m, 1 H) 7.02 (d, J=6.85 
Hz, 1 H) 7.36 - 7.57 (m, 2 H) 7.58 - 7.69 (m, 1 H) 7.89 (br. s., 1 H).  Note that 
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paramagnetic broadening by the nitroxide radical results in some peaks not 
being detected or giving poor integration in the proton NMR spectrum. 
Ʋmax (ATR-FTIR) cm
-1: 3400-3100 (OH, NH2), 2971 and 2960 (alkyl CH3 and 
CH2), 2214 (CΞC), 1668 (NC=O), 1593 (aryl C-N), 1521 (aryl C-C), 1487 (N-
CO), 1374 (N-O), 1259, 1206 (H-NCO), 1156, 1083 (C-O-C). 
Melting point: 188–190 °C. 
HRMS (ESI): m/z calcd for C33H43N7O5+ [M + H]: 617.3326, found: 617.3296. 
EPR (methanol): typical 3-line nitroxide signal, g 1.9913, aN 1.4200 mT.  
HPLC purity- >99.9%. 
7.2.49 Synthesis of 2-((1,1,3,3-tetraethylisoindoline-2-yloxyl)-5-
ethynyl)adenosine-5-N-ethylcarboxamide (182). 
 
1 M HCl solution (5 mL) was added slowly.in a stirring solution of compound 
181 (70 mg, 0.94 mmol, 1 equiv) was dissolved in MeCN (5.0 mL).  The 
reaction mixture was stirred for 3 h at 55–60 °C, and the reaction progress was 
followed by TLC analysis in 100% EtOAc.  Upon completion, the solution was 
basified up to pH 8 by adding saturated NaHCO3 solution (25 mL).  The 
resulting suspension was extracted with EtOAc (5 x 50 mL).  The organic 
extracts were washed with water (3 x 25 mL) and brine solution (3 x 25 mL) and 
dried over anhydrous Na2SO4, filtrated.  The solvent was evaporated under 
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reduced pressure and the resulting residue was purified by silica gel column 
chromatography using EtOAc to give 2-((1,1,3,3-tetraethylisoindoline-2-yloxyl)-
5-ethynyl)adenosine-5-N-ethylcarboxamide (182) as a tan solid (57 mg, 88%), 
Rf = 0.53 (100% EtOAc). 
1H NMR (400 MHz, CDCl3) δ ppm: 0.73 (br. s., 3 H) 0.81 - 1.00 (m, 8 H) 1.11 
(s., 2H)1.23 (br. s., 15 H) 2.02 (br. s., 5 H) 2.97 (s, 3 H) 3.47 (br. s., 2 H) 3.54 - 
3.74 (m, 4 H) 4.49 - 4.69 (m, 1 H) 4.89 (br. s., 1 H) 5.68 - 5.88 (m, 1 H) 7.00 (d, 
J=5.18 Hz, 1 H) 7.44 (d, J=1.52 Hz, 1 H) 7.52 (d, J=6.46 Hz, 1 H) 7.58 - 7.69 
(m, 1 H) 7.90 (br. s., 1 H) Note that paramagnetic broadening by the nitroxide 
radical results in some peaks not being detected or giving poor integration in the 
proton NMR spectrum. 
Ʋmax (ATR-FTIR) cm
-1: 3400-3100 (OH, NH2), 2971 and 2960 (alkyl CH3 and 
CH2), 2214 (CΞC), 1668 (NC=O), 1593, 1521, 1487, 1374 (N-O), 1259, 1206, 
1156, 1083, 861,796. 
Melting Point: 196–198 °C (decomp). 
HRMS (ESI): m/z calcd for C30H39N7O5
+ [M+H]: 577.3013, found: 577.3012. 
EPR (methanol): typical 3-line nitroxide signal, g 1.9928, aN 1.4113 mT. 
HPLC purity- >99.9%. 
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7.2.50 Synthesis of 2-((1,1,3,3-tetraethylisoindoline-2-yloxyl)-5-ethyl)-2,3-
O-isopropylideneadenosine-5-N-ethylcarboxamide (183). 
 
Palladium (10 % charcoal = 50 mg) was added in a stirring solution of 
compound 181 (68 mg, 0.11 mmol, 1.0 equiv) in MeOH (4 mL).  The reaction 
mixture was stirred at room temperature under a balloon full of H2 gas for 12 h 
and the reaction progress was followed by TLC analysis in (DCM: MeOH, 9:1).  
The mixture was filtered through celite and the solvent was evaporated under 
reduced pressure.  The resulting residue was dissolved in MeOH and added 
lead oxide (100 mg).  The mixture was stirred for 1 h at room temperature after 
which time filtered and dried through anhydrous Na2SO4 and the solvent was 
evaporated under reduced pressure.  The resulting residue was purified by 
silica gel column chromatography using CHCl3 to give 2-((1,1,3,3-
tetraethylisoindoline-2-yloxyl)-5-ethyl)-2,3-O-isopropylideneadenosine-5-N-
ethylcarboxamide (183) as a yellow solid (66 mg, 96.5%), Rf = 0.76 (DCM: 
MeOH, 9:1). 
1H NMR (400 MHz, CDCl3) δ ppm 0.68 (t, J=6.90 Hz, 3 H) 1.38 (s, 12 H) 1.52 - 
1.65 (m, 11 H) 2.84 - 2.86 (m, 2 H) 3.07 - 3.12 (m, 4 H) 4.68 (s., 1 H) 5.52 (br s, 
2 H) 6.09-6.12 (s, 1 H) 6.18 (br s, 2 H) 6.89 (s, 1 H) 6.94 - 6.99 (m, 1 H) 7.12 - 
7.14 (d, 1 H) 7.79 (br. s., 1 H). 
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 13C NMR (101 MHz, CDCl3) δ ppm: 9.0, 25.3, 26. 9, 33.8, 34.4, 67.9, 82.1, 
83.1, 83.3, 83.8, 87.3, 90.0, 91.4, 103.7, 110.0, 114.0, 118.3, 139.7, 168.5, 
185.2, 217.3.  
Melting point: 88–90 °C. 
HRMS (ESI): m/z calcd for C33H47N7O5
+ [M+H]: 621.3639, found: 621.3630. 
HPLC purity: 88.72%. 
EPR (methanol): typical 3-line nitroxide signal, g 1.9892, aN 1.4462 mT. 
7.2.51 Synthesis of 2-((1,1,3,3-tetraethylisoindoline-2-yloxyl)-5-
ethyl)adenosine-5-N-ethylcarboxamide (184). 
 
1 M HCl solution (5 mL) was added slowly in a stirred solution of compound 183 
(66 mg, 0.106 mmol, 1 equiv) in MeCN (5.0 mL).  The solution was stirred for 5 
h at 55–60 °C and the reaction progress was followed by TLC analysis in DCM: 
MeOH (9:1).  Upon completion, the solution was basified up to pH 8 by adding 
saturated NaHCO3 solution (25 mL).  The resulting suspension was extracted 
with EtOAc (5 x 50 mL).  The combined organic phases were washed with 
water (3 x 25 mL) and brine solution (3 x 25 mL) and filtered and dried over 
anhydrous Na2SO4.  The solvent was evaporated under reduced pressure 
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to give a tan solid, which was recrystallised (MeCN) to give 2-((1,1,3,3-
tetraethylisoindoline-2-yloxyl)-5-ethyl)adenosine-5-N-ethylcarboxamide (184) 
as a pale yellow solid (43 mg, 70%).  Rf = 0.69 (DCM: MeOH, 9:1). 
Ʋmax (ATR-FTIR) cm
-1: 3400-3100 (NH2, OH,), 2925 (alkyl CH3), 2214 (CΞC), 
1636 (NC=O), 1581(aryl C-N), 1459 (N-CO), 1389 (N-O), 1119, 1046 (C-O-C). 
Melting point: 138–140 °C  
HRMS (ESI): m/z calcd for C30H43N7O5
+ [M+H]: 581.3326, found: 581.3277. 
HPLC purity:- 99.99%. 
EPR (methanol): typical 3-line nitroxide signal, g 1.9921, aN 1.4609 mT. 
7.2.52 Synthesis of 2-(2-Phenylethynyl)-2,3-O-isopropylideneadenosine -
5-N-ethylcarboxamide (185). 
 
Compound 149 (100 mg, 0.211 mmol, 1 equiv), phenylacetylene 123 (57 mg, 
0.232 mmol, 1.1 equiv), Pd(PPh3)2Cl2 (15 mg, 0.021 mmol, 0.1 equiv), copper 
iodide (8 mg, 0.042 mmol, 0.2 equiv), and triethylamine (0.3 mL) were 
combined in a mixture of freshly distilled DCM (6 mL) and anhydrous MeCN (3 
mL).  Argon was bubbled through a mixture for 10 minutes.  The reaction 
mixture was stirred at room temperature for 15 h and the reaction progress was 
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followed by TLC analysis in (DCM: MeOH, 9:1).  The CHCl3 was added to a 
mixture and resulting solution was washed with water (3 x 25 mL) and brine 
solution (3 x 25 mL).  The solvent was evaporated under reduced pressure and 
the resulting residue was purified by silica gel column chromatography using 
CHCl3 to give 2-(2-Phenylethynyl)-2,3-O-isopropylideneadenosine-5-N-
ethylcarboxamide (185) as a brownish solid (91 mg, 97%).   
1H NMR (400 MHz, CDCl3) δ ppm: 0.94 - 1.00 (m, 3 H) 1.36 (s, 3 H) 1.62 (s, 3 
H) 3.16 - 3.30 (m, 1 H) 3.37 (dt, J=13.60, 6.94 Hz, 1 H) 4.69 (s, 1 H) 5.24 (d, 
J=5.18 Hz, 1 H) 5.30 (br. s., 1 H) 6.00 (d, J=1.37 Hz, 1 H) 7.35 (br. s., 1 H) 7.35 
- 7.40 (m, 3 H) 7.58 – 7.61(m, 2H). 
13C NMR (101 MHz, CDCl3) δ ppm: 14.7 , 25.3 , 27.3 , 34.1 , 76.7 , 77.0 , 77.2 , 
77.3 , 82.0 , 83.4 , 84.9 , 114.9 , 128.4 , 129.5 , 132.3 , 168.5 . 
Ʋmax (ATR-FTIR) cm
-1: 3356 (NH2), 3156 (OH), 2214 (CΞC), 1654 (NC=O), 
1588 (aryl C-N), 1522 (aryl C-C), 1492, 1457 (N-CO), 1380, 1203 (H-NCO), 
1155, 1082 (C-O-C). 
Melting point: 174–176 °C ;(lit ) 
HRMS (ESI): m/z calcd for C23H25N6O4+ [M + H]: 449.1937, found: 449.1881. 
HPLC purity- 99.99%. 
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7.2.53 Synthesis of 2-(2-phenylethyl)-2,3-O-isopropylideneadenosine-5-
N-ethylcarboxamide (187). 
 
Palladium (10% charcoal = 80 mg) was added to a stirred solution of compound 
185 (80 mg, 0.178 mmol, 1.0 eq) in MeOH (10 mL).  The reaction mixture was 
stirred at room temperature using a balloon of H2 gas atmosphere for 12 h and 
the reaction progress was followed by TLC analysis in (DCM: MeOH, 9:1).  The 
mixture was filtered through celite and the filtrate was evaporated under 
reduced pressure.  The resulting residue was purified by silica gel column 
chromatography using a DCM: MeOH (9:1) to give 2-(2-phenylethyl)-2,3-O-
isopropylideneadenosine-5-N-ethylcarboxamide (187) as a yellow solid (75 mg, 
93 %).  Rf = 0.56 (DCM: Methanol, 9:1). 
1H NMR (400 MHz, CDCl3): δ ppm 0.67 (t, J=7.24 Hz, 4 H) 1.37 (s, 3 H) 1.58 (s, 
3H) 2.77 - 2.86 (m, 1 H) 2.99 - 3.05 (m, 1 H) 3.05 - 3.14 (m, 4 H) 4.65 (d, J=1.66 
Hz, 1 H) 5.25 (d, J=4.65 Hz, 1 H) 5.47 - 5.55 (m, 3 H) 6.05 (d, J=1.37 Hz, 1 H) 
7.15 (d, J=6.60 Hz, 1 H) 7.19 - 7.23 (m, 3 H) 7.76 (s, 1 H). 
13C NMR (75 MHz, DMSO- d6): δ ppm: 14.1, 25.2, 26.9, 33.7, 34.5, 40.5, 83.2, 
83.8, 86.2, 91.4, 114.0, 118.3, 125.8, 128.3, 128.4, 139.7, 141.5, 155.5, 165.4 
and 168.5.   
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Melting point: 70–72 °C.  
HRMS (ESI): m/z calcd for C23H29N6O4
+ [M+H]: 453.2250, found: 453.2243. 
HPLC purity- 98.32%. 
7.2.54 Synthesis of 2-(2-phenylethyl)adenosine-5-N-ethylcarboxamide 
(188). 
 
1 M HCl solution (6 mL) was added slowly in a stirring solution of compound 
187 (70 mg, 0.155 mmol, 1 equiv) in MeCN (6.0 mL).  The reaction mixture was 
stirred for 5 h at 55–60 °C and the reaction progress was followed by TLC 
analysis in (DCM: MeOH, 9:1).  Upon completion, the solution was basified up 
to the pH 8 by adding saturated NaHCO3 solution (25 mL).  The resulting 
suspension was extracted with EtOAc (5 x 25 mL) and the combined organic 
layers were washed with water (3 x 25 mL) and brine solution (3 x 25 mL) and 
dried over anhydrous Na2SO4.  The solvent was evaporated under reduced 
pressure to give a brownish solid which was recrystallised (MeCN) to give 2-(2-
phenylethyl)adenosine-5-N-ethylcarboxamide (188) as a pale yellow solid (60 
mg, 94%).  Rf = 0.38 (DCM: MeOH, 9:1). 
1H NMR (400 MHz, CDCl3) δ ppm: 1.06 (t, J=7.26 Hz, 3 H) 2.03 (s, 2 H) 3.07 (d, 
J=4.55 Hz, 4 H) 3.16 - 3.21 (m, 1 H) 3.37 - 3.43 (m, 1 H) 4.57 (s, 1 H) 4.63 - 
255 
 
4.68 (m, 2 H) 5.63 (br. s, 2 H) 5.83 (d, J=5.48 Hz, 1 H) 7.15 - 7.19 (m, 3 H) 7.23 
(br. s., 1 H) 7.24(br. s, 1 H) 7.84 (s, 1 H). 
13C NMR (101 MHz, CDCl3) δ ppm: 14.7 , 25.3 , 27.3 , 34.1 , 76.7 , 77.0 , 77.2 , 
77.3 , 82.0 , 83.4 , 84.9 , 114.9 , 128.4 , 129.5 , 132.3 and 168.5. 
Ʋmax (ATR-FTIR) cm
-1: 3330 (NH2), 3225 (OH), 2921 (aryl C-H), 1643 (NC=O), 
1588 (aryl C-N), 1522 (aryl C-C), 1467 (N-CO), 1396, 1315, 1203 (H-NCO), 
1196, 1143, 1115, 1080 (C-O-C), 1043, 968, 870. 
Melting point: 216-217 °C.(decomp.)  
HRMS (ESI): m/z calcd for C20H25N6O4
+ [M+H]: 413.1937, found: 413.2019. 
HPLC purity- 100%. 
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